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ABSTRACT  
Cationic lipids have been comprehensively studied as non-viral vectors for gene therapy, 
focusing on improving the gene transfer efficiency and the safety profile. However, clinical 
applications of cationic lipid/DNA lipoplexes are restricted due to their low physical stability in 
aqueous formulations. One specific group of cationic lipids that showed efficient transfection 
activity is the gemini surfactants.  
Two main objectives were determined in this work. The first was to evaluate the feasibility 
of lyophilization as a formulation technique for preparing gemini surfactant-based lipoplexes 
with long-term stability. The second objective was to establish a universal tandem mass 
spectrometric “fingerprint” of novel amino acid modified gemini surfactants as a pre-
requirement for the identification and quantification of gemini surfactants in different 
pharmaceutical matrices.   
In order to investigate the influence of lyophilization on the essential physiochemical 
properties and the in vitro transfection efficiency of gemini surfactant-lipoplexes, a diquaternary 
ammonium gemini surfactant (12-7NH-12) and plasmid DNA (pDNA) encoding for interferon-γ 
(IFNγ) were used to prepare pDNA/gemini surfactant [P/G] lipoplexes. Helper lipid DOPE [L] 
was incorporated in all formulations producing a [P/G/L] system. Several excipients were 
utilized as stabilizing agents. Lipoplexes formulated with the cryoprotectant were subjected to a 
lyophilization/rehydration cycle. Transfection activity was assessed by measuring the level of 
expressed IFNγ and cellular toxicity (MTT assay). The results showed that the physiochemical 
properties of gemini surfactant-based lipoplexes were dependent on the nature of the stabilizing 
agents used to prepare the lipoplexes. Disaccharide sugars, sucrose and trehalose, provided the 
most efficient cryoprotectant effect based on their ability to physically stabilize the lipoplexes 
during the lyophilization process. The transfection efficiency of the lyophilized lipoplexes 
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increased 2-3 fold compared to fresh formulations upon lyophilization. This effect can be 
attributed to the improvement of DNA compaction and changes in the lipoplex morphology due 
to the lyophilization/rehydration cycles. 
Based on these results, we evaluated the ability of lyophilization to improve the stability of 
gemini surfactant-based lipoplexes. Four lyophilized formulations were stored at 25˚C for three 
months. The formulations were analyzed monthly for physical appearance, physiochemical 
properties (particle size and zeta potential, pDNA compaction, gemini surfactant:pDNA 
interaction) and in vitro transfection. The physiochemical properties of the lyophilized 
formulations were maintained throughout the three month study. All lyophilized formulations 
showed a loss of gene transfection activity after three months of storage. Nevertheless, no 
significant losses of transfection efficiency were observed for three formulations after two 
months storage at 25 ˚C. These findings suggest that lyophilization significantly improved the 
physiochemical stability of gemini surfactant-based lipoplexes compared to liquid formulations. 
As well, lyophilization improved the transfection efficiency of gemini surfactant-based 
lipoplexes. The loss of transfection activity upon storage is most probably due to the 
conformational changes in the supramolecular structure of the lipoplexes as a function of time 
and temperature, rather than to DNA degradation. 
To establish a foundation for employing the mass spectrometric methods in the evaluation 
of the chemical stability of the gemini surfactant, we evaluated the tandem mass spectrometric 
(MS/MS) behavior of six amino acid/di-peptide modified gemini surfactants that were 
synthesized based on the precursor compound 12-7NH-12. This was accomplished by using a 
hybrid quadrupole orthogonal time-of-flight mass spectrometer (QqToF-MS) and a triple 
quadrupole linear ion trap mass spectrometer (QqQ-LIT MS) equipped with electrospray 
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ionization (ESI) source. The single stage QqToF-MS data obtained in the positive ion mode 
verified the molecular composition of all tested gemini surfactants. Tandem mass spectrometric 
(MS/MS) analysis showed common fragmentation behavior among all tested compounds, 
allowing for the establishment of a universal fragmentation pattern. The fragmentation pathway 
was confirmed by MS/MS/MS experiments utilizing a Q-TrapTM 4000 LC/MS/MS system and 
(MS/MS) analysis of the deuterated form of 12-7N(Glycine)-12 gemini surfactant. Unique 
product ions, originating from the loss of one or both head groups along with the attached tail 
region(s), confirmed the chemical structure of the tested compounds. 
In conclusion, different lyophilization strategies and analytical methods have been 
established to develop and examine the physiochemical stability of gemini surfactant-based 
lipoplex. A tandem mass spectrometric fragmentation pathway was established to enable the 
identification and quantification of these compounds in pharmaceutical formulations.  
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  Chapter 1 
Literature Review 
1.1. Introduction  
Gene therapy is a promising therapeutic approach that has the potential to significantly 
improve human health. Achieving the ultimate goal of gene therapy depends on the design of 
efficient, safe and stable gene delivery systems. Viral and non-viral systems have been 
extensively investigated for gene delivery. Viral vectors (e.g. adenoviral and retroviral vectors) 
are the most effective gene delivery agents that have been tested in several clinical trials. 
However, they suffer from numerous toxicity-related drawbacks. On the other hand, non-viral 
chemically mediated vectors, such as cationic lipids, exhibit low toxicity and show no 
immunogenic activity compared to viral vectors. One specific group of cationic lipids that 
demonstrated efficient transfection activities in vitro and in vivo are cationic gemini surfactants. 
They are dimeric surfactants comprised of two hydrophobic tail regions which are covalently 
attached to cationic head groups (linked by spacer region) [Figure 1.1]. Two major disadvantages 
of cationic lipid-DNA complexes (lipoplexes) that limit their clinical applications are the low 
transfection efficiency and physical instability.  
Over the last decades, numerous cationic lipids were synthesized and modified to 
overcome their low transfection activity. The transfection efficiency of lipoplex-based systems 
depends on the integrity of various components of the delivery system and their related 
physiochemical properties. The stability of non-viral gene delivery systems is complicated as it 
involves the structural integrity of the genetic material, the physical, chemical and 
conformational stability of the DNA-carrier complexes. Therefore, investigation of the 
physiochemical stability of the lipoplex vectors during the manufacturing and treatment is 
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required to understand the behavior of such complex systems. To date, lyophilized lipoplex 
formulations have shown the most promising stability. However, the influence of the 
lyophilization process on the supramolecular structure of lipoplex systems formulated with 
different cationic lipids is not fully elucidated.  
The purpose of my research is to develop qualitative and quantitative analytical methods 
that can be used to evaluate the physiochemical stability of gemini surfactant/plasmid DNA 
lipoplexes used for gene delivery. As well, the feasibility of the lyophilization technique for 
preparation of stable gemini surfactant-based lipoplexes was evaluated. Mass spectrometry is 
employed to confirm the molecular structure of six amino acid/di-peptide modified gemini 
surfactants and to establish a universal fragmentation fingerprint that can be used to identify and 
quantify these compounds in different matrices (including pharmaceutical formulations). Also, 
different analytical methods are developed to evaluate the in vitro transfection activity, cellular 
toxicity and physiochemical stability of lyophilized gemini surfactants/plasmid DNA (pDNA) 
formulations during three months of stability studies. These methods include: enzyme-linked 
immunosorbent assay (ELISA), MTT assay, dynamic light scattering (DLS), zeta potential 
measurements, gel electrophoresis, circular dichroism spectroscopy and Karl Fischer titration. 
 
 
Figure 1.1: General structure of cationic gemini surfactants 
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1.2. Background  
1.2.1. Gene therapy: Successes, setbacks and future 
Significant advances in the biomedical and biotechnological sciences in the last few 
decades have contributed to a better understanding of the human biology. The completion of the 
sequencing of the human genome by the Human Genome Project has provided information 
regarding the role of genes in disease initiation and progression, which also expedites the 
development of gene therapy. Gene therapy can be defined as the introduction of exogenous 
nucleic acids into targeted cells for the purpose of preventing, terminating or reversing the 
progress of a pathological condition.
1
 Nucleic acid based therapy is employed to manage a wide 
variety of acquired and genetic diseases in order to: 1) repair or substitute a defective gene, 2) 
stimulate humoral and cell-mediated immune responses to protein antigens – genetic 
immunization or 3) silence a defective gene expression at cellular mRNA level – gene 
knockdown.
1
 Therefore, gene therapy introduces unique and promising prospects for the 
treatment of many diseases where traditional medicine and treatment methods lack efficiency.  
Two main approaches have been exploited for gene transfer (transfection): ex vivo and in 
vivo.
2
 In the ex vivo approach, the targeted cells are isolated from the patient, purified and treated 
outside the body. The genetically treated cells are re-infused into the patient’s body. The in vivo 
method involves direct gene transfer to targeted cells. The first human clinical trial was 
performed by Rosenberg and his group, (at the National Cancer Institutes in Bethesda, MD, 
USA), in 1989. Their aim was to validate the safety and efficacy of using a virus-based gene 
transfer coding for resistance to neomycine into human tumor-infiltrating lymphocytes as a 
potential treatment for metastatic melanoma.
3
 This groundbreaking study has initiated exploring 
the practicality of gene therapy as a novel medical technology to fight diseases at the genetic 
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level. Subsequently, a four-year clinical trial was conducted using retroviral-based gene 
transduction of adenosine deaminase gene into T-lymphocyte cells of two children with severe 
combined immune deficiency.
4
 This trial was the first actual attempt to clinically evaluate gene 
therapy. Since then, over 1,785 clinical trials have been registered by the end of 2011 .
5
  Around 
65% of these clinical trials aimed to treat cancer. In addition, thousands of studies have been 
published regarding different types of transgene (genetic material used for gene therapy) and 
delivery systems.  
The clinical momentum of gene therapy suffered a setback in 1999 due to the death of an 
18-year old participant in a gene therapy pilot safety study that included 18 patients suffering 
from ornithine transcarboxylase deficiency.
6
 The death was caused by severe systemic 
inflammatory response syndrome and multiple organ system failure triggered by the virus capsid 
used as gene delivery vector
6
.  Due to this event, FDA halted all the gene therapy clinical trials at 
the University of Pennsylvania School of Medicine where the incident happened.
7
  In 2000, a 
French team reported the successful treatment of ten children with severe X-linked combined 
immunodeficiency using a retrovirus–derived vector.8 However, in 2002, two of the participant 
children suffered from severe leukemia-like symptoms due to the integration of the transgene 
into the chromosome of the treated cells.
9,10
 These unanticipated outcomes raised a debate over 
the safety and future of manipulation of human cells at the gene level and led the USA and 
several European countries to suspend several clinical trials at that time to reevaluate the ethics 
and the safety procedures of human gene therapy. This action had a negative impact on the 
reduced number of human clinical trials between 2000 and 2003.  
In spite of these setbacks, in 2003 the Chinese State Food and Drug Administration 
approved the world’s first commercially available gene therapy medication Gendicine® 
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(Shenzhen Sibiono Genetech Co. Ltd, China) for the treatment of head and neck cancer.
11,12
 
However, due to safety concerns associated with viral-based gene therapy, several non-viral 
delivery systems have been developed and investigated extensively as safe alternative 
approaches.
13,14
 Generally, the non-viral gene delivery systems are classified into 1) physically 
mediated and 2) chemically mediated gene delivery systems.   
In the following section, I will discuss the different gene delivery systems (viral and non-
viral) with focus on the cationic lipid based gene delivery vectors. 
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I.2.2. Gene delivery systems 
1.2.2.1.Viral gene delivery systems  
Viruses have the ability to transfer genetic materials to the host cells as infective agents. 
Scientists have capitalized on this property to develop gene delivery systems. New strains of 
nonpathogenic attenuated viruses have been used in numerous studies as viral vectors with 
significant transfection levels being achieved in different tissues, such as the lung, eye, kidney, 
muscle , and the ovary.
15-19
 The most frequently used vectors in gene therapy which have 
reached advanced stages of clinical trials are viral vectors; around 65% of human clinical trials in 
gene therapy have used virus-based vectors.
5
 The major advantage of the viral vectors compared 
to physical and chemical vectors is their high transfection efficacy. For instance, a study 
demonstrated that the transfection ability of adenoviral vectors in human monocyte-derived 
macrophages and African green monkey kidney fibroblast (COS-7 cells) was higher than that 
achieved by lipid-mediated vectors.
20
 When COS-7 cells were infected with the adenoviral 
vectors, all cells expressed the transgene while only 30% of COS-7 cells were able to show gene 
expression after lipofection.
20
 Furthermore, the ability to target certain cells or tissue and to 
control the gene expression are two advantages of viral vectors.
21-23
 Targeting the viral vectors 
has been achieved either by genetically mutating the virus
24,25
 or by modifying the virus with 
targeting ligands or antibodies.
26,27
  
Despite the advantages of viral-based systems, there are several concerns about the safety 
of using viruses as gene delivery vectors. The major drawback is the reported cases of mortality 
and strong immune responses associated with the administration of viral gene therapy in clinical 
trials.
6,9
 In addition, the long term effects of viral vectors in humans and the possibility of gene 
mutation are still unclear.
28
 Besides the safety concerns, other shortcomings may limit the use of 
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viruses as gene delivery agents. For instance, the tendency of the viral vectors to lose their 
transfection activity during storage in conventional pharmaceutical formulations is considered to 
be a main stability issue.
29,30
 However, the recent progresses in biotechnology and 
bioengineering technologies have improved the efficiency and stability of the viral vectors, 
keeping viral vectors at the forefront of gene delivery methods.
31-33
    
1.2.2.2.  Non-viral gene delivery systems  
1.2.2.2.1. Naked DNA delivery  
The simplest non-viral gene delivery method is the direct delivery of the genetic material 
(DNA) into the targeted cells. However, there are many obstacles that hinder this method. To 
achieve efficient gene expression, the DNA must 1) be stable in the biological system until it 
reaches the targeted cells, 2) be internalized by the cell and 3) enter the cell nucleus. DNA is 
easily destroyed by plasma and cellular nuclease enzymes and scavenger cells limiting its serum 
half-life to 10 minutes.
34,35
 Additionally, the cell membrane has a dynamic lipophilic structure 
which restrains the uptake of large hydrophilic and charged molecules such as DNA. However, 
direct injection of naked DNA into the organ or targeted tissue of laboratory animals has led to 
successful gene expression in the liver, the muscle, the lung, the heart, the kidney and solid 
tumors.
36-41
 Similarly, direct intravascular injection could deliver naked DNA in vivo.
42,43
 Liang 
et al reported successful delivery of semi-systemic pDNA encoding full-length dystrophin 
through the intra-artery and tail vein of mdx mice and wild-type C57. 
43
 The purpose was to treat 
Duchenne muscular dystrophy, showing a significant restoration of dystrophin protein in all 
muscles of both hind limbs.
43
 However, inefficient gene expression and the need for a large 
amount of genetic material are the drawbacks of naked DNA delivery method.
44
 To improve the 
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cellular uptake and achieve higher gene expression levels, different physical methods have been 
employed to deliver naked genetic materials.  
1.2.2.2.2. Physical gene delivery systems 
 In an attempt to increase cellular uptake of naked pDNA, different physical methods have 
been used to disturb the plasma membrane and facilitate the diffusion of genetic materials into 
cells. These  methods have the potential to evade biological barriers, providing a significant level 
of transfection in comparison to the delivery of naked pDNA. Physical gene delivery methods 
include: particle bombardment (gene gun transfer), electroporation, ultrasound induced pores 
(sonophoresis), and magnetic field assisted transfection (magnetofection).
45-48
  
Although numerous physical methods have been developed for gene delivery purposes, 
only a few have been successfully evaluated in clinical trials. Particle bombardment , a gene 
delivery method based on carrying the transgene coated on the surface of non-toxic inert 
particles into the targeted cells using a gene gun, has been evaluated for safety and efficacy in 
several clinical trials as a genetic vaccination method.
45,49,50
 Electroporation, where electrical 
pulses are applied to enhance gene transfer, is another physical method that has been 
demonstrated to be the most feasible in gene transfer activity among other physical methods.
51,52
 
Almost all physical delivery methods suffer from major disadvantages, namely damage to 
cellular membrane and inefficient gene transfer.
53
  
Chemically mediated gene delivery systems, on the other hand, are considered more 
promising gene delivery vectors due to numerous factors. They have low immunogenicity and 
cytotoxicity, can carry large genes, can be modified for cellular targeting, and are easy to 
synthesize on a large scale under good manufacturing practice (GMP) conditions.
54-57
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In the following section, I will discuss the chemically-mediated gene delivery systems 
focusing on cationic lipid based vectors that have shown the most promising gene delivery 
activity. 
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1.2.2.2.3. Chemical gene delivery systems 
The ideal chemical gene vector should have the following properties: 1) the ability to 
protect the transgene (DNA) from the biological degradative environment until full delivery to 
the cell nucleus, 2) the ability to release the DNA once having reached the site of action, 3) 
minimum side effects without any immune response, 4) specificity to the targeted cell or tissue, 
and 5) the ability to maintain the stability of the vector.
58
 Therefore, chemical gene delivery 
systems are considered a promising gene delivery vector in gene therapy. Diethylaminoethyl 
dextran (DEAE-dextran), and calcium phosphate co-precipitation were the first chemical carriers 
used to deliver nucleic acid to cells and achieve gene expression.
59,60
 The two main classes 
currently used as chemical non-viral gene delivery systems are polymer-based and lipid-based 
vectors. 
Polymer-based gene delivery 
Cationic polymers are a group of polymeric compounds that either condense and protect 
the DNA or carry the genetic materials without condensing.
61
 The DNA-polymer complex is 
known as a "polyplex". Polyethylenimine (PEI) was the first polymer utilized in gene therapy. It 
is a cationic polymer that can be in two forms: linear or branched.
62
 PEI contains several amine 
groups which offer pH-dependent protonation (proton sponge effect) that trigger the DNA 
release upon uptake
63
. It has been established that the transfection efficiency of PEI is 
proportional to its molecular weight. However, high molecular weight polymers exhibit high 
cytotoxicity.
64
  
Poly-L-lysines (PLL) are polymeric vectors that have been studied extensively for DNA 
transfection.
56
 The presence of an є-amino acid in the structure of the PLL facilitates the 
endosomal escape of the DNA due to the protonation at physiological pH.
65
 High molecular 
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weight PLL polymers condense DNA effectively but they show high cytotoxicity. In addition, 
high molecular weight PLL-DNA complexes have the tendency to aggregate in biological 
systems leading to low gene expression.
66
 To overcome such drawbacks, PLL was chemically 
modified by poly(ethylene glycol) reducing the formation of aggregates.
67,68
 Other types of 
cationic polymers that have been utilized in gene therapy include polymethacrylate, 
carbohydrate-base polymers and linear poly(amino-amine), PAA, among others.
56,61,63
 
A special class of polycationic non-viral vector is the dendrimer-based vectors.
69,70
 
Polyamidoamine (PAMAM) and phosphorus-containing dendrimers have been investigated as 
gene transfer vectors.
69,71,72
 Dendrimers bind to the DNA electrostatically through the terminal 
amino groups and form DNA-dendrimer complexes. The DNA- dendrimer polyplexes exhibit 
good endosomal escape due to the availability of the internal tertiary amines groups that facilitate 
the release of the DNA after cellular internalization via the proton sponge mechanism.
73
 The new 
generations of dendrimers provide structural flexibility due to hydrolytic degradation in aqueous 
medium.
74
 This phenomenon triggered the swelling of the endosome and facilitated the release of 
DNA resulting in 50-fold improved transfection, compared to previous generations.
74
 Other 
types of dendrimers have also been developed for gene therapy, including poly(propylenimine), 
poly(L-lysine) and carbosilane dendrimers.
56,61
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Lipid-based gene delivery 
The introduction of a cationic lipid as DNA carrier was first reported in 1987 by Felgner 
and colleagues when they used liposomes formed from cationic lipid N-[1-(2,3-
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and helper lipid 1,2-di-(9Z-
octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) as a transfection agent.
75
 This work 
has pioneered the use of cationic lipids in gene therapy leading to the commercial production of 
the first lipid based transfection agents (Lipofectin®).
76
 The basic structure of all cationic lipids 
consists of polar head group(s) attached by linker (spacer) chain to hydrophobic groups (which 
may be single or double fatty acids, alkyl or cholesterol moieties).
77
 At a specific concentration 
(i.e., critical micelle concentration, CMC), these agents self-assemble to form supramolecular 
structures, such as liposomes, micelles and cubic- or rod- like structures. The assembly is an 
important step in DNA binding and compaction process.
78
 A large variety of compounds can be 
synthesized by chemically modifying the hydrophobic, hydrophilic as well as the spacer regions. 
Therefore, cationic lipids can be produced with different physiochemical properties and uses. 
DNA delivery efficiency of cationic lipids is attributed to the following factors: 1) the ability of 
cationic lipids to condense and encapsulate DNA forming a supramolecular complex known as a 
"lipoplex" through the electrostatic interaction of the polar head group of the lipid and the 
negatively charged phosphate groups of the nucleic acid, 2) cationic lipid/DNA complexes 
(lipoplexes) can be formulated to have an overall net positive charge that allows the association 
of lipoplex with the negatively charged cell membrane promoting cellular uptake, and 3) the 
fusogenic property of cationic lipids as a function of the hydrophobic alkyl tails promotes the 
escape of the entrapped DNA to the nucleus.
57,79
 Based on these requirements, structural 
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manipulations with the basic components of cationic lipids have been applied aiming to improve 
transfection efficiency and reduce cytotoxicity.
77,80-82
   
The polar head group(s) of cationic lipids play a major role in DNA condensation and 
compaction through neutralization of the negatively charged DNA phosphate backbone 
facilitating the formation of the lipoplexes and cellular uptake. The charge ratio of cationic lipids 
to anionic phosphate groups of DNA (+/- ratio) is an important factor that determines the 
transfection efficiency of the cationic lipid/DNA lipoplexes, as well as the cytotoxicity of the 
system. Based on the chemical structure of the cationic head group(s), cationic lipids are 
classified into the three main categories: quaternary ammonium salt lipids, lipopolyamines
83-86
 
and amidinium/guanidinium salt lipids.
87-90
 
In the following section, I will discuss the quaternary ammonium salt lipids as this group 
of cationic lipids has shown the most promising transfection activity among other cationic lipid 
classes. Additionally, I will explore diquaternary ammonium gemini surfactants as a subgroup of 
cationic lipids, as it represents the group of compounds I used in my research work.  
  
14 
 
Quaternary ammonium salt lipids 
Quaternary ammonium salt lipids are the oldest and the most extensively developed 
cationic lipids group used for gene delivery which was introduced by Felgner et al, (i.e. 
DOTMA).
75
 DOTMA co-formulated with helper lipid DOPE (commercially known as 
Lipofectin
TM
) was the gold standard for developing and designing cationic lipids in this group 
[Figure 1.2]. The replacement of the di-ether linkage in DOTMA with a more biodegradable di-
ether linker produced 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) which showed a 
reduction in the cytotoxicity of the parent compound.
91
 Several other compounds were 
synthesized based on the structure of DOTMA and DOTAP in order to investigate the effect of 
structural modification of the head group and the alkyl tail regions on the physiochemical 
properties and the transfection efficiency.
91-94
  One of the most efficient compounds that was 
found in this group is 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide 
(DMRIE) which showed superior activity compared to DOTAP and its analogs in different 
transfection conditions; evaluated in vitro on COS-7 cells and pDNA encoding RSV-β-
galactosidase. DOPE was used as helper lipid with all tested cationic lipids.
92
  
(a) DOTMA75 
 
(b) DOPE 
 
Figure 1.2: The chemical structure of (a) DOTMA, the first quaternary ammonium salt lipid used 
for gene delivery. (b) neutral lipid DOPE  
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Banerjee and co-workers synthesized a new class of non-glycerol quaternary ammonium 
cationic lipids where the quaternary nitrogen atom of the head group is directly linked to a 16-
carbon atom hexadecyl tail(s) [Figure 1.3].
95
 Additionally, two hydroxyethyl groups were 
attached to the polar head group aiming to enhance the cellular uptake of the lipoplexes. Two 
compounds were synthesized: N-n-hexadecyl-N,N-dihydroxyethylammonium bromide 
(HDEAB) bearing a single side chain, and N,N-di-n-hexadecyl-N,N-dihydroxyethylammonium 
bromide (DHDEAB) with a di-alkyl tail region.
95
 HDEAB co-formulated with cholesterol 
showed to be the least efficient compared to dioctadecyldimethylammonium bromide (DDAB) 
(the parent compound without the hydroxyethyl groups in the polar head), DHDEAB, and 
Lipofectamine
TM
. This observation suggested that the double chain alkyl tail is an essential 
element in lipoplex formation.
95
 The transfection efficiency of DHDEAB, co-formulated with 
cholesterol on a 1:1 molar ratio, was assessed in vitro in green monkey fibroblasts cell lines 
(COS-1cells). DHDEAB showed a 2-3-fold increase in transfection efficiency compared to 
(DDAB).
95
 This finding proved that the introduction of a hydroxyethyl moiety to the head group 
improved the transfection activity of the lipoplexes. The enhancement of the activity was 
partially due to the hydrogen-bonding interactions between the lipid head groups and the cell 
membrane. Based on these outcomes, the same research group developed four more compounds 
by attaching simple sugars (arabinose and xylose) to the polar head group as multiple hydroxyl 
moieties.
96
 All four cationic lipids demonstrated high levels of in vitro gene expression with a 
superior performance for 1-deoxy-1-[dihexadecyl(methyl)-ammonio]-D-xylitol, which showed a 
doubling in transfection activity compared to the parent compound DHDEAB.
96
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Figure 1.3: The chemical structure of quaternary ammonium salt lipids, without spacer region 
(non-glycerol) , one/two alkyl chain tail(s)  
The first introduction of cationic surfactants as a transfection agent was in 1989 by 
Pinnaduwage et al,  when they synthesized a group of quaternary ammonium detergents 
(dodecyl, tetradecyl-, or cetyl-trimethylammonium bromide) for DNA delivery.
97
 However, 
these compounds showed lower gene expression activity compared to Lipofectin® and caused 
relatively high cellular toxicity even when these surfactants were used in combination with 
DOPE.
97
 Another method that has been employed to produce quaternary ammonium cationic 
lipids that can be used in DNA delivery, is by mimicking the single head, double tailed lipids, 
through joining two single-tailed quaternary ammonium surfactants together via a spacer moiety 
producing diquaternary ammonium gemini surfactants.
98-103
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Diquaternary ammonium gemini surfactants  
Gemini surfactants [Figure 1.1] are dimeric surfactants with a characteristically low 
surface tension making them suitable for use in material sciences as solubilizing and emulsifying 
agents.
104
 In recent years, gemini surfactants have been investigated intensively as non-viral gene 
delivery carriers for both in vitro and in vivo transfection due their ability to compact DNA to 
form nano-sized lipoplexes, versatility in chemical structure, relatively low toxicity and 
inexpensive production.
102,103
 Similarly to other cationic lipids, the transfection activity of 
gemini surfactants is influenced by the chemical nature of the head groups, length and saturation 
of the hydrophobic chains, and the chemical composition and length of the spacer.   
In an effort to develop effective and safe gene delivery vectors, a series of diquaternary 
ammonium gemini surfactants were developed in our laboratory as non-viral gene delivery 
agents [Table 1.1].
105-109
 These gemini surfactants were classified into three generations, based 
on modification within the molecular structure. The first generation gemini surfactants have the 
simplest structure which consists of two hydrophobic alkyl tail regions (m) attached to 
diquaternary ammonium head groups separated from each other through an alkyl spacer region 
(s) (i.e., structure of m-s-m).
105,110
 A variety of gemini surfactants within this generation have 
been produced by changing the length of the spacer region and the alkyl chain tails. The gemini 
surfactants were able to compact pDNA forming nanoparticles with a particle size below 200 nm 
which is a requirement for successful endocytosis of the gemini surfactant/DNA complex.
110
 In 
vivo transfection studies of these gemini surfactants showed the transfection activity to be 
dependent on the spacer length with the most efficient transfection observed with 12-3-12 and 
16-3-16 gemini surfactants.
105
 The cytotoxicity profile was considerably lower in comparison 
with the commercial Lipofectamine Plus gene delivery agent.
105
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Based on the above mentioned findings, a new generation (second generation) of gemini 
surfactants has been synthesized by inserting in the alkyl spacer region, nitrogen substituted 
moieties (e.g., N or NH).106,111 The introduction of such functional groups created pH-
sensitive gemini surfactants that facilitated fusion and endosomal escape of DNA from the 
transfection complex after cellular uptake.
106
 A transfection study of nanoparticles constructed 
from the 12-7NH-12  gemini surfactant, pDNA and the helper lipid (DOPE) showed a 9-fold 
increase in transfection compared to complexes formed with 12-2-12 gemini surfactant.
106
 In an 
attempt to enhance the efficiency of gemini surfactants, chemical derivatization of the 12-7NH-
12 compound was performed through the coupling of various biocompatible amino acids 
moieties to the spacer region producing the third generation gemini surfactants.
108,109
 
Transfection efficiency of these novel amino acid substituted gemini surfactants was assessed in 
different epithelial cell lines.
109
 The amino acid-substituted gemini surfactants (specifically, 12-
7N(Glycine)-12) transfected all cell lines with a higher level of gene expression compared to the 
unsubstituted compound.
109
 More recently, the cellular toxicity of these novel gemini surfactants 
has been evaluated revealing no change in the toxicity profile compared to 12-7NH-12, but a 
significant improvement when compared to Lipofectamine® Plus.
114
  
More gemini surfactants were produced by the introduction of complexed moieties to polar 
head, spacer and tail regions. Cationic gemini surfactants with branched head groups, (e.g., 
polylysine-based gemini surfactants) showed considerable gene transfer activity.
112
 The ability of 
a sugar based gemini surfactant-DNA complex to undergo a morphological change from lamellar 
to inverted hexagonal structures in low pH medium promoted the endosomal escape of the DNA, 
resulting in efficient transfection.
113,114
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1. First generation 
gemini surfactant 
(m-s-m) 
105,110
 
 
 
 
 
 
2. Second 
generation gemini 
surfactant (amine 
substituted spacer) 
106,111
  
 
 
 
 
 
3. Third 
generation gemini 
surfactant (amino 
acid substituted 
spacer) 
108,109
 
N
+
N
+
N
CH3
CH3
CH3
CH3
CH3
CH3
R
R=  Glycine : 12-7N(Gly)-12
 Lysine: 12-7N(Lys)-12
 Histidine: 12-7N(His)-12
 Glycyl-Lysine: 12-7N(Gly-Lys-12
 Lysyl-Lysine: 12-7N(Lys-Lys)-12
 Glycyl-Glycine: 12-7N(Gly-Gly)-12
 
Table 1.1: The general structure of three classes of diquaternary ammonium gemini surfactant 
based on chemical modifications.  
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Cationic lipid gene delivery vectors in clinical trials  
The high level of transfection and low toxicity achieved in in vivo studies using lipoplexes 
for gene delivery have prompted the use of these unique systems in human clinical trials.  By the 
end of 2011, lipoplex-based gene therapy has been employed in 110 clinical trials around the 
world (6 % of all approved trials) with a majority in phase I or II trials.
5
 Cancer and cystic 
fibrosis are the primary interest areas in the development of lipofection agents. DC-Chol (3β-[N-
(N',N'-dimethylaminoethane)-carbamoyl]cholesterol) was the first cationic lipid that had been 
approved for human clinical trial for gene therapy of a lung disease, cystic fibrosis.
115
 This study 
illustrated the concept and safety of using cationic lipid-based gene delivery. DC-Chol in 
combination with DOPE lipoplexes also were evaluated in several other clinical trials for breast 
and ovarian cancer, melanoma, head and neck cancer.
116-118
 DMRIE was another cationic lipid 
that has been evaluated in several clinical trials for managing a wide range of cancers, namely 
melanoma, prostate cancer, renal cell carcinoma, head and neck cancer using different pDNA.
119-
125
 Recently, a large randomized controlled phase 3 clinical trial was completed that compared 
the efficacy of pDNA/DMRIE/DOPE lipoplexes encoding HLA-B7 and β-2 microglobulin genes 
versus dacarbazine (antineoplastic chemotherapy drug) in patients with stage III or stage IV 
melanoma.
126
 The full results of the study have not yet been published. 
With all of the success in lipoplex-based gene delivery, two major difficulties are still 
limiting their broad clinical applications; the low transfection efficiency compared to viral-based 
vectors and the instability of lipid-based gene delivery vectors in conventional pharmaceutical 
dosage forms.
127,128
 As discussed in a previous section, large numbers of cationic lipids have 
been synthesized and modified to overcome the low transfection activity, with little attention to 
their stability from a pharmaceutical perspective. The transfection efficiency of lipoplexes 
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depends on the integrity of the delivery system components and their related physiochemical 
properties (particle size and surface charge ratio).
129-131
 Stability of non-viral gene delivery 
systems is complicated as it involves 1) the conformational and chemical stability of genetic 
material, 2) the physical stability of DNA-carrier complexes and 3) the chemical stability of the 
carrier.
132-134
 
In the following section I will discuss the factors influencing the stability of a cationic 
lipid-based gene delivery system in pharmaceutical formulations and the techniques used to 
optimize shelf-life stability of such systems.   
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1.2.3. Stability of cationic lipid-based gene delivery systems in pharmaceutical formulations  
The chemical and physical stability of pharmaceutical formulations during manufacturing, 
shipping and storing is of critical importance to produce marketable therapeutic products. On one 
hand, for conventional pharmaceutical formulations, the main concern is the chemical stability of 
the active ingredient. The long-term stability can be assessed by monitoring the biological 
activity and degradation by-products using different analytical techniques.
135
 On the other hand, 
the stability of multi-component drug delivery systems such as lipoplex-based vectors is a more 
complicated issue. The transfection efficiency of lipoplexes depends on both the chemical 
integrity of the components of the delivery system and conservation of their related 
physiochemical properties (e.g., particle size and surface charge ratio).
129-131
 The stability of 
DNA-lipoplexes involves: 1) the chemical and conformational stability of pDNA, 2) the 
chemical stability of the carrier, and 3) the physical stability of the complexes.
132-134
 
Plasmid DNA  is an extra-chromosomal, circular double stranded DNA that encodes for 
protein of interest.
136
 The use of pDNA, as a therapeutic agent, has increased in the last few 
decades, especially in gene therapy research and DNA vaccination.
137,138
 pDNA exists in three 
different forms: supercoiled, open circular and linear. It has been established that the supercoiled 
form has the highest gene expression activity compared to the other forms.
139
 However, like 
other genetic materials; pDNA is sensitive to environmental conditions and undergoes several 
degradation pathways. In aqueous medium, DNA is subjected to two degradation processes: 1) 
depurination/β-elimination, and 2) free radical oxidation leading to strand breakage.140 The 
depurination/β-elimination process is the rate limiting degradation process and is catalyzed in 
acidic environment resulting in the formation of open-circular DNA. The depurinated DNA is 
consequently degraded into linear DNA if stored in a basic pH  enviroment.
140
 From this 
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perspective, two issues should be taken into consideration when incorporating DNA in 
pharmaceutical formulations: the pH profile of the final product and the presence of any free 
radicals such as reactive oxygen species (ROS) and trace metals. Evans et al evaluated the 
degradation pathways for pDNA via accelerated stability studies using different buffer systems, 
metal ion chelators and free ion scavengers.
141
 They found that depurination/β-elimination was 
the rate limiting process if the plasmid was stored in demetalated buffer systems with EDTA and 
ethanol. A minimum conversion of the supercoiled DNA to open circular and linear forms was 
observed at pH values of 7.5 – 9.141 While the chemical structure of DNA is well established, the 
stability of DNA in the different pharmaceutical formulations still requires more investigation. 
As mentioned earlier, one of the major disadvantages of the lipoplex-based vectors is their 
poor physical stability in aqueous medium. This physical instability results from the inability to 
maintain optimal physiochemical properties of such systems (particle size and positive surface 
charge). In aqueous formulations, positively charged lipoplex particles tend to form micro-sized 
aggregates as a function of random collisions, Brownian motion, and gravity forces.
128,142-144
 
Consequently, disassociation of DNA from the lipoplexes may occur leading to the loss of the 
biological activity.
143
 To evade such a stability issue, most of the studies that employed cationic 
lipids as non-viral carrier for gene delivery used freshly prepared lipoplexes for the transfection 
studies. Three different formulation strategies have been investigated to optimize the 
physiochemical stability of cationic lipid/DNA complexes: 1) liquid formulations, 2) frozen 
formulations, and 3) dehydrated formulations.
128
  
To minimize the aggregation of lipoplexes in liquid formulations, different methods have 
been explored.
145-147
 For instance, Hong et al employed two approaches to stabilize cationic 
lipid-DNA complexes in aqueous media.
145
 In the first approach, a small amount of 
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poly(ethylene glycol)-phospholipid conjugate was incorporated to the DNA-lipid complexes to 
provide a steric stabilization to prevent particle aggregation. The second approach involved the 
condensation of the DNA with polyamines (spermidine) before the complexation with the 
cationic lipid. Both approaches were successful in maintaining the original transfection activity 
levels up to two months when stored at 4 ˚C.145 However, almost all liquid formulations needed 
to be stored under special conditions (e.g., refrigeration) and only short term stability (3-8 
months) was achieved.
145-147
   
Freezing technique is a formulation strategy that has been investigated for producing 
lipoplexes with long term stability.
148-151
 However, freezing is a physical stress that can 
negatively impact the physical stability of the lipoplexes and cause damage to DNA 
structure.
148,152,153
 In addition, the requirement for maintaining the freezing condition during 
transportation and shipping increases the production cost. Considering the deficiencies of liquid 
and frozen formulations, more interest was focused on dehydrated formulations that showed the 
most promising shelf life stability.
154
  
Dehydrated formulations provide several advantages including long-term physical and 
chemical stability of the dried products that can be stored at room temperature. In addition, the 
dehydrated formulations are highly resistant to stress and agitation occurring during 
transportation. The most common dehydration technique that has been widely investigated in 
non-viral gene delivery DNA vectors is freeze-drying (lyophilization).
133,155-158
 However, 
lyophilization is a complicated process that includes many physical stresses. In the following 
section, I will discuss the use of lyophilization as a formulation technique for chemically-
mediated gene delivery with long term stability.   
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For clarity of the following section, four concepts related to the freeze-drying technique 
need to be defined: 
Glass transition temperature (Tg): temperature at which the amorphous material changes 
from a rigid glassy state to a liquid-like form, 
Glass transition temperature of frozen component (Tg'): the temperature at which the 
amorphous material is transformed into the rigid glassy state, 
Eutectic temperature (Teu): the critical temperature at which the water and dissolved 
solutes crystallize,  
Collapse temperature (Tc): the temperature at which the amorphous structure collapses. 
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1.2.4.  Freeze-drying in chemically mediated gene delivery systems   
Freeze-drying (lyophilization) is a widely employed technique for conferring long-term 
stability at ambient temperature to physically unstable bio-pharmaceuticals and liposomal drug 
delivery systems.
159
 In general, freeze-drying is a dehydration technique in which the liquid 
formulation  tranitions into the solid phase by freezing, then the frozen water is removed through 
sublimation under low pressure conditions.
160
 In addition to long-term stability, lyophilized 
products are easily handled and transported. Freeze-drying in the pharmaceutical industry was 
used primarily for the production of parenteral drugs and bio-products (e.g., vaccines, proteins, 
and peptides). Lyophilization has also been investigated for stabilizing non-viral gene delivery 
systems.
133,155-158
 Lyophilized non-viral delivery vectors showed promising results that can be 
utilized for the production of highly stable formulations with good manufacturing procedures.  
The standard freeze-drying protocol includes two major steps: a freezing step and a drying 
step. Both steps must be optimized to ensure long-term stability of the formulations.
160
 These 
two steps are considered physical stresses that have been reported to damage the components and 
the supramolecular structure of the non-viral vectors.
155,161
 In addition, lipid phase transition in 
lyophilized liposomal formulations during dehydration-rehydration has been reported.
155,162
 For 
the highest stability, the DNA-carrier complexes must retain the original physiochemical 
properties and complex morphology that govern the transfection activity during both steps of 
lyophilization protocol. The optimization of the freeze-drying protocol and the incorporation of 
certain stabilizers, known as cryo- or lyo-protectant agents, have been employed to improve the 
stability of the chemical carrier-based DNA formulations.
155,156
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In the following section I will discuss the major aspects that must be considered during 
each step of the freeze-drying of chemically mediated-DNA vectors, particularly lipoplex-based 
vectors. 
1.2.4.1.Freezing step  
In the freezing step, the liquid solution containing DNA-carrier complexes and other 
excipients is frozen to the solid state at a temperature below the freezing point of the sample. To 
obtain the desirable stable final product, several aspects should be considered in the freezing 
process: the components of the sample, the freezing rate and the use of cryoprotectant agents. 
Different methods of freezing have been employed to produce frozen formulations including 1) 
super-freezing by immersing the sample in liquid nitrogen, 2) placing the sample on precooled 
shelves (e.g., at -20, -40, -80 ˚C) or 3) placing the sample in a ramped cooling chamber.160,163 
During the freezing step, different solid phases are formed in the non-frozen portion depending 
on the components of the formulations: water ice crystals, crystalline solutes and amorphous 
phases. The increase in the concentration of the formulation component within the non-frozen 
part is known as freeze-concentrate or cryo-concentration effect.
160,163
  
Two parameters must be monitored during the freezing cycle: glass transition temperature 
(Tg') for substances forming amorphous phase in frozen state (e.g., sugars) and eutectic 
temperature (Teu) for substances forming crystalline phase (e.g., salts). The glass transition is a 
reversible transition of amorphous material in the liquid from solid-like structure (glassy 
structure) to fluid-like structure (rubbery or viscous structure).
164
 During the freezing cycle, the 
temperature at which the amorphous material is transferred into the rigid glassy state is known as 
the glass transition temperature (Tg'). Generally, the presence of salts in the chemically mediated 
gene delivery systems can cause aggregation of the DNA, thus buffer salts are rarely used to 
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prepare such formulations. Therefore, during freeze-drying cationic carrier-DNA complexes, the 
Tg' is considered an essential property that has been found to influence the stability of the system 
during freezing. The glass transition temperature is dependent on the chemical composition and 
concentration of the formulation, and it can be measured via thermoanalytical methods (e.g, 
differential scanning calorimetry DSC).
164,165
  
The rate of the freezing can affect significantly the biological activity of non-viral DNA 
complexes.
148,153
 The phase separation and freeze-concentrate effects have been reported to cause 
aggregation of colloidal systems via several mechanisms: electrostatic interaction, liposomal 
fusion and particle collision.
155
 In addition, the formation of ice crystals in the formulation have 
been reported to damage the integrity of the liposomal and DNA-carrier complexes.
148,163
 A 
freeze-thaw study can be performed to assess the effect of the freezing on the physiochemical 
properties and biological activity of such systems.  
In cationic based-DNA lipoplexes, significant alteration in the physiochemical properties 
and loss of gene transfection activity were reported after freeze-thaw studies in the absence of 
stabilizing agents.
148,166,167
 For instance, Anchordoquy and co-workers found that transfection 
activity of cationic lipid-DNA complexes formed with three different cationic lipids (DMRIE, 
Lipofectamine and DOTAP:DOPE) showed significant reduction in in vitro transfection activity 
upon slow freezing-thawing cycle when no stabilizing agent (sucrose) was used.
148
 The reduction 
in the transfection activity upon freezing was associated with significant increase in particle size. 
On the other hand, when super-freezing was used (by submerging sample vials in liquid 
nitrogen) and then the formulations were thawed at room temperature, insignificant loss of 
transfection activity of the lipoplexes was reported.
148
 The loss of activity and the original 
physiochemical properties during the slow freezing cycle, in comparison to super-freezing, can 
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be rationalized by two explanations. Firstly, super-freezing generally results in the formation of 
fine water crystals which have been found to have little effect on the liposomal bilayer 
systems.
148,168,169
 Conversely, large ice crystals are formed when the slow-freezing method is 
used which has harmful effects on the supramolecular structures.
148,168,169
 The second 
explanation for the alteration of the properties of the lipoplexes is liposomal fusion. During the 
slow-freezing cycle, particle collision can be augmented in the non-freezing part of the sample 
encouraging liposomal fusion and particle aggregation and this effect develops as cryo-
concentration increases.
148,155
 It can be eliminated in the super-freezing cycle by reducing the 
time required for diffusion. Similar observations were reported during the freezing of polymer-
based DNA polyplexes and solid lipid-DNA vectors.
158,170
 Therefore, the use of freezing 
protectant agents (known as cryoprotectants) is essential to stabilize the DNA-complexes and 
retain the physiochemical properties of the systems and the transfection activity.  
Several classes of excipients have been used for the preparation of lyophilized 
formulations as cryoprotectants: monosaccharaides (glucose), disaccharides (sucrose, trehalose), 
oligosaccharides (inulin), polymers (dextran, povidone, polyethylene glycol) and sugar alcohols 
(mannitol, glycerol, sorbitol).
150,171-175
 Different mechanisms have been proposed to explain the 
protective action of the cryoprotectants in colloidal systems and proteins: preferential 
exclusion
176,177
, vitrification
178,179
, and particle isolation hypothesis.
166
  
The preferential exclusion hypothesis was proposed to explain the protective effect of 
sugars on the macromolecular structures of proteins during the freezing process. Based on this 
hypothesis, the sugar molecules do not access the surface of the protein in the formulation, 
hence, preferentially are excluded from the surface and form a layer around the protein. During 
the freezing, these sugar layers protect the protein structure and prevent protein unfolding. The 
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applicability of preferential exclusion hypothesis as a protective mechanism for lipid-based DNA 
complexes is debatable since it assumes phase separation between the protein and the sugar layer 
which is not the case in liposomal based structure.
163
 In addition, previous studies investigating 
the lyophilization of chemically mediated non-viral vectors reported that a high concentration of 
sugars is required to stabilize the vectors during the freezing.
148,166
  
The vitrification (glass formation) hypothesis proposed that when the sample containing 
biologically active molecules and cryoprotectant agent is cooled to a temperature below the glass 
transition temperature (Tg'), the active molecules are entrapped in the cryoprotectant amorphous 
glass matrix, which inhibits the kinetic activity of the complexes.
178,179
 The formation of a 
cryoprotectant glassy matrix, an effect of cryo-concentration, strictly immobilizes the drug 
complexes and prevents the particles from aggregating and fusion of the drug from the 
complexes. Furthermore, the amorphous glass matrix of the cryoprotectant agent minimizes the 
damage caused by the formation of ice crystals. The vitrification hypothesis is widely applied as 
a protective mechanism when biological drug molecules or liposomal drug delivery systems are 
lyophilized.
163,178,180-182
 Several studies of lyophilized lipoplexes and polyplexes have explained 
the protective action of cryoprotectant sugars by the glass formation theory.
183,184
 However, the 
vitrification hypothesis is not applicable to the cryoprotectant agents which do not form glassy 
matrices (e.g., mannitol, dextran).  Allison et al. showed that the particle size and transfection 
activity of DMRIE-cholesterol:DNA lipoplexes was preserved after freezing the formulation 
with glucose as cryoprotectant agent at - 40 ˚C (Tg' for glucose is approximately - 43 ˚C).
166
 In 
brief, the glass formation hypothesis is not the only protective mechanism in case of lyophilized 
lipoplexes and some sugars are able to preserve the essential physiochemical properties of 
lyophilized lipoplexes even if the formulation is frozen above the sugar’s Tg'.  
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The particle isolation hypothesis proposes that the full cryoprotection effect can be 
achieved only at a crucial excipient:DNA weight ratio.
166
 At this ratio and during the freezing, 
the increase in the concentration of cryoprotectant agent and other suspended particles in the 
unfrozen fraction of the formulation (i.e., freeze-concentration effect) leads to the isolation of 
DNA:carrier complexes in the cryoprotectant viscous matrix and prevents the diffusion of 
complexes and aggregation of particles. Thus, the vitrification of the stabilizing agent is not a 
requirement to achieve the cryoprotectant action.
155,166,185
  
As mentioned earlier, the rate of freezing controls the size of the ice crystals formed in the 
frozen formulations. Super-cooling resulted in the formation of small ice crystals with small 
pores which can increase the time of drying and result in dried cake with high moisture content. 
On the other hand, when the formulation freezes at a slow rate large ice crystals are formed with 
larger pores accelerating the drying process, hence, this could augment particle aggregation.
155,163
  
1.2.4.2. Drying Step  
After the freezing step, the formulation is separated into two phases: ice crystals and the 
fraction of water containing the freeze-concentrated components.
155
 The drying process includes 
two steps: the primary drying (sublimation) and the secondary drying (water desorption). In the 
primary drying cycle, more that 90% of the water content of the frozen formulation is removed 
by sublimation of water-ice crystals.
160
 The sublimation process starts by reducing the pressure 
in the drying chamber to the level below the triple point of the formulation. The shelf 
temperature of the freeze-drier increases with time to drive the sublimation process by 
transferring heat to the vials. Several issues must be considered during the primary drying cycle 
to achieve stable and elegant dried product. The removal of ice crystals begins at the top of the 
frozen formulation by removing the ice and forming dried layers of the formulation. As a result, 
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the shape and dimensions of samples vials and depth of filling  affect the time required for 
drying and the appearance of the lyophilized cake.
160
 The temperature of the drying chamber, 
during the primary drying cycle, should be maintained below a critical temperature, known as the 
collapse temperature (Tc). The Tc of a product is almost similar to its Tg'. However, it has been 
reported that by reducing the water content from the frozen formulation during the drying 
process, Tc is increased.
186
 The increase in sample temperature during the primary drying above 
the Tc causes the collapse of the porous matrix. As a result, the collapsed structure hinders the 
removal of moisture content by sublimation which can increase the required time for drying and 
alters the appearance of the final dried product. Therefore, monitoring the Tc and Tg' during the 
primary during cycle is a key factor for successful lyophilization.  
Once all the ice crystals (free water) are removed from the frozen samples by sublimation, 
the secondary drying cycle takes place. The purpose of the second drying step (water desorption) 
is to remove bound water from the freeze-concentrated fraction, to increase the glass transition 
temperature Tg of the dried product and to achieve long shelf-life. By the end of this step, the 
moisture content of the dried product is reduced to a level below 2%.
160
 The secondary drying 
cycle is accomplished by increasing the shelf temperature providing heat energy necessary to 
release the bound water. At this stage, since all the ice crystals are already removed, the product 
temperature can exceed the (Tc), but not (Tg). However, caution should be taken to avoid 
excessive heating that may cause product degradation.  
As discussed previously, the drying process could cause a physical stress to the DNA-
carrier complexes leading to changes in their physiochemical properties and loss of transfection 
activity. In fact, the removal of the hydration shell from non-viral vector complexes could cause 
more damage to the supramolecular morphology than the freezing step.
155,156
 Dehydration-
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rehydration studies are routinely conducted to evaluate the influence of the drying process on the 
cationic carrier-DNA vectors.
158,183,187
 The use of lyoprotectants, which are usually polyhydroxy 
compounds such as sugars, is essential to preserve the structure of the biologically active 
compounds and liposomal structure during the dehydration.
159,163,177
 In the freeze-drying 
processes of protein- and liposome-based structures, lyoprotection by polyhydroxy compounds is 
explained by two major hypotheses: water replacement hypothesis and vitrification 
hypothesis.
163,176
  
The water replacement hypothesis proposes that lyoprotectant sugars are able to form 
hydrogen bonds with the protein and with the lipid phase of liposomes, replacing the water 
hydration shell, while stabilizing the structure of protein and liposomal membrane during the 
dehydration process.
188,189
 The water replacement hypothesis has been used to explain the 
protective effect of sugars (especially disaccharide sugars) and the changes in the 
physiochemical properties of lyophilized cationic non-viral DNA complexes.
156-158,183
  Several 
studies demonstrated that the entrapment of  liposomal structures in the freeze-concentrated glass 
matrix of sugar during freezing  (vitrification hypothesis) could prevent the phase transition of 
lipid resulting from the dehydration.
163
 In addition to the aforementioned hypothesis, the particle 
isolation theory has recently emerged in the field of lyophilization of non-viral vectors. It has 
been utilized to explain the lyoprotective effect of agents that crystallized during freezing 
without forming hydrogen bonds with the cationic carrier such as dextran and polyethylene 
glycol polymer (PEG).
155,157
  
However, the protective effect of lyoprotectants during lyophilization of multi-component 
systems such as cationic non-viral vectors is still not widely explored and more investigations are 
required to fully understand the effect of dehydration on the components of these systems.   
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1.2.4.3. Stability of lyophilized lipoplex vectors   
Optimization of the freeze-drying parameters can significantly improve the stability of 
lipoplex-based vectors. In addition, successful lyophilization of lipoplexes leads to reproducible 
production of gene delivery systems that can be controlled and monitored under good 
manufacturing practice. The stability of lyophilized lipoplexes during storage was evaluated in 
numerous studies using different cationic lipids and excipients.
155,156,184,187,190,191
 Several factors 
influence the stability of lyophilized lipoplexes: formulation composition, storage temperature, 
moisture content in the dried cake, and the presence of reactive oxygen species (ROS).
134,192,193
 
Li  et al, reported that the physical properties and transfection activity of lyophilized cationic 
lipid-protamine-DNA (LPD) complexes (formulated using DOTAP/cholesterol and protamine 
liposomes in 10% sucrose) were not significantly altered when stored at room temperature for 8 
weeks.
194
 Similarly, Clement et al proposed a continuous-mixing followed by lyophilization 
technique for large-scale production of lipoplexes with long shelf-stability.
190
 Following this 
technique, pDNA:DC-Chol/DOPE lipoplexes were able to maintain the original size and 
biological activity up to 18 months when stored at 4-8 ˚C.190    
The most extensive stability evaluation for lyophilized lipoplexes was performed by 
Molina and co-workers.
184
 In this study, the long-term stability of lyophilized lipoplexes 
constructed from pDNA:DOTAP/DOPE using different stabilizing agents (glucose, sucrose or 
trehalose) was evaluated. Lyophilized formulations were stored for two years at five storage 
temperatures -20, 4, 22, 40 and 60 ˚C. The physiochemical properties (particle size and zeta 
potential), DNA-lipid interaction (ethidium bromide accessibility), pDNA supercoiled content, 
moisture content and in vitro transfection activity of lyophilized formulations were analyzed at 
multiple sampling points. Additionally, the level of ROS was assessed in the lyophilized cake. 
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The results from the stability study showed progressive decrease in transfection activity at all 
storage conditions, including samples stored at – 20 ˚C.184  The reduction in transfection activity 
was attributed to the continuing reduction of supercoiled content of pDNA and the changes in the 
conformational state of the lipoplexes, particularly when samples were stored at high 
temperatures (above 22 ˚C). The loss of transfection activity for samples stored at – 20 ˚C and 4 
˚C was partially due to the oxidative stress resulting from the formation of ROS in dried cake.184 
In fact, the same research group investigated the effect of ROS on the stability of individual 
components of the lyophilized lipoplexes (e.g., lipid, pDNA, and sugar).
133,134
 The results 
suggested that ROS caused the degradation of the lyophilized lipid (DOTAP-DOPE) and had a 
less damaging effect on the free lyophilized pDNA. This damaging effect can be minimized by 
the incorporation of antioxidant agents (e.g., α-tocopherol) or metal chelator agents such as 
diethylenetriaminepentaacetic acid (DTPA) and by optimizing the drying process to reduce the 
moisture content in dried cake.
133,134
  
To date, most of the studies that employed lyophilization techniques in cationic lipid 
based-vectors utilized commercially available cationic lipids (such as DOTAP, DC-Chol, 
DMRIE) which bear one singly-charged cationic group. In addition, no work monitored the 
degradation of the lipid phase component (cationic lipid or neutral lipid). It is an essential 
requirement for all drug authorities around the world to examine the chemical stability of all 
components in drug formulations and to identify potential degradation by-products.
195,196
 
Different analytical techniques can be utilized to characterize and to quantify the degradation by-
products of pharmaceutical formulations during stability studies. Mass spectrometry is one of 
these techniques that shows a great ability in pharmaceutical analysis.  In the following section, I 
will briefly discuss the applications of mass spectrometry in drug discovery and development.   
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1.2.5. Mass spectrometry in drug discovery and development   
In the last three decades, there has been a significant development in the capabilities of 
mass spectrometry (MS) and its use as an analytical tool. Major developments in soft ionization 
techniques and high resolution mass analyzers have made MS a powerful technique in chemical 
analyses.
197
 Unlike other usual physiochemical analytical techniques (namely, UV, IR and 
NMR), MS provides several advantages including, high-throughput analysis, high sensitivity and 
selectivity, and the capability of coupling with chromatographic techniques.
198-201
 MS is an 
excellent tool to distinguish between different molecules with small variations in their molecular 
masses, especially when used in conjugation with a chromatographic technique.  
Before the invention of atmospheric pressure ionization (API) sources, the coupling of MS 
to liquid chromatography (LC) was a very difficult and complicated process. The first interface 
was the moving belt interface, using electron impact (EI) and chemical ionization (CI).
202
 The 
major shortcomings of the moving belt interface were that the analyte had to be thermostable and 
the cleaning of the belt was a difficult task. Other ionization methods have subsequently been 
developed including: thermospray
203
, continuous flow fast atom bombardment (CF-FAB)
204
 and 
particle beam interface.
205
 The introduction of API-based ionization sources allowed for efficient 
combination of MS and liquid chromatography. The advantage of API sources, when coupled 
with LC, is that the high vacuum in MS is not interrupted. This is because the analyte ionizes 
outside the spectrometer at atmospheric pressure and only the resulting ions are introduced into 
the instrument. In addition, API-based sources are considered a ‟soft” ionization technique, in 
comparison to old interfaces, that can be used for thermolabile molecules without degradation. 
Currently, electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) 
are the most widely used ionization methods in pharmaceutical analysis 
206
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Taking advantage of the rapid improvements of MS instrumentations and hyphenated MS 
technologies (e.g. LC-MS), MS has become widely utilized in qualitative and quantitative 
analyses in the drug development processes. Several MS-based strategies have been developed to 
accelerate the drug discovery and development processes. In fact, MS is broadly used in 
numerous pharmaceutical analyses, including high-throughput screening
207,208
, studies of drug 
metabolites 
209,210
, pharmacokinetic studies
200,211
, and in the identification of pharmaceutical 
impurities and degradation products.
212-214
 
Mass spectrometry in high-throughput screening of drug molecules  
Mass spectrometric techniques are routinely utilized for high-throughput screening of 
bioactive compounds for qualitative and quantitative analyses with high accuracy and 
precision.
215-218
 For example, ESI-quadrupole time-of-flight tandem mass spectrometric (ESI-
Qq-ToF MS/MS) analysis determined the exact molecular structure of Lipid A moieties isolated 
from mutant and wild-type Aeromonas salmonicida lipopolysaccharide, that has been evaluated 
for therapeutic activity in immune disease and as a potential anticancer agent.
217
 Similarly, the 
use of ESI multiple-stage tandem mass spectrometry (ESI-MS
n
) to analyze saponins, naturally 
occurring glycosides with a variety of biological activities (e.g., antimicrobial and anti-
inflammatory), allowed for structural differentiation between several types of saponins.
218
 
Subsequently, a liquid chromatography (LC)-MS/MS method was also developed for quick and 
precise quantification of different saponins from plant extract.
218,219
  
Mass spectrometry in pharmacokinetic and metabolomics studies  
Qualitative and quantitative determination of drug metabolites and drug pharmacokinetic 
studies are another area in the drug development process where MS and hyphenated MS 
techniques are employed extensively.
220,221
 MS is capable of providing detailed structural 
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information for metabolites which usually have a similar chemical structure as the original drug. 
Different LC/MS methods have been described for the determination and the monitoring of drug 
metabolites in different human fluids and tissues.
222-227
 For instance, an HPLC-ESI-MS/MS 
method was developed to detect and identify the potential reactive metabolites of tamoxifen, an 
antiestrogen agent used in the treatment of breast cancer, in the plasma of breast cancer 
patients.
226,228
 The LC/MS analysis of human Hep G2 cell line extract, after incubation with 
tamoxifen, showed five metabolites in the positive ESI mode. These metabolites, in addition to 
three others, were observed in plasma samples obtained from a patient that had been treated with 
tamoxifen for a long period (more than 6 months).
226
 Tandem mass spectrometric (MS/MS) 
analysis of tamoxifen and its potential metabolites showed a common fragmentation pattern 
confirming the proposed structure of the metabolites and allowed for the identification of the 
metabolic pathway of tamoxifen.
228
 Similarly, Hodel et al described a LC-MS/MS method for 
monitoring the human plasma level of 14 different antimalarial agents and some of their active 
metabolites using ESI-triple quadrupole mass spectrometry.
227
 LC-MS/MS provides a simple, 
fast, sensitive and selective technique that can be used for pharmacokinetic studies of these drugs 
and to evaluate the treatment regime.  
Mass spectrometry in drug impurity profiling  
In addition to screening bio-active compounds and pharmacokinetic studies, MS 
techniques are widely utilized in drug impurity and degradation by-product profiling. In the 
pharmaceutical industry, profiling of unknown impurities, especially when present in excess of 
threshold limits, is very important for safety and to address shelf-stability concerns.
195,196
 During 
the synthesis of new drug substances, the identification of the chemical structure of the 
intermediate and by-product impurities can help researchers identify the source of these 
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impurities and, as a result, to avoid or at least minimize the production of these impurities by 
changing the reaction conditions. In addition, impurity profiling can be used as a “fingerprint” 
for the quality and level of consistency of the manufacturing process.
229
  MS is one of the most 
powerful tools in the analysis of drug impurities and degradation by-products that has been used 
as a qualitative and quantitative method.
230-236
 For instance, during the development of 
Caspofungin, a semi-synthetic antifungal drug, an impurity was observed under HPLC 
conditions at 0.1% level.
234
 Using triple quadrupole MS and ESI in positive ion mode, and the 
same HPLC mobile phase, four major peaks were observed in the full-scan spectrum; three peaks 
were attributed to the original drug molecules and a peak to the impurity. Using 
hydrogen/deuterium (H/D) exchange and the LC-MS method, the structure of the impurity was 
elucidated and confirmed; this helped the chemists to minimize the formation of this impurity by 
eliminating the oxidation source during the manufacturing process.
234
 Similar to drug impurity 
profiling, MS and MS-LC methods were developed to monitor and identify the degradation 
products of drugs during stability studies. Shah et al used multiple stage MS analysis (MS
n
) to 
establish the mass spectrometric fragmentation pathway of atorvastatin, a lipid-lowering 
medication.
235
 The proposed fragmentation pattern was utilized to study the degradation of the 
drug under controlled stress (e.g., hydrolysis, oxidation and photolysis). By utilizing liquid 
chromatography/time-of-flight mass spectrometric (LC/ToF-MS) analyses, the structure of six 
degradation by-products was identified.
235
 Thus, MS techniques provide a rapid and accurate tool 
to elucidate the structure of drug impurities and degradation products.    
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Chapter 2 
Rationale, hypothesis and objective 
In our research group, a series of cationic gemini surfactants were developed as chemical 
carriers for DNA delivery.
105,106,109
 Although, significant improvements in gene expression 
activity and enhancement in the cellular toxicity profile were achieved, the instability of the 
pDNA/gemini surfactant lipoplexes in aqueous formulation remained an issue. Lyophilization 
showed promising results to improve the physical stability of lipoplex-based vectors.
133,155-158
 
However, the lyophilization process must be optimized to avoid damages, caused by the freezing 
and dehydration steps, to the structure of lipoplex and to ensure long-term stability.
155,157
 
Therefore, development and optimization of analytical methods are essential to characterize and 
monitor the structure and various components of lipoplex vectors.  
In this study, I have focused on evaluating the ability of lyophilization to improve the 
stability of pDNA/gemini surfactant lipoplexes. In addition, I have investigated the influence of 
the lyophilization and storage conditions on the essential physiochemical properties of the 
lipoplexes and their in vitro transfection. This was achieved by developing different quantitative 
and qualitative methods. 
To achieve the overall goal of this study, I proposed two hypotheses each with their 
respective objectives.  
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2.1. Formulation strategies to optimize the physiochemical stability of gemini surfactant-
based lipoplexes   
2.1.1. Research hypothesis: 
Optimization of the formulation compositions and the lyophilization processes of the 
gemini surfactant/DNA lipoplexes will lead to long-term physiochemical stability of the 
pharmaceutical preparations while maintaining transfection efficiency. 
2.1.2. Objective:  
To develop quantitative and qualitative methods that will be used to evaluate the feasibility 
of lyophilization as a formulation technique for preparing gemini surfactant-based lipoplexes 
with long term stability.  
2.1.3. Specific objectives:  
To develop qualitative and quantitative analytical methods for: 
 Assessing the influence of different excipients and lyophilization strategies on the 
physiochemical properties and the transfection activity of the lipoplex formulations  
 Assessing the influence of storage conditions on the physiochemical properties and the 
transfection activity of the lyophilized lipoplex formulations 
  
42 
 
2.2. Mass spectrometric analysis of cationic gemini surfactant 
2.2.1. Research hypothesis: 
Tandem mass spectrometric (MS/MS) analysis of cationic diquaternary ammonium gemini 
surfactants is a suitable method for the assessment of the stability and the identification of 
possible degradation by-products of gemini surfactant-based DNA formulations 
2.2.2. Objective:  
To evaluate the suitability of mass spectrometric and tandem mass spectrometric (MS/MS) 
techniques in the identification and characterization of amino acid/di-peptide gemini surfactants. 
2.2.3. Specific objectives:   
 To confirm the molecular structure of amino acid/di-peptide substituted gemini 
surfactants using electrospray-Time-of-Flight mass spectrometer. 
 To establish a universal tandem mass spectrometric fragmentation pattern of the amino 
acid/di-peptide substituted gemini surfactants. 
 To establish a quantification method using MS techniques.  
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3.1. Abstract 
Purpose 
Clinical applications of cationic lipid/DNA lipoplexes are restricted by their low physical 
stability in aqueous formulations. In this work, we describe the effects of different cryoprotectant 
agents on the physiochemical properties (particle size and surface charge density) and in vitro 
transfection of gemini surfactant-based lipoplexes. Additionally, we investigated the ability of 
these agents to maintain the physical stability and biological activity of the lipoplexes during the 
freeze-drying cycle.  
Methods 
Plasmid DNA, diquaternary ammonium gemini surfactant and helper lipid DOPE were used to 
prepare [P/G/L] lipoplexes. A series of 35 formulations were prepared using different classes of 
cryoprotectant agent (sucrose, trehalose, lactose, polysorbate 80, PEG 1450, PEG 8000, glycerin, 
and their combinations) The influences of these agents on the physiochemical properties (particle 
size and zeta potential) were evaluated. Lipoplexes formulated with the cryoprotectant were 
subjected to lyophilization/rehydration evaluations. The appearance of the lyophilized cake and 
the clarity of the formulations after rehydration were evaluated. The lyophilized formulations 
were evaluated for transfection activity (ELISA) and cellular toxicity (MTT assay). The stability 
of the formulations was evaluated in a three-month stability study at two storage temperatures 
(25 ˚C and 40 ˚C).  
Results 
The physiochemical properties of gemini surfactant-based lipoplexes were altered based on the 
stabilizing agents used to prepare the lipoplexes. Disaccharide sugars sucrose and trehalose and 
their combination with glycerin provided the most efficient cryoprotectant effect based on the 
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ability to physically stabilize the lipoplexes during the lyophilization process. The transfection 
efficiency of most formulations was lost after lyophilization and rehydration. On the other hand, 
the transfection activity of lyophilized lipoplexes prepared in 10% trehalose significantly 
increased upon lyophilization.  
Conclusion 
A wide variety of excipients were evaluated as cryoprotective agents to enhance the physical 
stability of [P/G/L] lipoplexes during the freeze-drying cycle. Disaccharide sugars sucrose and 
trehalose were the most efficient cryoprotectant agents to maintain the physiochemical 
characteristics of [P/G/L] lipoplexes after lyophilization and rehydration. However, stabilizing 
the particle size and positive zeta potential was not sufficient to preserve the transfection activity 
during freeze-drying as the activity dropped significantly in most of the formulations upon 
lyophilization/rehydration cycle. Interestingly, the use of trehalose as a cryoprotectant caused a 
significant enhancement in gene expression after freeze drying. In this respect, optimization of 
the lyophilization process and the use of appropriate stabilizing agents could improve the long-
term stability of gemini surfactant-based lipoplexes.    
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3.2. Introduction 
Chemically mediated gene delivery systems have been proposed as a safe and versatile 
alternative to viral vectors for gene therapy.
1,2
 Among chemically mediated-vectors, cationic 
lipid based systems have demonstrated the highest gene expression activity with relatively low 
toxicity both in vivo and in vitro.
3,4
 The promising results have prompted the use of these unique 
systems in human clinical trials. By the end of 2011, lipoplex-based gene therapy have been 
employed in 110 clinical trials around the world (6 % of all approved trials) with a majority in 
phase I or II trials.
5
  
The basic structure of all cationic lipids consists of polar head group(s) attached by linker 
(spacer) chain to hydrophobic groups (which may be single or double fatty acids, alkyl or 
cholesterol moieties).
4
 The transfection efficiency of cationic lipids depends upon the following 
properties: 1) the ability of the cationic lipid to condense and encapsulate DNA by electrostatic 
interaction, forming a supramolecular complex known as a lipoplex with certain size and 
morphology, 2) cationic lipid/DNA lipoplexes must have an overall net positive charge that 
allows the association of the lipoplex with the negatively charged cell membrane promoting 
cellular uptake, and 3) the fusogenic property of cationic lipids as a function of the hydrophobic 
alkyl tails promotes the escape of the entrapped DNA to the nucleus.
6,7
 
One specific group of cationic lipids that has demonstrated efficient transfection activity 
is the gemini surfactant family.
8,9
 Gemini surfactants [Figure 3.1] are dimeric surfactants with 
characteristically low surface tension activity primarily used for material sciences.
10,11
 In recent 
years, gemini surfactants have been investigated extensively as non-viral gene delivery carriers 
for both in vitro and in vivo applications.
12-14
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Notwithstanding their successful applications as gene delivery systems, two major 
difficulties are still limiting their broad clinical use: 1) the low transfection efficiency compared 
to viral-based vectors and 2) the instability of lipid-based gene delivery vectors in aqueous 
pharmaceutical dosage forms.
15,16
 Extensive work has been conducted toward improving the 
transfection efficiency of cationic lipoplex-based vectors by modifying the chemical structure of 
the cationic lipid.
17-19
 However, little concern has been given to the physical and chemical 
stability from a pharmaceutical standpoint. The stability of a non-viral gene delivery system is 
complicated as it involves the physical stability of DNA-carrier complexes, conformational 
structure of the genetic material and the chemical stability of the carrier.
20-22
 
Lyophilization (freeze-drying) has been employed as a practical technique to produce 
non-viral vectors with long-term stability.
23-25
 However, the lyophilization process includes three 
stress steps that could destabilize the lipoplexes: freezing, drying (dehydration) and 
rehydration.
26
 The optimization of the freeze-drying protocol and incorporation of certain 
stabilizing agents, known as cryo- or lyo-protectant agents, have proven to improve the stability 
of cationic lipid-based DNA formulations.
26,27
 Different classes of stabilizer have been used for 
the preparation of lyophilized non-viral gene delivery systems: monosaccharaides (glucose), 
disaccharides (sucrose, trehalose), oligosaccharides (inulin) and polymers (dextran, povidone, 
polyethylene glycol).
28-30
 Different mechanisms have been proposed to explain the protective 
action of the cryoprotectants in colloidal systems and proteins: preferential exclusion, 
vitrification, and particle isolation hypothesis.
31-35
 
It has been reported that freeze-drying cycles induced changes in the physiochemical 
properties (particle size and surface charge density) of lipoplex-mediated gene delivery vectors 
even when a cryoprotectant agent was used.
36-39
 The alteration of physiochemical properties of 
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lipoplexes is usually associated with changes in transfection efficiency. Although, many studies 
have been carried out to explore the effects of stabilizing agents and freeze-drying cycles on the 
physiochemical properties and transfection activity of cationic lipid-DNA vectors, all of them 
have employed mono-cationic lipids (e.g., DOTAP, DC-Chol, DMRIE).
23,37,39,40
  From this 
perspective, the aims of this work were 1) to evaluate the effects of several stabilizing agents on 
the physiochemical properties (i.e., particle size and surface charge density) of di-cationic gemini 
surfactant-based lipoplexes 2) to investigate the ability of these agents to physically stabilize the 
lipoplexes during freeze-drying cycle and 3) to observe the influence of the freeze-drying cycles 
on the properties and transfection activity of lipoplexes.  
 
Figure 3.1: General structure of cationic gemini surfactant. 
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3.3. Materials and Methods 
3.3.1. Materials 
Two plasmids were used in this work. The pG.td.Tomato, encoding for tomato red 
protein, was obtained from Clontech Laboratories, Inc. (Mountain View, CA, USA). This 
plasmid was used for formulation development and physiochemical characterization purposes. 
The plasmid (pGThCMV.IFN-GFP)
12
, encoding for murine interferon gamma (IFN-γ) and green 
fluorescent protein (GFP), was used for in vitro transfection evaluations. Plasmids were 
amplified and purified using QIAGEN Plasmid Giga Kit (Mississauga, ON, Canada) following 
the manufacturer’s protocols. The synthesis and characterization of the gemini surfactants used 
in this study have been previously described.
14,41
 Aqueous solutions of 3 mM gemini surfactant 
were used to prepare lipoplexes. Helper lipid 1,2 dioleyl-sn-glycero-phosphatidylethanolamine 
(DOPE) (Avanti Polar Lipids, Alabaster, AL) was co-formulated in all formulations. Stabilizer 
excipients (analytical grade) sucrose and trehalose were obtained from Sigma Aldrich (Oakville, 
ON, Canada), lactose, glucose, polysorbate 80 (tween 80) and glycerin from Spectrum Chemical 
(Gardena, CA, USA) and polyethylene glycol (PEG) from Union Carbide Corporation (Houston, 
TX, USA). All excipients were used without further purification. Chemical solvents (GS grade) 
were obtained from EMD Chemicals Inc. (Gibbstown, NJ, USA). 
3.3.2. Preparation of lipoplexes 
Lipoplexes were formulated using a pDNA to gemini surfactant charge ratio of 1:10 in 
the presence of DOPE as co-lipid creating plasmid/gemini surfactant/lipid lipoplexes [P/G/L]. 
DOPE lipid vesicles were prepared using a sonication technique as described previously.
12
 The 
DOPE film was dispersed in the specific stabilizing solution at 1 mM DOPE final concentration 
and filtered through Acrodisc® 0.45 µm syringe filters (Pall Gelman, Ann Arbor, MI). The 
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stabilizing solutions were prepared by dissolving the stabilizing agent [Table 3.1] in nuclease-
free ultrapure water (Gibco, Invitrogen Corporation, Grand Island, NY, USA) on a 
weight/weight percentage (w/w%) and the pH was adjusted with NaOH solution to 9.The 
plasmid/gemini surfactant [P/G] lipoplexes were prepared by mixing an aliquot of 200 µg pDNA 
aqueous solution with an appropriate amount of 3 mM gemini surfactant solution to obtain the 
1:10 charge ratio and incubated at room temperature for 20 minutes. The [P/G/L] systems were 
prepared by mixing [P/G] lipoplexes with the DOPE vesicles at gemini surfactant to DOPE 
molar ratio of 1:10 and incubated at room temperature for 20 minutes. 
Table 3.1: Examples of stabilizing solutions used for preparing DOPE lipid and the role  of each 
ingredient 
ID 
Solution used to re-suspend 
DOPE film (% w/w) 
Role of ingredient 
1 9.25 % Sucrose Sucrose: isotonic agent, cryoprotectant 
2 10% Trehalose Trehalose: cryoprotectant sugar 
3 10% Glucose Glucose: cryoprotectant sugar 
4 10% Lactose Lactose: cryoprotectant sugar 
5 5% PEG 1450 PEG 1450: cryoprotectant polymer 
6 5% PEG 8000 PEG 8000: cryoprotectant polymer 
7 1% Tween 80 Tween 80: surfactant polymer  
8 
9.25% Sucrose + 
1% Glycerin 
Sucrose: cryoprotectant sugar 
Glycerin: antifreeze cryoprotectant 
9 
9.25% Sucrose + 
0.5% Glycerin 
Sucrose: cryoprotectant sugar 
Glycerin: antifreeze cryoprotectant 
10 
10% Trehalose+ 
1% Glycerin 
Trehalose: cryoprotectant sugar 
Glycerin: antifreeze cryoprotectant 
11 
10% Trehalose+ 
0.5% Glycerin 
Trehalose: cryoprotectant sugar 
Glycerin: antifreeze cryoprotectant 
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3.3.3. Extraction of pDNA from lipoplexes 
Several methods were evaluated to extract pDNA from the [P/G/L] and [P/G] systems. A 
brief description of each method is shown in Table 3.2. Gel electrophoresis was used to validate 
the efficiency of the method to extract pDNA from the lipoplexes as follows: the extracted 
portion (containing 0.4 µg pDNA) was tested in 1% agarose gel stained with ethidium bromide-
EtBr (0.01%) using a Bio-Rad PowerPac HC electrophoresis apparatus (Biorad, Mississagua, 
ON, Canada) in tris-acetate-EDTA (TAE) buffer at 100 V for 45 minutes. EtBr was visualized 
by UV fluorescence using an AlphaImager™ (Alpha Innotech, San Leandro, CA, USA). 
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Table 3.2: Summary of methods used for extraction of pDNA from freshly prepared [P/G/L] and 
[P/G] lipoplexes. 
Method ID    Description 
M-1
42
 
1. Freshly prepared [P/G/L] or [P/G] systems containing 15 µg DNA were 
mixed with sodium dodecyl sulfate (SDS) solution to a final concentration of 
SDS of 25 mM 
2. The resulting solution  as incubated in  ater bath at  5  C for 15 min then 
allowed to cool to room temperature 
3. Aliquots of solution containing 0.4 µg were used in gel electrophoresis. 
M-2 
1. The same steps 1 and 2 from method M-1 were performed 
2. The SDS solution containing the pDNA was mixed with isopropyl alcohol 
(0.7 volumes), and  centrifuged at  4 000 rpm at 4  C for 15 min 
3. The supernatant was decanted and the precipitated pDNA pellet was washed 
with  0  ethanol and centrifuged at  4 000 rpm at 4  C for  5 min 
4. The supernatant was decanted, and the pellet was reconstituted in nuclease-
free ultrapure water (40 µL) 
5. Aliquots of solution containing 0.4 µg were used in gel electrophoresis 
M-3 
1. Similar to M-2 but the samples were incubated at room temperature for 30 
min with continuous mixing instead of thermal treatment at  5  C for 15 min 
M-4 
1. 1 mL of freshly prepared [P/G/L] system containing 15 µg DNA was mixed 
with an equal volume of 1% Triton X-1 solution (Spectrum Chemical, 
Gardena, CA, USA) and incubated at room temperature for 15 min 
2. The resulting solution was mixed with isopropyl alcohol (0.7 volumes), 
centrifuged at 14,000 rpm and 4  C for  5 min 
3. The supernatant was decanted and the precipitated pDNA pellet was washed 
with 70% ethanol and centrifuged at 14,000 rpm and 4  C for  5 min 
4. The supernatant was decanted, the pellet was reconstituted in nuclease-free 
ultrapure water (40 µL) 
5. Aliquots of solution containing 0.4 µg were used in gel electrophoresis 
M-5 
1. pDNA was isolated and extracted following the QIAGEN® plasmid 
purification method 
2. An a liquot of extracted solution containing 0.4 µg was used in gel 
electrophoresis 
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3.3.4. Lyophilization of the formulations 
Volumes of 3 mL of different [P/G/L] formulations containing a total of 22.2 µg pDNA 
were transferred to 15 mL polypropylene copolymer centrifuge tubes (VWR International, 
Mississauga, ON, Canada). The top of the tubes were covered with delicate-task wipes (Kimtech 
Science® Kimwipes®, VWR International, Mississauga, ON, Canada) and stored at – 80 ˚C 
overnight. Tubes containing the formulations were then placed in the freeze dryer (Lyph-Lock, 6 
liter bench freeze-dryer, Labconco, Kansas City, MO, USA). Samples were lyophilized for 48 
hours. After the freeze-drying cycle, the tubes were flushed with nitrogen gas (Praxair Canada 
Inc., Mississauga, ON, Canada) and capped. 
Four lyophilized formulations (FS, FSG, FT, and FTG) were selected for the pilot stability 
study to evaluate the efficiency of three stabilizing agents (sucrose, trehalose and glycerin) to 
preserve the physiochemical properties and biological activity of lyophilized lipoplexes [Table 
3.3]. In addition, formulation FS′, containing only the pDNA/gemini [P/G] surfactant lipoplexes, 
was lyophilized without including the DOPE vesicles or any stabilizing agent. 
Table 3.3: Preparation methods for the formulations used in the pilot accelerated stability study 
Formulation Stabilizing solution 
FS 
[P/G/L] system was prepared in 9.25% sucrose, then was lyophilized for 48 
hours 
FSG 
[P/G/L] system was prepared in 9.25% sucrose + 1% glycerin, then was 
lyophilized for 48 hours 
FT [P/G/L] system was prepared in 10% trehalose, then was lyophilized for 48 hours 
FTG 
[P/G/L] system was prepared in 10% trehalose + 1% glycerin, then was 
lyophilized for 48 hours 
FS′ 
[P/G] lipoplex was prepared and lyophilized for 48 hours, the lyophilized [P/G] 
lipoplex was rehydrated in DOPE vesicles prepared in 9.25% sucrose 
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3.3.5. Rehydration of the lyophilized formulations 
Lyophilized formulations containing the [P/G/L] system and the excipient were 
rehydrated to a final volume of 3 mL with ultrapure water (Gibco, Invitrogen Corporation, Grand 
Island, NY, USA) and incubated for 30 minutes at room temperature prior to the physiochemical 
and biological evaluation. Lyophilized formulation containing the [P/G] lipoplex (i.e., 
formulation FS′) was rehydrated, firstly, in 222 µL of ultrapure water and incubated for 30 
minutes at room temperature. After 30 minutes, freshly prepared DOPE vesicles in 9.25% 
sucrose were added to the rehydrated lipoplexes to a final volume of 3 mL. Appropriate volumes 
of rehydrated formulation, containing 0.2 µg pDNA, were used for in vitro transfection 
evaluation and physiochemical characterization measurements. 
3.3.6. Stability study 
For the accelerated stability study, the lyophilized formulations were stored in stability 
chambers at two storage conditions: 1) 25 ˚C and 75% relative humidity (RH) (Sanyo growth 
cabinet MLR-350, Sanyo, Osaka, Japan) and 2) 40 ˚C and 75% RH (Caron environmental test 
chambers 6010, Caron, Marietta, OH, USA) for three months. Sampling points were determined 
at one week, and one, two and three month storage periods. Formulations were prepared and 
analyzed in triplicate (n=3). 
3.3.7. Size and ζ-potential measurements 
Fresh and rehydrated formulations (800 µL) were transferred into a special cuvette 
(DTS1061, Malvern Instruments, Worcestershire, UK) for size distribution and zeta-potential 
measurements using a Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, 
UK). Each sample was measured four times, and the results were expressed as the average ± 
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standard deviation (SD) of three samples (n=3) with a corresponding polydispersity index (PDI) 
value. 
3.3.8. Cell culture and in vitro transfection 
COS-7 African green monkey kidney fibroblasts cell line (ATCC, CRL-1651) were 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum and 1% antibiotic and incubated at 37 ˚C with 5% CO2. On the day before transfection, 
the cells were seeded in 96-well tissue culture plates (Falcon, BD Mississauga, ON, Canada) at a 
density of 1.5×10
4
 cells/well. One hour prior to transfection, the supplemented DMEM was 
replaced with DMEM. The cells were transfected with 0.2 µg pGThCMV.IFN-GFP plasmid/well 
in quadruplicate. Lipofectamine Plus reagent (Invitrogen Life Technologies) was used as a 
positive control according to the manufacturer’s protocol  ith 0.2 µg pDNA/ ell in 
quadruplicate. The 96-well tissue culture plates were then incubated at 37 ˚C in CO2 for five 
hours. The transfection agents were removed and replaced with supplemented DMEM. 
Supernatants containing the secreted IFN-γ  ere collected at 24  48 and  2 hours and replaced 
with fresh supplemented DMEM. The collected supernatants were stored at -80 ˚C. 
3.3.9. Cell toxicity assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to 
evaluate the effect of lyophilization and storage conditions on the cellular toxicity of [P/G/L] 
systems in COS-7 cell line. A sterile solution of 4 mg/mL of MTT (Invitrogen Corporation, 
Grand Island, NY, USA) in PBS buffer was prepared. The COS-7 cell lines were seeded on 96-
well plate and transfected with fresh and lyophilized formulations (as described above). After 72 
hour, the cell lines were evaluated for the cell toxicity. The supplemented DMEM was removed 
from the well and replaced with 0.45 mg/mL MTT in supplemented D    and incubated at     
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C in CO2 for 3 hours.  The supernatant was removed, and each well washed with PBS. The 
formed purple formazan crystal was dissolved in dimethyl sulfoxide (spectroscopy grade, Sigma-
Aldrich, Oakville, ON, Canada). Plates were incubated for 10 minutes at     C. Absorbance was 
measured at 550 nm using a BioTek microplate reader (Bio-Tek Instruments, VT, USA). The 
cellular toxicity is expressed as a percentage of the non-transfected control cells ± SD. 
3.3.10. Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) was performed using flat bottom 96-well 
plates (Immulon 2, Greiner Labortechnik, Frickenhausen, Germany) following the BD 
Pharmingen protocol and as described earlier
12. The concentration of expressed IFNγ  as 
calculated from a standard IFNγ curve using recombinant mouse IFN-γ standard (BD 
Pharmingen, BD Biosciences). 
3.3.11. Statistical analysis 
Statistical analyses were performed using SPSS software (Version 17.0). Results 
expressed as the average of n ≥   ± SD. One  ay analysis of variance (ANOVA) and Pearson’s 
correlation were used for statistical analyses.  Significant differences were considered at p<0.05 
level. 
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3.4. Results and Discussion 
3.4.1. Effects of the stabilizing agents on the physiochemical properties of gemini 
surfactant- lipoplexes after lyophilization/rehydration cycle 
It has been established that the physiochemical properties of lipoplex-based gene delivery 
vectors (namely particle size and positive surface charge) are essential factors that govern the 
cellular uptake and consequently the transfection activity of such systems.
17,43,44
 The 
lyophilization process includes three stress steps that have been reported to destabilize the 
lipoplexes: freezing, drying (dehydration) and rehydration.
26,45
 Our data showed that, [P/G/L] 
lipoplexes prepared without using any protectant agents [Formulation 0, Table 3.4], upon 
lyophilization, aggregated into large particles (average particle size of 642±247 nm with broad 
range of particle distribution as expressed by PDI value of 0.708) having negative zeta potential 
values. In this section we report on the ability of the added excipients to preserve the primary 
physiochemical characteristics of the lipoplexes. A series of 35 formulations were developed 
using the stabilizing agents as solutions for the [P/G/L] systems. In all formulations, the pDNA 
was complexed with the gemini surfactant to form [P/G] lipoplexes first and the DOPE vesicles 
prepared in the stabilizing solution were incorporated afterward. The lipoplexes were formulated 
at 1:10 plasmid to gemini surfactants charge ratio, as established earlier.
12
 Stabilizing agents 
used in this work were: monosaccharides (glucose), disaccharides (sucrose, trehalose, lactose), 
polymers (polyethylene glycol), surfactant polymer (polysorbate 80) and simple polyol 
(glycerin). These agents have been widely employed as a cryoprotectant agent during the 
lyophilization of liposomal structures and lipoplex-based gene delivery systems.
28-30,46-48
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The influence of the freeze drying process on the physiochemical properties (particle size and 
zeta potential) of selected formulations prepared using different stabilizing agents was evaluated 
[Table 3.4].  
  
  
7
7
 
 
Table 3.4.: The components of selected formulations and the influence of lyophilization on the physiochemical properties 
(size distribution and zeta potential). 
ID# 
Stabilizing agents 
solution used to 
prepare DOPE film 
Fresh Formulation Lyophilized Formulation 
Particle Size (PDI) 
Nm 
Zeta potential 
mV 
Particle Size (PDI)  
nm 
Zeta potential 
mV 
0 
PBS (no stabilizing 
agent) 
 45±  (0.  ) -  ±  642±24  (0.  ) -  ±  
  9.25  Sucrose  6. ±0.6 (0. 9)  0±2  25±2 (0. 8) 29±  
2 
9.25  Sucrose + 
0.5 Glycerin 
8 ±2 (0. 9)  2±2 99±2 (0.20)  8±  
  
9.25 Sucrose + 
  Glycerin 
 9 ±2 (0. 9)  0±2 96±  (0.2 )   ±  
4  0  Trehalose 9 ±  (0. 9) 24±   62±9 (0. 8) 24. ±0.6 
5 
 0 Trehalose + 
0.5 Glycerin 
 0 ±2 (0.22) 28±2  09±  (0.  )  5±  
6 
 0  Trehalose + 
  Glycerin 
 09±  (0.  )   ±2  26±  (0. 9)   ±  
  
9.25  Sucrose + 
0.5   T een 80 
 4.6±0.  (0.49)  ±   00±0.5 (0.52) 2±4 
8 1% Tween 80 54±  (0.25) - 6±4 192±4  (0.56) - 1.9±0.2 
9 5  P G  450 88. ±0.5 (0.29) -  6±   0 ±5 (0.4 ) -2 ±  
 0* 9.25  Sucrose 80±0.  (0.2 )   ±  131.6 ± 5.47 (0.23) 24.0 ± 1.0 
Values are shown as the average of 4 measurements; (PDI) is indicated for size distribution measurements. Formulations (0-9) prepared with 
pDNA:12-7NH-12:DOPE [P/G/L] lipoplexes in the indicated stabilizing solution. * In formulation (10); pDNA:12-7NH-12 lipoplexes [P/G] 
lyophilized and rehydrated with DOPE suspension. 
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The clarity of the fresh formulations, (i.e., turbidity) was assessed visually. Formulations 
showing sedimentation or large visible particles were discarded. Particle size distribution and 
zeta potential of the clear formulations were measured using the dynamic light scattering (DLS) 
technique. Fresh formulations used in lyophilization/rehydration evaluation were selected based 
on two criteria: positive zeta potential and particle size < 200 nm (with PDI< 0.4). After 
lyophilization, the physical state of lyophilized formulations was evaluated again (physical 
appearance of the lyophilized cakes). In addition, the appearance of rehydrated formulations was 
evaluated for clarity. 
The results showed that the size and zeta potential of the lipoplexes varied based on the 
excipient that was used to prepare the formulations [Table 3.4]. Not all stabilizers were efficient 
in preserving the physiochemical characteristics of the fresh corresponded formulations. 
Sugars are widely used as cryoprotectants and stabilizing agents for lyophilized lipid-based 
gene delivery systems.
25,28,36
 Disaccharide sugars sucrose and trehalose were the most efficient 
cryoprotectant agents in terms of maintaining the particle size (resulting particle size was in the 
range of 70 -200 nm) and positive zeta potential values of the lipoplexes after lyophilization. 
These observations were similar to previous assessments that evaluated these agents during the 
lyophilization of synthetic gene delivery vectors.
37,38,49
 A moderate increase in the particle size 
was observed with both sugars after lyophilization [Formulations 1 and 4, Table 3.4]. 
Lyophilization of lipoplexes with trehalose and sucrose produced a powder-like lyophilized cake. 
Lyophilization with lactose as a stabilizing agent showed similar cake structure but the original 
size and zeta potential value were not preserved. Fresh lipoplexes prepared with monosaccharide 
sugar (glucose) showed a particle size of 70± 1 nm and a negative zeta potential value (-24± 2 
mV) with collapsed cake. Lactose and glucose were eliminated from further investigations for 
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two reasons: 1) both sugars failed to preserve the essential physiochemical properties of the 
[P/G/L] systems after lyophilization and 2) they could chemically destabilize the lyophilized 
lipoplexes during storage (both are reducing sugars).
23,50,51
 
The addition of glycerin as anti-freeze bulking agent at 0.5 and 1% w/w concentrations to 
disaccharide sugar solutions (i.e, sucrose and trehalose) had no significant effects on the 
physiochemical properties compared to formulations containing only the sugar. However, 
glycerin was able to minimize the increase in particle size after the lyophilization [Formulations 
2,3,5 and 6, Table 3.4]. The use of polymeric cryoprotectant agents (polyethylene glycol PEG 
450, PEG 8000) caused aggregation of the lipoplexes (particle sizes of 300-400 nm) and shifted 
the zeta potential to negative values. The addition of Tween 80 as surfactant polymer to sucrose 
solution [Formulation 7, Table 3.4] caused significant reduction in particle size (more than 50% 
reduction) compared to lipoplexes formulated in sucrose only and a slightly positive zeta 
potential was observed. Upon lyophilization, the particle size significantly increased (almost a 2 
fold increase) with no change in zeta potential compared to fresh formulation.  
Helper lipid DOPE is frequently used to enhance the transfection activity of cationic lipid 
mediated gene delivery. The synergistic effect of DOPE is attributed to its ability to undergo 
polymorphic phase transition that facilitates cell membrane fusion and enhances pDNA 
endosomal escape.
52,53
 To provide this action, it is essential that DOPE vesicles be formed under 
special conditions with specific morphology. It has been reported that the dehydration-
rehydration process could cause lipid phase transition in lyophilized liposomal formulations.
26,54
 
Therefore, we lyophilized pDNA:gemini surfactant lipoplexes without the incorporation of  
DOPE or any stabilizing agents to investigate the effects of lyophilization cycles on the [P/G] 
system. After the freeze-drying cycle, the lyophilized [P/G] lipoplexes were rehydrated with 
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DOPE vesicles prepared in 9.25% sucrose solution [Formulations 10 Table 3.4]. There were no 
significant changes in particle size or zeta potential compared to fresh lipoplexes (Formulation 
1). 
Based on these findings, we selected sucrose and trehalose and these sugars in combination 
with glycerin as stabilizing agents to investigate their influence on the biological activity of the 
gemini surfactant lipoplexes before and after lyophilization. Table 3.5 shows the composition of 
seven formulations that were evaluated. 
Table  .5: Lyophilized formulations used for biological activity (transfection activity and 
cytotoxicity).  
ID# 
pDNA:gemini surfactant 
(-/+) charge ratio 
System lyophilized 
Stabilizing agents 
solution used to 
prepare DOPE film 
F  
pDNA: 2- NH- 2 
 : 0 
[P/G/L] 9.25  Sucrose 
F2 
pDNA: 2- NH- 2 
 : 0 
[P/G/L] 
9.25  Sucrose + 
0.5  Glycerin 
F  
pDNA: 2- NH- 2 
 : 0 
[P/G/L] 
9.25 Sucrose +  
   Glycerin 
F4 
pDNA: 2- NH- 2 
 : 0 
[P/G/L]  0  Trehalose 
F5 
pDNA: 2- NH- 2 
 : 0 
[P/G/L] 
 0 Trehalose + 
0.5  Glycerin 
F6 
pDNA: 2- NH- 2 
 : 0 
[P/G/L] 
 0  Trehalose + 
   Glycerin 
F * 
pDNA: 2- N(Glycine)- 2 
 : 0 
[P/G] 9.25  Sucrose 
*In formulation (F7), [P/G] system was lyophilized without the incorporation of DOPE or stabilizing agent 
and then and rehydrated with DOPE suspension prepared in the indicated sugar solution. 
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3.4.2. Effect of stabilizing agents and lyophilization process on the biological activity of 
gemini surfactant-lipoplexes 
The effect of disaccharide sugars sucrose and trehalose alone, and in combination with 
glycerin on the transfection activity and cytotoxicity were evaluated [Figure 3.2, white bars].  
Fresh formulation F1, [P/G/L] system formulated using 12-7NH-12 gemini surfactant in 
9.25% sucrose, is the standard formulation that was comprehensively characterized in our 
previous work.
41,55
 In vitro transfection of fresh formulation F1 showed 2.5±0.8 ng of 
IFNγ/ .5× 04 COS-7 cells was expressed after 48 hours of treatment. The addition of glycerin to 
the sucrose solution [Formulations F2 and F3 in Table 3.5] caused significant reduction in 
transfection activity (approximately 80%) at both concentrations [Figure 3.2]. Similarly, the 
replacement of sucrose with trehalose [Formulation F4] severely hampered the transfection 
activity  and a more than 85  reduction in the IFNγ levels  as observed compared  ith the 
fresh F1. However, the introduction of glycerin as stabilizing agent to trehalose solution [F5 and 
F6] enhanced the transfection activity compared to fresh formulation prepared with 10% 
trehalose. Formulation F5 prepared in 10% trehalose and 0.5% glycerin efficiently transfected 
COS-7 cells and 1.3±0.4 ng IFNγ/ .5× 04 COS-7 cells was expressed. However, the increase of 
glycerin concentration to 1% [F6] significantly reduced the transfection activity to 0.32±0.23 ng 
IFNγ/ .5× 04 COS-7 cells. There was no correlation between the changes in physiochemical 
properties (size and zeta potential) and transfection activity. 
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Figure 3.2: The influence of stabilizing agents (white bars) and lyophilization process (gray bars) 
on the in-vitro transfection activity (ELISA-IFNγ). Results are average of four measurements 
(n=4), error bars ± SD. 
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The effect of stabilizing agents on cellular toxicity was also evaluated by using the MTT 
assay [Figure 3.3., white bars]. No significant changes in cytotoxicity were observed between 
lipoplexes formulated with sucrose and trehalose [F1 and F4], when used alone (cell viability of 
64±1.4% and 59±7.5%, respectively) [Figure 3.3]. The addition of glycerin to sucrose or 
trehalose improved the cell viability compared with lipoplexes formulated with sugar alone. The 
highest cell viability was observed when 0.5% glycerin was added to 10% trehalose 
[Formulation F5, 77±1.7% cell viability, Figure 3.3]. This formulation showed 15% 
enhancement in cell viability compared to formulation F4 using 10% trehalose. 
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Figure 3.3: The influence of stabilizing agents (white bars) and lyophilization process (gray bars) 
on the cellular toxicity (MTT assay). Results are expressed as percentage of un-treated cells 
(100%). Results are average of four measurements (n=4), error bars ± SD.  
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We performed a lyophilization/rehydration study on the seven formulations described in 
Table 3.5 to investigate the effect of the lyophilization process on the biological activity [Figure 
3.2, gray bars]. Upon lyophilization/rehydration, four formulations showed more than 70% loss 
in transfection activity in comparison with the corresponding fresh formulations [Formulations 
F1, F2, F3 and F5, Figure 3.2.]. Among these formulations, only F1, standard formulation in 
9.25% sucrose, was able to express an adequate level of IFNγ after the lyophilization/rehydration 
cycle (0.47±0.16 ng IFNγ/ .5× 04 COS-7). It should be noted that fresh formulation F1 showed 
the highest gene expression activity among all fresh formulations evaluated in this study as 
discussed early. Formulation F6 (in 10% trehalose + 1% glycerin) showed the least loss in 
transfection activity after lyophilization process (approximately 25% loss compared with fresh 
F6). 
One of the most interesting findings in this study was the influence of lyophilization on 
the transfection activity of [P/G/L] lipoplexes formulated in 10% trehalose [Formulation F4, 
Figure 3.2]. A significant increase in transfection efficiency (10 fold increase) was observed 
upon lyophilization/rehydration of formulation F4 ( .6±0.22 ng IFNγ/ .5× 04 COS-7).  
Lyophilized [P/G] lipoplexes without the incorporation of helper lipid DOPE or any 
stabilizing agents [formulation F7, Table 3.5, Figure 3.2] were able to preserve approximately 
40% of the activity of the original formulation F1. Compared with lyophilized [P/G/L] in 9.25% 
sucrose (lyophilized F1), lyophilization of [P/G] without the stabilizing sugar, (lyophilized F7) 
was more efficient in maintaining the transfection activity as the level of expressed IFN was 
465±161 ng and 886±72 ng, respectively. Therefore, it may be concluded that the loss of 
transfection activity in case of the lyophilization of [P/G/L] systems can be attributed to the 
conformational changes in the supramolecular structure of the lipid phase of the lipoplexes and 
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to the possibility of the loss of pDNA morphology. In fact, previous work showed that the 
electrostatic interaction of the hydroxyethylated cholesterol-based cationic lipid with pDNA was 
able to protect the pDNA during the freeze drying cycle when no cryoprotectant agent was 
used.
56
 Therefore, the incorporation of stabilizing agent during the freeze-drying cycles is more 
important in preserving the conformational structure of the lipoplex systems than the pDNA 
content.
40
 To prove that, we evaluated different methods to extract the pDNA from the [P/G/L] 
and [P/G] systems aiming to investigate the effect of the lyophilization process on pDNA content 
[Table 3.2.].  Unfortunately, all the methods failed to isolate the pDNA from the [P/G/L] 
systems. pDNA from [P/G] lipoplexes was detected only with methods M-2 and M-3. We 
believe that the presence of DOPE vesicles in high concentrations in the [P/G/L] system hindered 
the release of the pDNA.  
In addition to the transfection activity, the effect of freeze-drying on the cellular toxicity 
of gemini surfactant-based lipoplexes [Figure 3.3., gray bars] was evaluated. Upon 
lyophilization/rehydration cycles slight improvement in cell viabilities were observed with most 
formulations. Lyophilization of standard formulation (F1) caused approximately 15% reduction 
in cell viability compared with the fresh F1. Similarly, 25% reduction in cell viability was 
observed when lyophilized [P/G] lipoplexes without stabilizing agent was used as transfection 
vector (compared to fresh F1). 
Based on findings illustrated in previous sections, we selected five formulations to 
evaluate the influence of lyophilization parameters and storage temperature on the physical and 
biological activity of lyophilized gemini surfactant-based lipoplexes [Table 3.3]. 
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3.4.3. Stability of lyophilized lipoplexes 
We evaluated the effect of the storage temperature and aging on the physiochemical 
properties (particle size and zeta potential) and transfection activities of lyophilized gemini 
surfactant-based lipoplex by conducting a three-month stability study at two storage conditions 
(25 ˚C/ 5  RH and 40 ˚C/ 5  RH). 
The stability of lyophilized lipoplex-based vectors depends on several factors. The 
optimization of freeze drying cycles (i.e., freezing and drying cycles) and the incorporation of 
proper stabilizing agents are essential to maintain the physiochemical properties and transfection 
activity of lipoplex systems.
26,37,49
 In addition, the long-term stability of the lyophilized 
lipoplexes can be influenced by: formulation composition, storage temperature, moisture content 
in the lyophilized cake, and the presence of reactive oxygen species (ROS).
22,37,42
 
Unfortunately, the inability of the freeze dryer to handle large amounts of the formulations 
resulted in lyophilized products with high levels of moisture content. This caused the collapse of 
the dried cake of lyophilized lipoplexes formulated with a sugar component (sucrose and 
trehalose) after one  eek of storage of at 25 ˚C [A and B  Figure  .4]. The lyophilized cake of 
formulations containing 1% glycerin (FSG and FTG) showed a gummy texture that was unable to 
rehydrate easily [C and D, Figure 3.4]. This can be attributed to the fact that glycerin inhibits the 
growth of ice crystals which leads to the formation of small pores in frozen lipoplexes during the 
freezing cycle.
57
 This effect could increase the time required for the drying process and lead to 
the formation of dried cake with a high moisture content.
58,59
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[A] Lyophilized (FS) [B] Lyophilized (FT) 
  
[C] Lyophilized (FSG) [D] Lyophilized (FTG) 
Figure 3.4: The appearance of lyophilized cake of four lyophilized formulations after one week 
of storage at 25 ˚C. 
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Despite the inefficiency of the lyophilization, we continued the physiochemical and 
biological assessments during the three months stability study. The purpose of continuing the 
study was to evaluate the feasibility of the developed analytical techniques to identify the 
changes in the physiochemical properties (particle size and zeta potential) and the transfection 
efficiency of the lyophilized formulations during the stability study. Therefore, the results from 
the stability study were insignificant to be discussed.  
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3.5. Conclusion  
Gemini surfactant-based [P/G/L] lipoplexes were prepared with different stabilizing 
agents and the physiochemical properties of [P/G/L] systems before and after freeze-drying 
cycles were evaluated. These properties varied based on the stabilizing agents used to prepare the 
lipoplexes. Sucrose and trehalose alone and in combination with glycerin were able to maintain 
the particle size and positive zeta potential upon lyophilization/rehydration. However, even with 
preserving the physiochemical properties, the transfection activity of lyophilized lipoplexes was 
severely hampered compared with freshly prepared lipoplexes. The only exception was trehalose 
used at 10% concentration as a /stabilizing agent; the transfection activity of lyophilized 
lipoplexes was significantly higher than the corresponding fresh formulation. The findings from 
this study provide information about the effects of stabilizing agents and the lyophilization 
process on the physical stability of gemini surfactant-based lipoplexes that can be used for 
further investigation in order to optimize long-term stability of lyophilized [P/G/L] systems.  
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4.1. Abstract  
Purpose  
Cationic lipid-based gemini surfactants have been extensively studied as non-viral vectors for gene 
therapy. Clinical applications of cationic lipid/DNA lipoplexes are restricted by their instability in 
aqueous formulations. In this work, we investigated the influence of lyophilization on the essential 
physiochemical properties and in vitro transfection of gemini surfactant-lipoplexes. Additionally, we 
evaluated the feasibility of lyophilization as a technique for preparing gemini surfactant-lipoplexes with 
long term stability.  
Methods  
A diquaternary ammonium gemini surfactant [12-7NH-12] and plasmid DNA encoding for interferon-γ 
were used to prepare gemini surfactant/pDNA [P/G] lipoplexes. Helper lipid DOPE [L] was 
incorporated in all formulation producing a [P/G/L] system. Sucrose and trehalose were utilized as 
stabilizing agents. To evaluate the ability of lyophilization to improve the stability of gemini surfactant-
based lipoplexes, four lyophilized formulations were stored at 25˚C for three months. The formulations 
were analyzed at three different time-points for physical appearance, physiochemical properties (particle 
size and zeta potential, gemini surfactant pDNA interaction) and in vitro transfection. 
Results 
The results showed that both sucrose and trehalose provided the anticipated stabilizing effect. The 
transfection efficiency of the lipoplexes increased 2-3 fold compared to fresh formulations upon 
lyophilization. This effect can be attributed to the improvement of DNA compaction and changes in the 
lipoplex morphology due to the lyophilization/rehydration cycles. The physiochemical properties of the 
lyophilized formulations were maintained throughout the three month study at 25 ˚C. All lyophilized 
formulations showed a significant loss of gene transfection activity after three months of storage. 
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Nevertheless, no significant losses of transfection efficiency were observed for three formulations after 
two months storage at 25 ˚C.  
Conclusion 
Lyophilization significantly improved the physiochemical stability of gemini surfactant-based lipoplexes 
compared to liquid formulations. As well, lyophilization improved the transfection efficiency of gemini 
surfactant-based lipoplexes. The loss of transfection activity upon storage is most probably due to the 
conformational changes in the supramolecular structure of the lipoplexes as a function of time and 
temperature rather than to DNA degradation.  
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4.2. Introduction  
Gene therapy is a promising therapeutic approach that has the potential to improve, significantly, 
human health.
1
 Successful gene therapy depends on the design of efficient, safe and stable gene delivery 
systems. Chemically mediated non-viral vectors, such as cationic lipids, exhibit low immunogenicity 
compared to viral vectors.
2,3
 One specific group of cationic lipids that has demonstrated efficient 
transfection activity is the gemini surfactants [Figure 4.1].
4,5
 They are dimeric surfactants primarily used 
in material sciences because of their characteristic low surface tension.
6,7
 In recent years, gemini 
surfactants have been investigated extensively as a non-viral gene delivery carriers for both in vitro and 
in vivo applications. These agents have versatile chemical structure, can be produced easily on a 
laboratory scale, are able to compact DNA to nano-sized lipoplexes, and show relatively low toxicity 
compared to monomeric surfactants.
4,8,9
 
 
Figure 4.1: General structure of cationic gemini surfactants 
The low transfection efficiency and the instability of lipid-based gene delivery vectors in liquid 
pharmaceutical dosage forms are two major deficiencies that limit their wide clinical application.
10,11
 
Over the last decade, a large number of cationic lipids have been synthesized and modified to overcome 
their low transfection activity, but little concern has been given to the stability of lipoplexes from a 
pharmaceutical perspective. The transfection efficiency of lipoplexes depends not only on the stability 
and integrity of all components of the delivery system but also on the maintenance of their related 
physiochemical properties (particle size and surface charge ratio).
12-14
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delivery system depends upon the conformational integrity of the genetic material, the chemical stability 
of the carrier and the physiochemical stability of the DNA-carrier complexes.
15-17
 In aqueous 
formulations, lipoplexes tend to aggregate and form large particles. This phenomenon can also lead to 
the dissociation of DNA from the lipoplexes and loss of the biological activity due to enzymatic 
degradation of the unprotected genetic material.
18
 To evade the stability issue, most of the studies that 
employ cationic lipids as a non-viral carrier for gene delivery use freshly prepared lipoplexes. Three 
different formulation methods have been explored to optimize the physical stability of cationic 
lipid/DNA complexes:  liquid, frozen, and dehydrated.
19
 To maintain the stability of the liquid and 
frozen formulations, special storage conditions and formulation strategies are needed that limit large 
scale production of the lipoplexes using good manufacturing procedures.
20-23
 Lyophilized (freeze-dried) 
formulations demonstrated the most efficient stability among these three formulation techniques.
24
  
  Lyophilization has been employed widely for the production of highly stable protein-based 
pharmaceutical products.
25,26
 Recently, lyophilization was also investigated as a practical technique to 
produce non-viral vectors with long-term stability.
27-29
 However, lyophilization is a complicated process 
that includes freezing and drying stresses which can damage the DNA structure and cause aggregation of 
lipoplexes.
24
 The damage to the DNA integrity and lipoplex structure during the freezing step can result 
from the increased concentration of the suspended materials (cryoconcentration effect) as the liquid 
freezes, leading to formation of larger aggregates in the unfrozen part. In addition, the formation of  ice 
crystals or the crystallization of solutes in the formulation have been reported to damage the lipoplex 
integrity.
22,30
 The removal of the unbound water and ice from the frozen formulations during the drying 
step can affect the lipoplexes as the condition shifts from a fully hydrated environment to a drier 
state.
24,30
 In addition, phase transition of lipid membrane in lyophilized liposomal formulations during 
dehydration-rehydration has been reported.
24
 The optimization of the freeze-drying protocol and 
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incorporation of certain stabilizers, known as cryo- or lyo-protectant agents, have been shown to 
improve the stability of the lipid-based DNA formulations.
24,31
 Different classes of stabilizing agent 
have been used for the preparation of lyophilized non-viral gene delivery systems: monosaccharaides 
(glucose), disaccharides (sucrose, trehalose), oligosaccharides (inulin) and polymers (dextran, povidone, 
polyethylene glycol).
23,32,33
 It has been reported that several aspects govern the ability of the 
lyophilization process to stabilize and preserve the activity of cationic lipoplexes: lyophilization 
protocol, type and amount of stabilizing agent, nature of the cationic lipid, DNA to cationic lipid charge 
ratio and incorporation of helper lipid.
19,28,29
  
Although several studies have investigated the influence of lyophilization on the cationic lipid-
DNA vectors, most of these studies utilized singly charged cationic lipids (e.g., DOTAP, DC-Chol, 
DMRIE).
27,34,35
 To the best of our knowledge, the effect of lyophilization on lipoplexes formed with 
multiply charged cationic lipids and high concentration of the helper lipid DOPE has not been 
addressed. The aim of this work was to evaluate the feasibility of lyophilization to stabilize gemini 
surfactant-based lipoplexes over long periods of storage at room temperature. The influence of the 
lyophilization process and stabilizing agents on the physiochemical properties, DNA compaction and in 
vitro transfection activity were investigated and the results are reported herein.  
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4.3. Materials and Methods  
4.3.1.Materials 
  The construction of the plasmid (pGThCMV.IFN-GFP), encoding for murine interferon gamma 
(IFN-γ) and green fluorescent protein (GFP), was described previously.4 Plasmid DNA was isolated and 
purified using QIAGEN Plasmid Giga Kit (Mississauga, ON, Canada) as prescribed in the 
manufacturer’s protocols. The synthesis and characterization of the gemini surfactants used in this study 
have been previously described.
36
 Aqueous solutions of 3 mM gemini surfactant were used to prepare 
plasmid DNA/gemini surfactant lipoplexes. Helper lipid 1,2 dioleyl-sn-glycero-
phosphatidylethanolamine (DOPE) (Avanti Polar Lipids, Alabaster, AL) was co-formulated in all 
formulations. Stabilizer agents (analytical grade) sucrose and trehalose were obtained from Sigma 
Aldrich (Oakville, ON, Canada). All excipients were used without further purification. 
4.3.2.Preparation of lipoplexes  
The plasmid/gemini surfactant [P/G] complexes were prepared by mixing an aqueous solution of 
pDNA with an appropriate amount of 3 mM gemini surfactant solution at 1:10 charge ratio and 
incubated at room temperature for 20 minutes. Lipoplexes were formulated in the presence of DOPE as 
helper lipid creating plasmid/gemini surfactant/lipid lipoplexes [P/G/L]. These [P/G/L] lipoplex systems 
were prepared by mixing [P/G] lipoplexes with the DOPE vesicles at gemini surfactant to DOPE weight 
ratio of 1:10 and incubated at room temperature for 20 minutes. The stabilizing solutions were prepared 
by dissolving the sugar in nuclease-free ultrapure water (Gibco, Invitrogen Corporation, Grand Island, 
NY, USA) on weight/weight (w/w) percentage basis and the pH was adjusted with NaOH solution to 9. 
These solutions were used to redisperse the DOPE, as described previously 
4
, at a final DOPE 
concentration of 1 mM and filtered through Acrodisc® 0.45 µm syringe filters (Pall Gelman, Ann 
Arbor, MI).   
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Gemini surfactant/DOPE [G/L] vesicles were prepared at a gemini surfactant to DOPE weight ratio 
1:10. A stock solution of 12-7NH-12 gemini surfactant was prepared in anhydrous ethanol and used to 
prepare a [G/L] film. Stabilizing solutions were used to re-disperse the [G/L] film and then filtered 
through Acrodisc® 0.45 µm syringe filters. An aliquot of plasmid solution and the G/L dispersion were 
mixed to obtain lipoplexes at a plasmid to gemini surfactant charge ratio of 1:10.  
Four formulations were prepared for the three-month stability study. Two were prepared as 
described earlier by complexing the DNA with the gemini surfactant first, then mixing with the DOPE 
vesicles dispersed in stabilizing solutions (S: sucrose, T: trehalose) [Method A, Table 4.1]. The 
lipoplexes were then lyophilized. For the other two formulations, P-[G/L-S]lyp  and P-[G/L-T]lyp, only 
the [G/L] component was lyophilized. Then fresh DNA solution was added to the reconstituted 
formulations for all assays. Table 4.1 summarizes the preparation methods of these formulations. In all 
analyses, triplicate batches of each formulation were evaluated.  
Table 4.1: Preparation methods for the formulations used in this study 
Formulation  Preparation 
method 
Description  
[P/G/L-S]lyp 
A 
P/G/L lipoplexes prepared with DOPE vesicles dispersed in  
9.25% sucrose solution were lyophilized for 48h 
[P/G/L-T]lyp 
P/G/L lipoplexes prepared with DOPE vesicles dispersed in  10% 
trehalose solution were lyophilized for 48h 
P-[G/L-S]lyp 
B 
G/L vesicles prepared in 9.25% sucrose were lyophilized for 48h 
and the plasmid solution was added to the lipid vesicles after 
reconstitution to prepare the lipoplexes 
P-[G/L-T]lyp 
G/L vesicles prepared in 10% trehalose were lyophilized for 48h 
and the plasmid solution was added to the lipid vesicles after 
reconstitution to prepare the lipoplexes 
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4.3.3.Lyophilization of the formulations 
A volume of 2 mL of freshly prepared formulations P/G/L-S and P/G/L-T, containing a total of 7.4 
µg/mL pDNA and G/L-S and G/L-T without pDNA, were transferred to 5-mL flat bottom low 
extractable borosilicate USP Type I lyophilization serum vials (Wheaton Industries Inc, Millville, NJ, 
USA). The vials were partially closed with three-legged lyophilization stoppers and stored at -80 ˚C for 
2 h. After freezing, the formulation vials were transferred to a Labconco® Freezone Plus 6 L cascade 
freeze dryer (Labconco, Kansas City, MO, USA) at -80 ˚C and 0.03 mBar pressure and lyophilized for 
48 h. The vials were removed from the freeze dryer, flushed with nitrogen gas, and the vial stoppers 
were fully closed and sealed with a crimp aluminum cap. All formulations were prepared under aseptic 
conditions.  
4.3.4.Stability study 
For the stability study, the lyophilized formulations were stored in a stability chamber at 25 ºC and 
75% relative humidity (RH) (Sanyo growth cabinet MLR-350, Sanyo, Osaka, Japan) for three months. 
Samples were tested at one, two and three month storage periods. Formulations were prepared and 
analyzed in triplicate (n=3). 
4.3.5.Rehydration of the lyophilized formulations  
Lyophilized formulations containing the pDNA, [P/G/L-S]lyp and [P/G/L-T]lyp, were rehydrated to 
a final volume of 2 mL with ultrapure water (Gibco, Invitrogen Corporation, Grand Island, NY, USA). 
Formulations [G/L-S]lyp and [G/L-T]lyp, without pDNA, were rehydrated using pDNA solution in 
UltraPure water to a final pDNA concentration of 7.4 µg/mL (1:10 plasmid to gemini charge ratio) and 
incubated for 30 minutes at room temperature, generating the P-[G/L-S]lyp and P-[G/L-T]lyp 
formulations. All rehydrated formulations, containing 0.2 µg pDNA, were used for in-vitro transfection 
evaluation. 
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4.3.6. Determination of moisture content 
Lyophilized formulations at the time of preparation and after 3 months of storage were evaluated 
for moisture content using a Karl Fisher Titrator (Automat Model 633; Metrohm, Herisau, Switzerland). 
The lyophilized formulations (approximately 45±5 mg of lyophilized cake) were dissolved in HPLC 
grade methanol (Fisher Scientific, Edmonton, AB, Canada) previously blanked with pyridine-free Karl 
Fischer reagent (BDH, Edmonton, AB, Canada) and titrated with the same reagent. Ten microliters of 
purified water (Milli-Q™ Water System, Milford, MA, USA) was used to standardize the Karl Fischer 
reagent. A 20 second delay was used to ensure end point stabilization. Formulations were analyzed in 
triplicate (n=3)..  
4.3.7. Size and ζ-potential measurements 
Fresh and rehydrated formulations were transferred into a cuvette (DTS1061, Malvern 
Instruments, Worcestershire, UK) for size distribution and zeta-potential measurements using a Zetasizer 
Nano ZS instrument (Malvern Instruments, Worcestershire, UK). Each sample was measured four times, 
and the results were expressed as the average ± standard deviation (SD) of three samples (n=3) with a 
corresponding polydispersity index (PDI) value. 
4.3.8. Ethidium bromide binding 
Fresh and rehydrated samples containing 0.5 µg pDNA were tested in 1% agarose gel stained with 
ethidium bromide (EtBr) (0.01%) using Bio-Rad PowerPac HC electrophoresis apparatus (Biorad, 
Mississagua, ON, Canada) in tris-acetate-EDTA (TAE) buffer at 100 V for 45 minutes. EtBr was 
visualized by UV fluorescence using an AlphaImager™ (Alpha Innotech, San Leandro, CA, USA). 
4.3.9.Circular dichroism spectroscopy 
Fresh, lyophilized, and stored formulations (3 months), prepared/reconstituted to a 15 µg/mL 
pDNA concentration, were evaluated by using circular dichroism (CD) spectroscopy. CD spectra were 
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obtained by using a Pi-star-180 instrument (Applied Photophysics, Leatherehead, UK) with 2 nm slit at 
37 ˚C under a N2 atmosphere.  
4.3.10. Cell culture and in vitro transfection  
COS-7 African green monkey kidney fibroblasts cell line (ATCC, CRL-1651) were cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
antibiotic and incubated at 37 ˚C with 5% CO2. On the day before transfection, the cells were seeded in 
96-well tissue culture plates (Falcon, BD Mississauga, ON, Canada) at a density of 1.5×10
4
 cells/well. 
One hour prior to transfection, the supplemented DMEM was replaced with DMEM. The cells were 
transfected with 0.2 µg pGThCMV.IFN-GFP plasmid/well in quadruplicate. Lipofectamine Plus reagent 
(Invitrogen Life Technologies) was used as a positive control according to the manufacturer’s protocol 
with 0.2 µg pDNA/well in quadruplicate. The 96-well tissue culture plates were then incubated at 37 °C 
in CO2 for five hours. The transfection agents were removed and replaced with supplemented DMEM. 
Supernatants containing the secreted IFN-γ were collected at 24, 48 and 72 h and replaced with fresh 
supplemented DMEM. The collected supernatants were stored at -80 ˚C. 
4.3.11. Enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assay (ELISA) was performed using flat bottom 96-well plates 
(Immulon 2, Greiner Labortechnik, Frickenhausen, Germany) following the BD Pharmingen protocol 
and as described earlier.
4
 The concentration of expressed IFNγ was calculated from a standard IFNγ 
curve using recombinant mouse IFN-γ standard (BD Pharmingen, BD Biosciences). 
4.3.12. Statistical analysis  
Statistical analyses were performed using SPSS software (Version 17.0). Results expressed as the 
average of n ≥ 3 ± SD. One way analysis of variance (ANOVA, Dunnett's test) and Pearson’s correlation 
were used for statistical analyses.  Significant differences were considered at p<0.05 level.  
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4.4. Results 
4.4.1.Characterization of fresh formulations  
Sugars are widely used as cryoprotectants and stabilizing agents for lyophilized lipid-based gene 
delivery systems.
29,32,37
 Based on preliminary formulation studies (results not shown), sucrose and 
trehalose were selected for this work. In addition, two different formulation approaches were developed 
in an aim to maintain the essential physiochemical properties of the P/G/L delivery system (i.e., particle 
size and zeta potential) upon lyophilization. For the first method [Method A, Table 4.1], the pDNA was 
complexed with the gemini surfactant to form P/G lipoplexes first, and the DOPE vesicles were 
incorporated afterward. [P/G/L-S]  lipoplexes prepared by this method, formulated in 9.25% sucrose, 
were comprehensively characterized in our previous work.
36,38
 The lipoplexes had a particle size of 
124±1.9 nm and zeta potential of +29±4.8 mV [Table 4.2-A]. However, when 10% trehalose was used in 
the formulation [P/G/L-T] instead of sucrose, a major drop in both size and zeta potential (average size 
of 81.7±0.6 nm, zeta potential of +21.4±2.5) were observed [Table 4.2-A].  
In addition to the previously established lipoplex preparation method [Method A], another 
formulation method was described in this work [Method B, Table 4.1]. In the P-[G/L-S] formulation, 
sucrose solution (9.25%) was used to prepare the G/L vesicles. While the composition of this 
formulation was the same as [P/G/L-S], this preparation method caused a significant increase in both 
particle size (by approximately 60 nm) and zeta potential (16 mV) [Table 4.2-A]. Similarly, trehalose 
was used as cryoprotectant to prepare formulation P-[G/L-T] following Method B [Table 4.1]. Both 
particle size and zeta potential showed in excess of 65% increase compared to the chemically identical 
formulation prepared by Method A [P/G/L-T].
 1
0
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Table 4.2: The influence of lyophilization process on the physiochemical properties (particle size, zeta potential and pH of lipoplexes   
Formulation 
[A] Fresh (time zero) [B] After lyophilization 
Size (nm) 
(PDI) 
Zeta potential 
(mV) 
pH Size (PDI) 
Zeta potential 
(mV) 
pH 
[P/G/L-S] 124.3±1.9 (0.220±0.007) 29.0±4.8 5.8±0.08 126.8±1.8 (0.237±0.023) 36.4±5.9 5.7±0.15 
[P/G/L-T] 81.7±0.6 (0.221±0.007) 21.4±2.5 7.4±0.17 100.8±1.3 (0.298±0.009) 23.3±2.3 7.0±0.07 
P-[G/L-S] 183.6±2.7 (0.393±0.012) 45.3±1.8 6.0±0.10 194.3±5.6 (0.377±0.012) 47.7±5.2 5.8±0.08 
P-[G/L-T] 158.7±2.7 (0.289±0.016) 35.8±1.5 6.8±0.17 199.7±4.0 (0.250±0.016) 49.7±4.0 6.8±0.17 
Values are shown as the average of three measurements of each formulation at [A] zero time (fresh) and [B] just after lyophilization cycle ± 
standard deviation.  
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Circular dichroism (CD) measurements showed that all fresh formulations induced changes in 
the native structure of the DNA, as observed in the alterations in the CD spectra [Figure 4.2]. The 
spectrum of free pDNA showed two positive peaks at 255 nm and 290 nm and a negative tail in the 
region of 240-250 nm [Figure 4.2-A]. Upon complexation of the pDNA with the fresh formulation 
[P/G/L-S], a blue-shift was observed for the positive peak at 290 nm and a depression of the 255 nm 
peak [Figure 4.2-B]. Conversely, the [P/G/L-T] formulation caused a red-shift of the positive peak at 
290 nm and a flattening of the 255 nm peak [Figure 4.2-C]. The complexation of pDNA with the [G/L] 
system caused a red-shift of the 290 nm peak with a negative tail for the area below 270 nm in both P-
[G/L-S] and P-[G/L-T] formulations. 
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Fresh pDNA 
 
Fresh Formulations 
 
 
Lyophilized Formulations 
 
 
Figure 4.2: Circular dichroism [CD] of [A] free pDNA, [B,C] fresh formulations and [D,E] the 
lyophilized formulations. Values are average of three measurements [n=3]. 
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The influence of different sugars and preparation methods on the in-vitro transfection activity of 
fresh formulations was also investigated [Figure 4.3, white bars]. All fresh formulations showed 
significant levels of gene expression compared to non-transfected COS-7 cells and cells treated with 
[G/L] system. The [P/G/L-S] formulation showed the highest gene expression activity with 8.2±2.6 ng 
of IFNγ/1.5×104 COS-7 cells after 72 hour of the transfection. The lowest gene expression among all 
fresh formulations was observed for the [P/G/L-T] formulation, which showed 2.3±1.9 ng IFNγ/1.5×104 
COS-7 cells. Formulation P-[G/L-S] [Method B] showed significantly lower gene expression activity 
compared with the corresponding [P/G/L-S] formulation. However, no significant difference between 
the transfection efficiency of the P-[G/L-T] and formulation [P/G/L-S] was observed.  
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Figure 4.3: Gene expression activity of lipoplex (ELISA-IFNγ) after 72 h. White columns 
represent fresh formulations. Grey columns represent the influence of lyophilization [lyophilized 
formulations]. Results are average of three samples of each formulation (n=3), error bars ± SD. * 
Indicates significant at p < 0.05. 
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4.4.2.Influence of lyophilization/rehydration processes  
4.4.2.1. Particle size and zeta potential 
The lyophilized formulations [P/G/L-S]lyp and [P/G/L-T]lyp showed particle sizes less than 130 nm 
whereas the particle size values of the formulations P-[G/L-S]lyp and P-[G/L-T]lyp were approximately 
200 nm [Table 4.2-B]. The lyophilization process caused a significant increase (p < 0.05) in the particle 
size of all formulations (11 to 41 nm) except for the [P/G/L-S] formulation (2 nm increase was 
observed). The zeta potential [Table 4.2-B] increased in all formulations upon lyophilization (2 to 13 
mV).  
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4.4.2.2. DNA compaction  
Similar to fresh formulations, lyophilized formulations altered the CD spectra of pDNA. The CD 
spectra of [P/G/L-S]lyp and [P/G/L-T]lyp showed an increase in the positive ellipticity of the 290 nm peak 
and a flat positive area above 290 nm. In addition, a blue-shift of the peak at 255 nm with a depression 
to negative values was observed [Figure 4.2, D and E, solid line]. 
The lyophilized [G/L] system in the case of formulations P-[G/L-S]lyp and P-[G/L-T]lyp caused a 
red-shift of the 290 nm peak to 295 nm and blue-shift of the 255 nm with a significant depression to 
negative values [Figure 4.2, D and E, dotted line]. 
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4.4.2.3. Ethidium bromide binding  
The influence of lyophilization on the interaction between the pDNA and gemini surfactant 
12-7NH-12 was assessed by using ethidium bromide binding assay and gel electrophoresis 
[Figure 4.4]. The gel image shows that the pDNA was completely retarded in all freshly prepared 
[P/G/L] and P-[G/L] systems incorporating both sucrose and trehalose cryoprotectants, 
indicating that it was totally shielded by the gemini surfactant [Figure 4.4-B]. The lyophilization 
process had no effect on the pDNA/gemini surfactant interaction as no pDNA migration was 
observed in any of the lyophilized formulations [Figure 4.4-C]. 
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[A] 
Free 
pDNA 
[B] 
Fresh Formulation 
[C] 
Lyophilized Formulations [Time Zero] 
[P/G/L-S] [P/G/L-T] P-[G/L-S] P-[G/L-T] [P/G/L-S]lyp [P/G/L-T] lyp P-[G/L-S] lyp P-[G/L-T] lyp 
   
Figure 4.4: Ethidium bromide binding assay using agarose gel 
electrophoresis [A] free pDNA 0.5 µg, [B] fresh formulations showed total 
binding of the pDNA to the gemini surfactant with no pDNA band being 
observed in all four formulations, [C] lyophilized formulations, no pDNA 
band was observed in all formulations upon lyophilization proving that the 
lyophilization process did not affect the pDNA-gemini surfactant binding.  
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4.4.2.4. In vitro transfection activity  
Lyophilized formulations were evaluated for their in-vitro transfection in COS-7 cell line 
to investigate the influence of the lyophilization process on the gene expression activity [Figure 
4.3, gray bars]. Interestingly, freeze-drying significantly improved the transfection activity of 
three formulations (p < 0.05) in comparison to corresponding fresh formulations. The P-[G/L-
S]lyp formulation showed the most significant improvement in transfection activity 
(approximately 3.5 fold). Similarly, the [P/G/L-T]lyp and P-[G/L-T]lyp formulations exhibited a 
significant increase (2.5 fold). The [P/G/L-S]lyp formulation showed no significant change in 
transfection activity after lyophilization.  
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4.4.3. Stability study  
4.4.3.1. Particle size and zeta potential  
The lyophilized cake of all formulations retained a free powdery appearance throughout 
the stability study [Figure 4.5]. The rehydrated formulations at all sampling times were clear 
dispersions with no visible particles.  
Particle size and zeta potential values, of the lyophilized formulations, were measured 
during the stability study, and compared to the corresponding fresh non-lyophilized formulations 
(time zero) [Figure 4.6].  
The particle size and PDI of the formulations preserved with sucrose, [P/G/L-S]lyp, 
revealed no significant changes during the three-month study compared with the fresh lipoplexes 
[P/G/L-S] at time zero. Conversely, the particle size and PDI values of the lyophilized [P/G/L-
T]lyp formulation, stabilized with trehalose, increased with time and displayed a significant size 
increase of approximately 20% within the first month of storage (p < 0.05).  
The values of the particle size of formulations P-[G/L-S]lyp and P-[G/L-T]lyp displayed 
some fluctuation during the study. For instance, in comparison to the fresh P-[G/L-S] at time 
zero, the particle size of lyophilized P-[G/L-S]lyp showed a significant decrease within the first 
two months of storage (p < 0.05). The particle size decreased significantly (p < 0.05) from 
183±2.7 nm at time zero to 113±3.9 nm at the second sampling point. After 3 months, an 
increase in particle size was observed (129 nm) in comparison to the value at the 2-month time. 
Nevertheless, the particle size remained within the range of 100-200 nm at all sampling points. 
The influence of storage on the zeta potential of lyophilized formulations was monitored 
through the three-month stability study [Figure 4.6-B]. In all lyophilized formulations, a positive 
zeta potential was maintained during storage. Formulations [P/G/L-S]lyp showed significant (p < 
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0.05) increase in zeta potential values upon storage with a maximum increase observed at the 
three month sampling point (46±5.1 mV). The zeta potential for formulations [P/G/L-T]lyp 
remained steady during storage (ranging from 20 to 24 mV), whereas, the P-[G/L-S]lyp 
formulation fluctuated slightly during storage. Finally, the zeta potential of lyophilized 
lipoplexes of P-[G/L-T]lyp showed a significant increase (20%, p < 0.05) after one month of 
storage followed by a significant, continuous decrease with time to the 3-month value of 
20.8+6.6 mV.  Overall, the zeta potential of all formulations remained positive throughout the 
storage period. 
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[P/G/L-S]lyp [P/G/L-T]lyp P-[G/L-S]lyp P-[G/L-T]lyp 
[A] Lyophilized formulations just after the freeze-drying cycle 
    
[B] Lyophilized formulations after three months of storage at 25 ˚C 
    
Figure 4.5: the appearance of lyophilized cake of four formulations [A] just after the freeze 
drying and [B] the influence of time after three months of storage at 25 ˚C. 
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Figure 4.6: The influence of time on [A] the particle size and [B] zeta potential 
stored at 25 ˚C. Results are average of three samples of each formulation 
(n=3), error bar ± SD.  
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4.4.3.2. Ethidium bromide binding  
The pDNA band was not observed in all lyophilized formulations after three months of 
storage at 25 
˚
C/75% RH. This observation provided evidence that the complete interaction of 
the pDNA with the cationic gemini surfactant was maintained throughout the study [Figure 4.7-
B]. 
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[A] 
Free pDNA 
[B] 
Lyophilized Formulations 25 ˚C 
[P/G/L-S]lyp [P/G/L-T] lyp P-[G/L-S] lyp P-[G/L-T] lyp 
  
Figure 4.7: Ethidium bromide binding assay using agarose gel 
electrophoresis [A] free pDNA 0.5 µg, [B] lyophilized formulations 
stored at 25 ˚C for three months. 
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4.4.3.3. Moisture content 
The moisture content of lyophilized formulations was determined to assess the efficiency 
of the freeze-drying process and to evaluate the effect of storage on the moisture content. 
Following the freeze-drying cycle, the moisture content in all formulations was less than 2% 
(w/w). After three months of storage at 25 ˚C, the moisture content in the lyophilized cake 
increased by 55-170% compared to the values reported just after the lyophilization [Table 4.3].  
 
Table 4.3: Moisture content of lyophilized formulations (%w/w) 
Formulation Before storage  After storage 
[P/G/L-S]lyp 1.8±0.2 2.8±0.2 
[P/G/L-T]lyp 1.5±0.3 3.1±0.5 
P-[G/L-S]lyp 1.3±0.2 3.5±0.2 
P-[G/L-T]lyp 1.5±0.3 3.0±0.1 
Values are shown as the average of three measurements of each formulation at each sampling point ± 
standard deviation.  
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4.4.3.4. In vitro transfection activity  
Upon storage at 25 ˚C, formulations P-[G/L-S]lyp and P-[G/L-T]lyp were able to preserve 
the transfection levels of their corresponding fresh non-lyophilized formulations for up to two 
months of storage [Figure 4.8].  
After three months, formulations [P/G/L-S]lyp, P-[G/L-S]lyp and P-[G/L-T]lyp showed a 
significant decrease in transfection activity with maximum reduction reported for formulations 
P-[G/L-S]lyp and P-[G/L-T]lyp (> 70% and 80% loss in activity, respectively, Figure 4.8). The 
transfection activity of [P/G/L-S]lyp was reduced by approximately 40% compared to the original 
activity of non-lyophilized [P/G/L-S]. Formulation [P/G/L-T]lyp was the most stable formulation 
in terms of retaining its starting transfection activity, with no significant change observed 
throughout the three month period of study.  
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Figure 4.8: In vitro transfection activity of the lyophilized formulations stored at 25 ˚C for three 
months (ELISA-IFNγ). Results are the average of three samples of each formulation (n=3), error 
bars ± SD. * Indicates significant at p < 0.05 level. 
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4.5. Discussion  
The purpose of this work was to evaluate freeze-drying as a technique to improve the 
stability of pDNA/gemini surfactant lipoplexes and to investigate the influence of the 
lyophilization and storage conditions on the essential physiochemical properties and in-vitro 
transfection activity of the lipoplexes. We have developed in recent years a series of cationic 
gemini surfactants as a chemical carrier for DNA delivery.
4,9,38,39
 Although a significant 
improvement in gene expression activity and improvement in the cellular safety profile have 
been achieved, the instability of the pDNA/gemini surfactant lipoplexes in aqueous formulations 
remained a concern. Due to several physical and chemical factors, freshly prepared formulations 
showed loss of transfection activity after one week of storage at room temperature (results not 
shown). The physical instability of the lipoplexes is a result of changes in physiochemical 
properties such as particle size and positive zeta potential. When stored at room temperature, 
these positively charged particles tend to form micro-sized aggregates as a function of random 
collisions, Brownian motion, and gravity forces.
18,40
 These changes can cause the loss of the 
supra-molecular structure of the lipoplexes leading to the leakage of the pDNA from the lipoplex 
and loss of its biological activity.
18,40
 The chemical stability of the different components of the 
lipoplexes (i.e., pDNA, gemini surfactant, DOPE) depends on the storage environment, namely 
pH of the formulation, temperature and the presence of metal contaminants.
15-17,27,41
 All these 
factors can lead to loss of the integrity of the lipoplexes and reduction of the gene delivery 
efficiency. Thus we investigated different formulation strategies to optimize the physiochemical 
stability of the lipoplexes and evaluate whether lyophilization could preserve their structural 
integrity and transfection efficiency.   
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As mentioned previously, the lyophilization process includes three stress steps that can 
destabilize the lipoplexes: freezing, drying (dehydration) and rehydration. Aggregation of the 
lipoplexes and a shift to negative zeta potential upon lyophilization/rehydration were observed 
when formulations were prepared without cryoprotectant agents (results not shown). For that 
reason, we evaluated several cryo-/lyo-protectants to determine whether they could stabilize and 
protect the lipoplexes during the freezing and lyophilization processes. The physiochemical 
properties that were examined included the particle size and zeta potential of the lipoplexes as 
several previous studies had reported a strong relation between the physiochemical properties of 
lipoplexes and cellular uptake and consequently, transfection activity.
12,42,43
 In the pilot 
evaluation of the cryoprotectant activity of different agents (data not shown), we assessed a 
number of stabilizing agents as a function of concentration and different combinations. These 
agents included monosaccharaides (glucose), disaccharides (sucrose, trehalose, lactose), 
polymers (polyethylene glycol) and simple polyol (glycerin). Disaccharide sugars, sucrose and 
trehalose, effectively maintained the particle size and the positive surface charge of the 
lipoplexes after lyophilization, similar to previous assessments that evaluated these agents during 
the lyophilization of chemically based gene delivery vectors.
29,34,44,45
 Based on these findings, 
sucrose and trehalose were selected as lyo-/cryo-protectant agents to investigate the factors 
affecting the long-term stability of lyophilized gemini surfactant based lipoplexes.  
4.5.1. Characterization of fresh formulations 
The physiochemical and biological properties of four different lyophilized formulations 
were evaluated for stability at room temperature (25 ˚C). Fresh formulation [P/G/L-S] prepared 
in 9.25% sucrose, our standard formulation, showed the highest gene expression activity among 
all fresh formulations evaluated in this work. The replacement of sucrose by 10% trehalose in the 
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formulation [P/G/L-T] caused significant changes in physiochemical properties, as the particle 
size and zeta potential both decreased. Additionally, CD results showed that the [P/G/L-T] 
altered the native structure of pDNA in a different manner compared to standard formulation 
[P/G/L-S].  As a result, the transfection activity was severely hampered resulting in a low level 
of IFNγ expression (60% reduction compared with [P/G/L-S]). The reduction in the particle size 
can be attributed to the pH-active imino group of the 12-7NH-12 gemini surfactant as the pH 
value of [P/G/L-T] formulation increased to 7.4 as compared to fresh [P/G/L-S] formulation (pH 
5.8) [Table 4.2-A].
38
 Given these results, we hypothesize that trehalose produces strongly 
compacted lipoplexes that hinders the release of the pDNA after the cellular uptake, thus causing 
a lower level of gene expression.  
Formulations P-[G/L-S] and P-[G/L-T] were prepared initially to investigate the effect of 
the lyophilization process and storage conditions on the gemini surfactant/DOPE [G/L] lipid 
structure. They have the same chemical composition as formulations [P/G/L-S] and [P/G/L-T], 
respectively. 
 However, elimination of the pDNA from the lyophilized complex could permit the 
determination of whether any alteration in transfection activity, upon lyophilization and storage, 
is a result of DNA degradation or due to changes in the [G/L] polymorphic structure. The 
modification of the preparation method led to changes in the physiochemical properties and 
transfection activity. Fresh formulations P-[G/L-S] and P-[G/L-T] formed lipoplexes with larger 
particle size and greater positive zeta potential values compared to formulations [P/G/L-S] and 
[P/G/L-T], prepared by method A. In the standard formulation method [Method A, Table 4.1], 
the primary lipoplexes are formed by the electrostatic interaction between the gemini surfactant 
and pDNA producing the [P/G] lipoplexes. After the formation of the P/G lipoplexes, addition of 
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DOPE vesicles can induce polymorphic changes in the lipoplex structure by producing a lipid 
bilayer packed in lamellar, cubic or inverse hexagonal morphologies.
8,38
 The excess of the 
gemini surfactant (10 to 1 positive to negative charge ratio) provides the positive surface charge 
for the P/G/L system. On the other hand, the first step in the preparation of P-[G/L] systems 
[Method B, Table 4.1] involves the formation of [G/L] vesicles by the incorporation of the 
gemini surfactant into the DOPE film. Therefore, it is assumed that different polymorphic 
structures were induced in which the gemini surfactant molecules with DOPE form a bilayer 
lipid membrane and the positively charged gemini surfactant molecules are distributed in both 
layers. The addition of pDNA to the [G/L] bilayer system caused the formation of lipoplexes 
with larger particles that are more positively charged than the [P/G/L] systems. The [G/L] lipid 
systems were able to completely interact with the pDNA as no pDNA bands were observed in 
ethidium bromide gel-electrophoresis [Figure 4.4-B] and this interaction caused changes in the 
pDNA structure as the CD spectra of pDNA was also shown to be altered. It is important to note 
that, CD spectra obtained from fresh P-[G/L-S] and P-[G/L-T] formulations were nearly identical 
but differed significantly from the spectra of the fresh [P/G/L-S] and [P/G/L-T] formulations 
[Figure 4.2-B,C].  
These modifications in physiochemical properties caused significant changes in the 
biological activity as observed by the levels of gene expression. In the case of P-[G/L-S] 
formulation, the transfection activity was considerably reduced (40%) in comparison to [P/G/L-
S]. Conversely, formulation P-[G/L-T] showed a substantial improvement in gene expression 
level compared to [P/G/L-T]. Since not all the gemini surfactant molecules in [G/L] vesicles 
were available to completely interact with the pDNA, the lipoplexes formed in the P-[G/L] 
formulations resulted in less compacted pDNA. Therefore, the lower gene expression activity of 
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the P-[G/L-S] systems could be related to the loose DNA-compaction that could cause premature 
release of the DNA before nuclear internalization. On the other hand, the subordinate pDNA 
compaction caused by [G/L-T] improved the transfection activity of P-[G/L-T] lipoplexes in 
comparison to highly compacted [P/G/L-T] lipoplexes.  
4.5.2. Influence of lyophilization on the lipoplexes properties  
A major focus of this work was to examine the effect of the lyophilization process on the 
transfection efficiency of the lipoplexes. A significant improvement in gene expression activity 
was observed for three formulations upon freeze-drying; [P/G/L-T]lyp, P-[G/L-S]lyp and P-[G/L-
T]lyp [Figure 4.3]. The  P-[G/L-S]lyp and P-[G/L-T]lyp formulations showed more than a 40% 
increase in gene expression levels compared to the activity of standard fresh formulation [P/G/L-
S].  
The results indicated that both particle size and zeta potential increased after lyophilization 
in all formulations [Table 4.2-B]. Additionally, the lyophilization altered the CD spectrum of 
pDNA in a different manner compared to the CD spectra obtained from fresh formulations 
[Figure 4.2, D and E]. We believe that these modifications were caused by changes in the lipid 
phase arrangement as a result of the freezing and dehydration cycles of the lyophilization 
protocol. In fact, previous studies reported relatively similar increases in transfection activity of 
cationic lipid/DNA complexes after freezing or lyophilization stresses. For instance, cationic 
hydroxyethylated cholesterol (DMHAPC-Chol) co-formulated with helper lipid DOPE as a 
system for gene delivery showed a four to five-fold increase in gene expression activity after 
lyophilization compared to the fresh non-lyophilized liposomes.
46
 The improvement in gene 
activity profile was correlated to the degree of hydration of the phosphate head groups of DOPE 
leading to polymorphic phase change as observed by NMR spectra of hydrated and dehydrated 
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lipid systems.
46
 Similarly, a three-fold increase in transfection activity of the DOTAP:DOPE 
system was observed after a freeze-thaw cycle compared to freshly prepared lipoplexes in the 
absence of the cryoprotectant.
22
 However, lyophilization did not increase the transfection 
efficiency of the lipoplexes prepared with sucrose as cryoprotectant, the activity remained at the 
level of the fresh formulation.
22
 The improvement in gene expression activity was only reported 
in lipoplexes co-formulated with DOPE and the increase of transfection activity of frozen 
formulation was justified by possible structural alteration of DNA/lipid complexes induced by 
the freezing stress.
22
  It should be noted that in both studies, no cryo- or lyo-protectant agents 
were employed during the freezing/drying cycles. 
In the present study, improvements of transfection activity were only observed for three 
lyophilized formulations and only when disaccharide sugars (sucrose or trehalose) were used. 
The improvement can be attributed to the alteration in the supramolecular structure of the 
lipoplexes induced by the disaccharide sugars during the freeze-drying cycle. A number of 
studies have proposed different hypotheses that explain the protective mechanisms of lyo-/cryo-
protectant agents during the freeze-drying process of biopharmaceutical products. These 
hypotheses include: preferential exclusion, vitrification, particle isolation and water replacement 
hypotheses.
47-51
 The water replacement hypothesis is a well-established hypothesis proposing 
that lyoprotectant sugars are able to form hydrogen bonds with the lipid phase of liposomes and 
replace the surrounding water molecules leading to stabilization of the structure of lipid 
membrane during the dehydration phase. 
50,51
 
Based on the water replacement hypothesis, we believe that the disaccharide sugars 
(sucrose and trehalose) form a hydrogen bond with the C=O and P=O moieties of the DOPE 
head group lipid molecules, more favorably than with the quaternary ammonium head group or 
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the nitrogen atom of the spacer region of the gemini surfactant.
52,53
 In addition, DOPE is more 
abundant on the outer surface of the lipoplexes compared to 12-7NH-12 molecules (1 to 10 
molar ratio). This interaction facilitates the preservation of the original supramolecular structure 
of the fully hydrated system during the drying step. Additionally, the effect of replacing water 
molecules by sugar can explain the increase of the particle size upon lyophilization. 
Consequently , after rehydration of lyophilized formulations,  we assume an alteration of the 
surface properties of [G/L]lyp  systems occurred due to partial rehydration of the DOPE 
molecules imposing the formation of an inverted hexagonal phase rather than the cubic or 
lamellar phases.
54,55
 Previous studies indicated that the [P/G/L] systems exist in a mix of 
polymorphic phases (i.e., lamellar, cubic and hexagonal).
8
 It was established that the inverted 
hexagonal phase is responsible for high transfection in in-vitro transfection.
56,57
 Thus, upon 
rehydration, the P/G/L system might assume more hexagonal structure rather than a polymorphic 
assembly. We plan to investigate the assembly of the rehydrated formulations in the future by 
small and wide angle x-ray scattering. 
Another potential explanation for the increase in the transfection activity might be due to 
the stress resulting from the freezing step (i.e., cryoconcentration effect) and the interaction of 
sugar molecules with the [G/L] lipid phase. It was established that this effect could cause fusion 
of the lipid bilayer membrane.
58,59
  Based on this, it is possible that during the freezing cycle, 
free 12-7NH-12 vesicles (or free molecules) present in the fresh formulations, particularly in the 
case of P-[G/L-S]lyp and P-[G/L-T]lyp, were incorporated in the G/L vesicles. Upon rehydration 
and the addition of pDNA, the lipoplexes might have formed at an higher apparent +/  charge 
ratio compared to fresh P-[G/L-S] and P-[G/L-T].
22
 In fact, this mechanism can explain the 
135 
 
increase in zeta potential values that are observed after the lyophilization/rehydration cycle 
[Table 4.2-B].  
4.5.3. Stability study  
We evaluated the stability of four lyophilized formulations stored at 25 ˚C for three 
months to investigate the ability of lyophilization to improve the shelf stability of gemini 
surfactant lipoplexes. It was found that the ability of the formulations to preserve the transfection 
activity was dependent on the formulation method and the nature of the protectant sugar.  
During the stability study, the lyophilized cake in all formulations maintained the original 
solid aspect and no shrinking or collapse of the lyophilized cakes was observed [Figure 4. 5-B]. 
Additionally, the lyophilized products were reconstituted to form clear dispersions with no 
aggregation or large particles. All lyophilized formulations retained particle size within the 
original size range (100-200 nm) and positive zeta potential values throughout the three months 
[Figure 4.6]. The lyophilized formulations containing the pDNA (i.e., [P/G/L-S]lyp and [P/G/L-
T]lyp) were able to preserve adequate levels of gene expression up to three months of storage. 
Formulation [P/G/L-S]lyp maintained the same transfection activity as the fresh formulation (time 
zero) for one month of storage and approximately 60% of original activity after three months of 
storage [Figure 4.8]. Formulation [P/G/L-T]lyp ,with trehalose as freeze-drying protectant agent, 
was able to preserve almost 70% of the gene expression activity of the fresh [P/G/L-T] 
formulation at the end of the study [Figure 4.8]. We believe that the partial loss of the 
transfection activity of [P/G/L-S]lyp and [P/G/L-T]lyp formulations is  due to conformational 
changes in the lipoplex structure, particularly in the presence of sucrose cryoprotectant [Figure 
4.6] 
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While formulations P-[G/L-S]lyp and P-[G/L-T]lyp stored at 25 ˚C were able to maintain 
their transfection activity for two months, during the third month both formulations lost more 
than 60% of their original transfection activity. As there was no difference between these 
formulations and the [P/G/L-S]lyp and [P/G/L-T]lyp formulations lyophilized and stored with the  
pDNA, we believe that the loss of the activity after three months of storage is a result of the loss 
of the [G/L] bilayer arrangement resulting from the freeze-drying cycle rather than DNA 
degradation.  
The moisture content of lyophilized formulations showed an increase with time for most 
of the formulations upon storage [Table 4.3]. However, no correlations were observed between 
the changes in the moisture content and the physiochemical properties and biological activity of 
the lyophilized formulations during the stability study at both conditions. In fact, Yu and co-
workers, found that there is no correlation between the biological activity of lyophilized DC-
Cholesterol:DOPE-based lipoplexes and the level of moisture content when samples were stored 
for three months at room temperature.
60
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4.6. Conclusion  
We evaluated the practicality of lyophilization to formulate cationic gemini surfactant-
based lipoplexes with long-term stability at room temperature. Both trehalose and sucrose were 
useful as lyoprotectant agents to stabilize the physiochemical properties of lipoplexes during the 
freeze-drying. Substantial enhancements in transfection efficiencies of gemini surfactant/DNA 
lipoplexes after lyophilization of G/L systems were observed. These observations were attributed 
to more balanced compaction of the DNA and the possible formation of inverted hexagonal 
phase lipoplexes.  Lyophilization appears to be acceptable as a formulation technique to prepare 
highly efficient gemini surfactant-based lipoplexes. The stability study at 25 ˚C showed that the 
lyophilized [G/L]lyp lipoplexes formulated with sucrose and trehalose can be stored at room 
temperature for up to two months without significant changes in physiochemical properties or 
gene expression activity. The loss of transfection activity upon storage is most probably due to 
the conformational changes in the supramolecular structure of the lipid phase that result during 
the lyophilization process.   
Detailed structural characterizations of the lyophilized gemini surfactant:DOPE 
complexes and [P/G/L] lipoplexes are essential for further optimizations of the formulation 
strategies and to improve the  lyophilization technique to achieve long-term stability. This can be 
achieved by using advance techniques like small and wide angle x ray scattering. Recently we 
developed a new series of cationic gemini surfactants with amino acid and small peptide moieties 
attached in the spacer region, and have observed an improvement in the biological activity and 
cellular toxicity.
9,61
 In addition, we have synthesized a novel gemini surfactant modified with a 
targeting peptide. We plan to evaluate the effect of lyophilization on the stability of these new 
vectors and investigate the stability of the carrier during the storage using mass spectrometry. 
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5.1. Abstract  
Lipid based gemini surfactant nanoparticles have been extensively studied as non-viral 
vectors for gene therapy. Novel amino acid substituted gemini surfactants have been recently 
developed with a molecular structure consisting of two positively charged quaternary ammonium 
head groups, symmetrical saturated dodecyl tails, and a spacer region containing a secondary 
amine group. Various amino acids were attached to the amine functional group. The purpose of 
this work was to confirm the molecular structure of six novel amino acid substituted gemini 
surfactants and to establish a universal fragmentation (MS/MS) pattern of the tested compounds 
(i.e., fingerprint). This was accomplished by using a hybrid quadrupole orthogonal time-of-flight 
mass spectrometer (QqToF-MS) and a triple quadrupole linear ion trap mass spectrometer (QqQ-
LIT MS) equipped with electrospray ionization (ESI) source. The single stage QqToF-MS data 
obtained in the positive ion mode verified the molecular composition of all tested gemini 
surfactants. Tandem mass spectrometric (MS/MS) analysis showed common fragmentation 
behavior among all tested compounds, allowing for the establishment of a universal 
fragmentation pattern. The fragmentation pathway was confirmed by MS/MS/MS experiments 
utilizing a Q-Trap
TM
 4000 LC/MS/MS system. Unique product ions, originating from the loss of 
one or both head groups along with the attached tail region(s), confirmed the chemical structure 
of the tested compounds. The established MS/MS fingerprint will be used for qualitative 
purposes as well as the development of future multiple reaction monitoring (MRM) HPLC-
MS/MS quantification methods. 
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5.2. Introduction 
Nucleic acids (DNA and RNA) have been widely investigated as therapeutic agents for the 
treatment of hereditary and acquired diseases in a promising medical approach known as gene 
therapy.
1-9
 However, the great potential of gene therapy will not be fully achieved until the issue 
of improved gene delivery is properly addressed. Gene delivery vectors can be categorized as 
viral or non-viral. Viral vectors (adenovirus and retrovirus vectors) are the most effective gene 
delivery agents and have been utilized in several clinical trials.
7-9
 However, they suffer from 
numerous toxicity-related drawbacks including mortality and morbidity.
10
 In addition, the severe 
immune response caused by the viral capsid and the limited loading capacity of viral vectors 
significantly limit their therapeutic applications.
6,11
 Conversely, non-viral vectors such as 
cationic lipids have exhibited low toxicity and no immunogenic activity.
12,13
 Cationic lipids are 
able to condense genetic materials, through electrostatic interaction with the phosphate backbone 
of nucleic acid, to a nano-sized complex (lipoplex).
14
 
One specific group of cationic lipids that have demonstrated efficient transfection activities 
in-vitro and in-vivo are the gemini surfactants. They are dimeric surfactants comprised of two 
hydrophobic tail regions, each of which is covalently attached to a cationic head group linked to 
each other by a spacer region [Figure 1].
15-17
 A wide range of gemini surfactants can be produced 
through chemical modifications within the head, spacer or tail regions. These modifications are 
intended to enhance the transfection efficiency of the lipoplex while reducing cytotoxicity.
18-20
 
For instance, the inclusion of  a secondary amine functional group in the spacer region of 1,9-
bis(dodecyl)-1,1,9,9-tetramethyl-5-imino-1,9-nonanediammonium dibromide gemini surfactant,  
resulted in a nine-fold increase  in transfection efficiency in various cell lines compared to non-
substituted gemini surfactants.
19
 This increase was attributed to the pH-dependent morphological 
147 
 
changes to the DNA-gemini complex, facilitating the cytoplasmic escape of the DNA. Additional 
structural modifications include the covalent attachment of biocompatible and biodegradable 
amino acids (glycine, lysine) and dipeptides (glycyl-lysine, lysyl-lysine) to the amino group in 
the spacer region, enhancing transfection efficiency in epithelial cells while maintaining a low 
cytotoxicity profile.
20,21
  
The transfection efficiency of lipoplex depends on the integrity of the various components 
of the delivery system and their related physiochemical properties. Therefore, investigation of 
the physiochemical stability of the lipoplex during the manufacturing process and, furthermore 
its biological fate after treatment, is essential to understand and evaluate the behavior of such 
complex systems. To date, most research in non-viral gene delivery has focused on the 
development of efficient delivery systems and less work has been done to investigate the 
chemical stability and biological fate of the vector. To achieve the last goal, proper analytical 
methods should be developed for both qualitative and quantitative applications. Mass 
spectrometry (MS) and tandem mass spectrometry (MS/MS) are ideally suited to achieve this 
goal.  
Tandem mass spectrometric MS/MS studies of bioactive materials are routinely utilized for 
quantitative and qualitative analyses with high accuracy and precision.
22-25
 For example, ESI-Qq-
ToF MS/MS analysis determined the exact molecular structure of Lipid A moieties isolated from 
mutant and wild-type Aeromonas salmonicida lipopolysaccharide.
24
 Similarly, the analysis of 
saponins, naturally occurring glycosides with varieties of biological activities, using electrospray 
ionization multiple-stage tandem mass spectrometry (ESI-MS
n
) allowed for structural 
differentiation between several types of saponins.
25
 Subsequently, a liquid chromatography (LC)-
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MS/MS method was also developed for quick and precise identification of different saponins 
from plant extract.  
Recently, we confirmed the molecular structure of ten un-substituted diquaternary 
ammonium gemini surfactants belonging to two different structural families G12-s and G18:1-s 
(where 12 and 18:1 correspond to the length and saturation of the alkyl tail, [-s] corresponds to 
the length of spacer region) using an electrospray ionization (ESI) quadrupole time-of-flight (Qq-
ToF) mass spectrometer.
26
 The Q-ToF (MS/MS) analysis showed significant similarities in the 
fragmentation pattern for all tested geminin surfactants. In addition, we expanded our studies for 
MS/MS behavior of non-substituted diquaternary ammonium gemini surfactants by including 29 
compounds categorized into four distinct families based upon the molecular composition of the 
spacer region and the length of the tail group.
27
 The similarities in the fragmentation behavior 
assisted us to establish a universal fragmentation pathway for these novel compounds.  In this 
study, we determined the tandem mass spectrometric behavior of novel amino acid/peptide 
modified diquaternary ammonium gemini surfactants, specially designed for gene delivery. Mass 
spectrometric analysis was performed by positive ESI on Time-of-Flight (Q-ToF) and triple 
quadrupole linear ion trap (QqQ-LIT) mass spectrometers. The suggested fragmentation patterns 
(i.e., fingerprints) of all compounds were confirmed by means of MS/MS/MS experiments. 
 
 
Figure 5.1: General structure of cationic gemini surfactants. 
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5.3. Experimental  
5.3.1. Gemini surfactant 
Six novel mono-amino acid/dipeptide-substituted gemini surfactants were provided by Dr. 
Ronald E. Verrall’s research group (Department of Chemistry, University of Saskatchewan). The 
synthesis of these gemini surfactants and their efficiency in gene transfer were recently 
reported.
20,21
 Tested compounds were given the designation of 12-7N(R)-12, where (12) is the 
number of carbon atoms in the tail region, (7) is the length of the amine substituted spacer region 
and (R) represents the amino acid(s) substituent: 
R= Glycine, Lysine, Histidine, Glycyl-Lysine, Lysyl-Lysine, Glycyl-Glycine 
The general molecular structure of these gemini surfactants is shown in Figure 5.2. 
Stock solutions of 3mM gemini surfactant were prepared in methanol/water 50:50 and 0.1 
% formic acid and stored at -20 ˚C.  Samples for the MS experiment were further diluted 1000x 
prior to injection using the same solvent.  
 
 
 
 
 
Figure 5.2: General structure of amino acid/di-peptide gemini surfactant 12-7N(R)-12 where (R) 
corresponds to the amino acid/di-peptide substituent.  
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 Glycyl-Glycine: 12-7N(Gly-Gly)-12
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5.3.2. Electrospray-Quadrupole Orthogonal Time-of-Flight Mass spectrometry (ESI-
QqToF MS) 
Gemini surfactants were analyzed in the positive ion mode by using an API QSTAR XL 
MS/MS hybrid QqToF tandem mass spectrometer equipped with an ESI source (Applied 
Biosystems Inc., CA, USA). The instrument parameters were optimized as follows: declustering 
potential 35 V and focusing potential of 290 V. Sample solutions were infused into the source 
chamber (Turbo Ionspray source) by using an integrated Harvard syringe pump (Harvard 
Apparatus, MA, USA) at a rate of 10 µL/min with the following parameters: spray chamber 
temperature 80 ˚C – 100 ˚C, needle voltage 5500 V. Nitrogen was used as the drying gas and ESI 
nebulizing gas.  Internal calibration was used to ensure high mass accuracies and to minimize 
errors in mass measurements. Similar to our recent work
26
, we used doubly charged standards 
given that the tested gemini surfactants are doubly charged species. These include [Glu1]-
Fibrinopeptide B, Human(peptide EGVNDEEGFFSAR,  m/z 785.4821), (BaChem Bioscience 
Inc., PA, USA), and the previously characterized diquaternary ammonium gemini surfactant 
N,N-bis(dimethyldodecyl)-1,2-ethanediammonium dibromide m/z 234.2685.
28-30
 Mass spectra 
acquisitions were analyzed using the Analyst software. 
Tandem mass spectrometric analysis was obtained by collision-activated dissociation 
(CAD) using nitrogen as collision gas. The collision energy (CE) values were optimized to allow 
for a dissociation of the gemini surfactant while ensuring the abundance of the precursor ion 
(ranging from 27-33 eV).  
5.3.3. Triple Quadrupole Linear Ion Trap Mass spectrometry (QqQ-LIT MS) 
The suggested fragmentation pathways were confirmed by performing MS/MS/MS 
experiments using a Q-Trap 4000 LC/MS/MS system (Applied Biosystems, Foster City, CA, 
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USA) a hybrid triple quadrupole linear ion trap mass spectrometer (QqQ-LIT) equipped with a 
“Turbo V Ion Spray” ESI source.  The QqQ-LIT system provides valuable structural information 
because of its ability to trap ions in the LIT analyzer and, subsequently, to perform MS/MS/MS 
experiments.
31,32
  
The MS/MS/MS analysis of the precursor ion and selected product ions of the tested 
gemini surfactants were acquired in the MS/MS/MS mode. Stock samples were diluted 1000x 
and infused directly into the ionization source by using a model 11 Plus syringe pump (Harvard 
Apparatus, MA, USA) at a flow rate of 50 µL/min. The declustering potential (DP) was set in the 
range of 40-100 V (compound dependent) and collision energy (CE) was optimized to obtain the 
greatest abundance of product ions.  Excitation energy (AF2), the energy used to fragment the 
second precursor ion, was set at 100 mV. 
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5.4. Results and Discussion  
5.4.1. Single stage QqToF analysis  
For all tested mono-amino acid and di-peptide gemini surfactants, abundant doubly 
charged [M]
2+
 species were observed during the full scan ESI- QqToF-MS analysis providing 
evidence for the presence of the diquaternary ammonium head groups. In addition, the exact 
mass for the tested compounds were assessed; mass accuracies were less than 10 ppm mass error 
using internal calibration [Table 5.1]. 
5.4.2. Tandem mass spectrometric Analysis  
The variation within the substituent of the amine group of the spacer region (i.e., amino 
acid/di-peptide substituents) resulted in the production of gemini surfactant-specific product ions 
upon collision-activated dissociation (CAD) positive ESI-QqToF MS/MS analyses. The 
formation of these compound-specific product ions follows a similar fragmentation pattern for all 
mono-amino acid and dipeptide gemini surfactants, which originates from the loss of one or both 
quaternary ammonium head group(s) along with the attached tail region(s). This allowed for the 
authentication of the molecular structure, confirming the attachment of the amino acid/di-peptide 
moieties to the amine group of the spacer region.  
The following sections include a detailed discussion of the fragmentation patterns of 12-
7N(Glycyl-Lysine)-12, illustrative of a di-peptide substituted gemini surfactants with the most 
complex MS/MS spectra among all tested compounds. In addition, the MS/MS behavior of 12-
7N(Glycine)-12, illustrative of mono-amino acid substituted gemini surfactants, will be 
discussed briefly to highlight the fragmentation with mono-amino acid substituted compounds. 
Table 5.2 displays the product ions of all gemini surfactants studied herein with their 
corresponding molecular formula and the theoretical m/z values.  
  
 
  
Table 5.1: Mass Accuracies obtained from single stage ESI-QqToF MS using internal calibration. 
Gemini 
Surfactants 
Molecular 
Formula 
Mono-isotopic Mass 
Theoretical 
m/z 
Observed 
m/z 
Mass Accuracy 
(ppm) 
12-7N(Glycine)-12 C36H78N4O 582.6164 291.3082 291.3094 4.1193 
12-7N(Lysine)-12 C40H87N5O 653.6899 326.8449 326.8462 3.9774 
12-7N(His)-12 C40H82N6O 662.6539 331.3269 331.3293 7.2436 
12-7N(Gly-Lys)-12 C42H90N6O2 710.7114 355.3557 355.3571 3.9397 
12-7N(Lys-Lys)-12 C49H99N7O2 781.7849 390.8924 390.8926 0.5116 
12-7N(Gly-Gly)-12 C38H81N5O2 639.6379 319.8189 319.8185 1.2507 
1
5
3
 
 Table 5.2: MS/MS product ion designations and corresponding theoretical mass-to-charge (m/z) values for all gemini surfactants 
evaluated. 
Gemini Surfactants  
12-7N(Glycine)-12 12-7N(Lysine)-12 12-7N(Histidine)-12 12-7N(Gly- Lys)-12 12-7N(Lys-Lys)-12 12-7N(Gly-Gly)-12 
Molecular Formula C36H78N4O C40H87N5O C40H82N6O C42H90N6O2 C49H99N7O2 C38H81N5O2 
Precursor ion   [M]
2+
 291.3082 326.84495 331.32695 355.3555 390.89245 319.81895 
 
Product ions  m/z m/z m/z m/z m/z m/z 
1 [M-C12H24]
 2+
  207.21 242.75 247.23 271.26 306.79 235.72 
2 [M-(C12H24)-(C2H7N)]
 2+
 184.68 220.22 224.70 248.73 284.26 213.19 
3 [M-C14H32N-(NH3)]
 2+
   211.70 216.19 240.22 275.75 204.68 
4 [M-C14H32N-( NH3)-(C2H4)]
 2+
   197.69  226.20 261.74   
5 
[M-C14H32N-( NH3)-(C2H4)-
(C3H5N)]
 2+
 
  170.17  198.68   
6 [C21H44N2O]
2+
 170.17 170.17 170.17 170.17 170.17 170.17 
7 [(ION 6)-(CHO
+
)]
+
 311.34 311.34 311.34 311.34 311.34 311.34 
8
++
 [M-2(C12H24N) -(C2H7N)]
2+
 100.59 136.12 140.69 164.63 200.17 129.10 
8
+
 [(ION 8
++
)-(H)
+
]
+
 200.17 271.24 280.21 238.27 399.34 257.19 
9
++
 [M-2(C12H24N) -2(C2H7N)]
2+
 78.06 113.59 118.08 142.11 177.64 106.57 
9+ [(ION 9
++
)-(H)
+
]
+
 155.11 226.19 235.15 283.21 354.28 212.14 
10
++
 
[M-2(C12H24N) -2(C2H7N)
 
-
(NH3)]
2+
 
 105.15  133.59 169.13 98.06 
10
+
 [(ION 10
++
)-(H)
+
]
+
  209.16  266.18 337.25 195.10 
11 [C14H32N]
 +
 214.25 214.25 214.25 214.25 214.25 214.25 
B1 
(N-Terminal ion from peptide 
bond cleavage) 
   155.11 226.19 155.11 
Y1 
(C-Terminal ion from peptide 
bond cleavage) 
   129.10 129.10 58.02 
 
  
1
5
4
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5.4.2.1. MS/MS fragmentation pathway of the di-peptide substituted gemini surfactants 
The di-peptide gemini surfactants include three novel gemini surfactants in which a di-
peptide substituent is attached to the amine group of the spacer region: 12-7N(Glycyl-Lysine)-
12,12-7N(Lysyl-Lysine)-12and 12-7N(Glycyl-Glycine)-12. Figure 5.3 shows the ESI-QqToF 
MS/MS spectrum of 12-7N(Glycyl-Lysine)-12, as a representative for this group, and the 
proposed fragmentation  pathway. The MS/MS spectra of and the corresponded fragmentation 
pathways of 12-7N(Lysyl-Lysine)-12 and 12-7N(Glycyl-Lysine)-12 are shown in Appendices 
5.1 and 5.2, respectively.   
The fragmentation pathway of 12-7N(Glycyl-Lysine)-12 (Figure 5.3a) starts with the 
formation of the minor diagnostic  doubly charged product ion designated as [M-C12H24]
2+
 at m/z 
271.26 (ion 1, Figure 5.3b) which is formed from the neutral loss of the aliphatic tail region of 
168.18 Da. It can be speculated that due to the possible close proximity of the two positively 
charged head groups, this ion is not stable and will fragment instantly; hence, being a 
substantially minor ion. In fact, ion (1) was observed in the MS/MS analysis of all tested 
compounds as a minor fragment ion. Ion (1) fragments to the major doubly charged product ion 
observed at m/z 248.73 (ion 2) through the neutral loss of N-methylmethanamine (i.e., head 
group). It is expected that the second charge within ion 2 is localized within the di-peptide 
(Glycyl-Lysine) terminal, possibly distant from the quaternary nitrogen; hence, enhancing their 
stability and abundance in comparison to (ion 1).  
Subsequently, product ion (2) fragments via three different mechanisms into three 
diagnostic product ions (ions 3, 8
++
 and 9
+
, Figure 5.3b). Product ion (3) at m/z 240.22 is 
formed by losing a (NH3) moiety, while product ion (8
++
) is generated by the neutral loss of the 
second tail region at m/z 164.63. Additionally, product ion (9
+
) at m/z 283.21 is formed through 
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the complementary loss of the singly charged ion of the tail region with the attached head group 
m/z 214.25 (11).  
The product ion (3), designated as [M-C14H32N-(NH3)]
+2 
, is the predominant product ion 
observed in the MS/MS spectrum of 12-7N(Gly-Lys)-12 and can undergo two main 
fragmentation process. Firstly, the loss of a (NH3) from ion (3) yields the product ion (3’) at m/z 
231.70. The second mechanism involves the loss of the ethene moiety from product ion (3) 
producing a doubly charged product ion at m/z 226.20 (ion 4). This product ion is further 
fragmented to several product ions resulting from various elimination processes within the 
dipeptide residue. The neutral loss of (C3H5N) from ion (4) produces a doubly charged fragment 
ion at m/z 198.68 (ion 5). Subsequently, the loss of a carbon monoxide moiety from ion (5) 
produces a unique product ion , (ion 5’) at m/z 184.68,  with a glycine residue within the spacer 
region. Furthermore, product ion (6) is formed by the neutral loss of a methyleneimine 
(methanimine) moiety (-CH2=NH) from the head group, producing a doubly charged fragment 
ion at m/z 170.17 (ion 6). The subsequent loss of oxomethylium (HCO
+
) from this ion produces a 
singly charged product ion observed at m/z 311.34 (ion 7).  Oxomethylium is a well identified 
loss in MS analysis that can occur in two isomeric forms; HCO
+
 and HOC
+
.
33,34
 Fragment ions 
(6) and (7) are common ions observed in the MS/MS analysis of all tested compounds.  
The second fragmentation mechanism for ion 2 involves the formation of product ion (8) 
which was observed as both; singly (8
+
) and doubly (8
++
) charged ions at m/z 328.27 and m/z 
164.63, respectively. The neutral loss of the second head group from product ions (8
+
/8
++
) 
produces the diagnostic product ions (9
+
/9
++
) at m/z 283.21 and m/z 142.11. The Q-ToF MS/MS 
analysis of the precursor ion and the QqQ-LIT MS/MS/MS spectrum of ion (9
+
) [Table 5.3] 
indicates that this ion produces three main elimination products. The loss of (NH3) from the di-
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peptide residue of product ion (9) leads to the formation of product ion (10) which was observed 
as doubly charged ion (10
++
) at m/z 133.59 and singly charged ion (10
+
) at m/z 266.18. The 
formation of singly and doubly charged product ions can be explained by the presence of 
multiple nitrogen centers in the spacer region of the di-peptide gemini surfactants that can easily 
capture a proton from other species within the collision cell.  
Unique breakage of the peptide bond between the glycine and lysine amino acids produced 
two complementary fragment ions; ion (B1) that corresponds to the N-terminal ion (glycine 
residual ion) at m/z 155.11 and ion (Y1) corresponding to the C-terminal ion (lysine residual ion) 
at m/z 129.10. Designations for these ions follow the Roepstorff nomenclature for mass 
spectrometry of peptides.
35
 It should be noted that ion (B1) can also originate from ions (3) and 
(4) upon the loss of the tail region, which is supported by MS/MS/MS results [Table 5.3]. 
MS/MS/MS analysis was informative and assisted in the confirmation of the proposed 
fragmentation mechanism. For instance, the MS/MS/MS spectrum of product ion (4) shows 
fragment ions at m/z 283.21 and 266.18, ions (4’) and (4’’), respectively [Figure 5.3b, Table 5.4]. 
These product ions have the same m/z values as product ions (9
+
) and (10
+
) which are fragments 
of ion (8
+
). This can be explained by the fact that two isomers having the same m/z values were 
formed for each product ion originating by different fragmentation mechanisms [Figure 5.3b]. 
MS/MS/MS analysis allowed for the differentiation of these structural isomers. 
12-7N(Lysyl-Lysine)-12 and 12-7N(Glycyl-Glycine)-12 compounds followed the same 
fragmentation pathway as the glycyl-lysine substituted gemini surfactant [Table 5.2].  
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Figure 5.3: (a) The ESI-QqToF MS/MS spectra of 12-7N(Glycyl-Lysine)-12 as a representative 
example of di-peptide gemini surfactants (Full MS spectrum in the box), (b) the MS/MS 
fragmentation pattern showing the most distinctive product ions, other non-diagnostic product 
ions are not included. 
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Table 5.3: Summary of MS/MS/MS experiment for 12-7N(Gly-Lys)-12, using QqQ-LIT 
MS/MS fragment ions of 
12-7N(Gly-Lys)-12 
MS/MS/MS fragment ions 
        
248.73 [2] 
 
240.22 [3] 
 
226.20[4] 
198.68 [5] 
170.17 [6] 
311.34 [7] 
214.25 [11] 
155.11 [B1] 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
226.20 [4] 
 
184.68 [5’] 
170.17 [6] 
214.25 [11] 
283.21 [4’] 
266.18 [4’’] 
    
 
  
 
 
 
 
 
 
    
 
 
328.27 [8
+
] 
 
283.21 [9
+
] 
266.18 [10
+
] 
155.11 [B1] 
    
 
  
 
 
 
 
 
 
    
 
 
283.21 [9
+
] 
 
266.18 [10
+
] 
155.11 [B1] 
129.10 [Y1] 
    
 
 
 
 
 
 
 
 
    
 
 
266.18 [10
+
] 
 
155.11 [B1] 
112.07 [Y’1] 
    
  
 
 
 
311.34 [7] 
 
     
 
 
214.25 [11] 
 
     
 
 
155.11 [B1] 
 
     
 
 
129.10 [Y1] 
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5.4.2.2. MS/MS fragmentation pathway of the mono-amino acid gemini surfactants 
Mono-amino acid gemini surfactants included three novel compounds in which a single 
amino acid is attached to the amine group of the spacer region: 12-7N(Glycine)-12 ,12-
7N(Lysine)-12 and 12-7N(Histidine)-12. Figure 5.4 shows the ESI-QqToF MS/MS spectrum of 
12-7N(Gly)-12, and the corresponding fragmentation pathway. The MS/MS spectra of and 
corresponding fragmentation pathway of 12-7N(Lysine)-12 and 12-7N(Histidine)-12 are shown 
in Appendices 5.3 and 5.4, respectively. 
Similar to the fragmentation pathway of the di-peptide substituted gemini surfactants, the 
fragmentation pathway of 12-7N(Glycine)-12 begins with the production of  the characteristic 
minor doubly charged product ion [M-C12H24N]
2+
 at m/z 207.21 (ion 1, Figure 5.4b) formed 
through the neutral loss of one hydrophobic tail region as explained earlier.  This fragment ion 
further fragments to the major doubly charged product ion observed at m/z 184.68 (ion 2) 
through the neutral loss of N-methylmethanamine (i.e., head group).   
Consequently, product ion (2) can undergo three fragmentation pathways producing 
fragment ions (6), (8
++
) and (9
+
) [Figure 5.4b]. The formation of commonly observed product 
ions (6) and (7) was mentioned previously in the discussion of di-peptide substituted gemini 
surfactants. The loss of neutral methylene (CH2) moiety from the spacer region of product ion (7) 
produces a singly charged fragment ion at  m/z 297.32 (ion 7’). 
As indicated earlier, product ion (2) also yields the formation of product ion (8) through 
the neutral loss of the second twelve carbon atom tail region. This ion can exist as a doubly 
charged species (ion 8
++
) at m/z 100.59 or singly charged ion (ion 8
+
) at m/z 200.17. A neutral 
loss of the remaining head group (i.e., CH3NHCH3) from product ion (8
+
/8
++
) results in the 
formation of ion (9) which also exists as a singly charged (ion 9
+
) m/z 155.11and doubly charged 
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(ion 9
++
) m/z 78.06 (not shown in the spectrum). Product ion (9) further fragments via two 
fragmentation mechanisms. In the first mechanism, product ion (9a) is formed through the same 
mechanism as fragment ion (6); i.e., via the neutral loss of the methanimine moiety producing 
product ion (9a) at m/z 126.09. The second mechanism involves neutral loss of ethyne 
(acetylene) moiety forming fragment ion (9b) at m/z 129.10. 
Finally, as explained earlier in the case of the 12-7N(Gly-Lys)-12 compound,  product ion 
(2) can also fragment through a third pathway and form product ion (9
+
). This mechanism can 
occur through the loss of the remaining tail region with the attached head group from product ion 
(2) as a singly charged protonated ion designated as [C14H32N]
+
 observed at m/z 214.25 (ion 11). 
Similar to the 12-7N(Gly-Lys)-12 compound, the proposed fragmentation pathway for the 
12-7N(Gly)-12 was confirmed via MS/MS/MS analysis using QqQ-LIT MS1. In addition, a 
deuterated form of glycine substituted gemini surfactant has been synthesized to be used as 
internal standard for the purpose of developing a quantitative multiple-reaction-monitoring LC-
MS/MS method. This deuterated compound retains two deuterated tail regions of dodeceyl-d25 
and has the designation 12D25-7N(Glycine)-12D25. The MS/MS analysis of this compound 
confirms the proposed fragmentation pathway by showing an increase in the m/z values of 
products ions  (2), (6), (7), and (11) corresponding to the presence of deuterium in the structure 
[Table 5.4]. On the other hand, fragment ions bearing no tail regions were identical (in terms of 
structure and m/z values) to those observed on the MS/MS analyses of non- deuterated 
compound.  
Both histidine and lysine-substituted gemini surfactants followed the same fragmentation 
pattern as 12-7N(Glycine)-12 with minor variations resulting from the differences in the 
molecular structure of the amino acid substituents. For instance fragment ions (3), (4), (5) and 
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(10
+
/10
++
) [Table 5.2] were not observed in the MS/MS spectrum of 12-7N(Glycine)-12 
compound. The formation of these product ions required the loss of the (NH3) moiety from the 
terminal amino acid which is not applicable in the case of the glycine amino acid substitution. 
For the same reason, we could not observe product ions (4), (5) and (10
+
/10
++
) in the MS/MS 
analysis of 12-7N(His)-12.  However, these product ions were detected in the MS/MS analysis of 
lysine-substituted gemini surfactant due to the presence of two amine groups in the structure of 
lysine. 
In addition to this difference, the 12-7N(His)-12 gemini surfactant showed an unique 
fragmentation mechanism resulting from the presence of the heterocyclic imidazole ring: product 
ion (3) is formed by the neutral loss of the (NH3) moiety from histidine, producing a doubly 
charged fragment ion at m/z 216.19 (ion 3, Table 5.2, Figure 5.5). Distinct from the 
fragmentation pattern of glycine and lysine substituted gemini surfactants, this product ion can 
undergo two fragmentation pathways that involve hydrogen relocalization. The first pathway 
produces the commonly observed product ion (6) at m/z  170.17 (Table 5.2, Figure 5.5). The 
second pathway results in the formation of  two complementary product ions that were 
designated as (3a) and (3b) resulting from the cleavage between the carbon atom of the carbonyl 
group and the adjacent carbon atom of histidine within product ion (3). Ion (3b) observed at m/z 
339.57 is the singly charged form of ion (6). However, the production of ions (6) and (3b) occurs 
concurrently by two different mechanisms as shown in Figure 5.5.  Ion (6) is produced by 
relocalizing the second charge from the imidazole ring to the secondary amine group of the 
spacer region (proton transfer), while the singly charged ion (3b) bears a tertiary amine. It is 
worth to mention that product ion (3b) was observed only in the MS/MS analysis of 12-7N(His)-
12 compound, which confirms the proposed fragmentation mechanism. This proposition is 
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supported by the formation of a complementary ion (3a) that was observed at m/z 93.1 which 
was detected during scanning for product ions below m/z 100 (data not shown). 
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Figure 5.4: (a) The ESI-QqToF MS/MS spectra of 12-7N(Glycine)-12 as a representative 
example of mono amino acid gemini surfactants (Full MS spectrum in the box), (b) the MS/MS 
fragmentation pattern showing the most distinctive product ions, other non-diagnostic product 
ions are not included,  
(a
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Table 5.4: The difference in m/z values between 12-7N(Glycine)-12 and its deuterated form 
12D25-7N(Glycine)-12D25 confirm the proposed fragmentation pathway. 
Product ion  12-7N(Glycine)-12 12D25-7N(Glycine)-12D25 m/z Difference 
Ion 2 184.68 197.26 12.58 
Ion 6 170.17 182.75 12.58 
Ion 7 311.34 336.49 25.15 
Ion 11 214.25 239.41 25.15 
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Figure 5.5: Fragmentation mechanisms of product ion (3) of 12-7N(Histidine)-12 
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5.4.2.3. Universal MS/MS Fragmentation Pattern  
Similarities in the MS/MS fragmentation behavior of the novel mono-amino acid/di-
peptide substituted gemini surfactants allowed for the establishment of a universal MS/MS 
fragmentation pattern. Formation of product ions observed in the universal MS/MS 
fragmentation [Figure 5.6]  starts with the homolytic cleavage of (-C-N-) bond between the 
twelve carbon atom tail region  and the quaternary ammonium head group producing a minor 
doubly charged product ion [M-C12H24]
2+
 (ion 1, Figure 5.6). It is noteworthy that we were 
unable to conduct a MS/MS/MS experiment with this ion since it was always observed with very 
low intensity (except in the case of 12-7N(Gly)-12).  Product ion (1) then produces product ion 
(2) and two pathways were proposed. The first mechanism was explained by the neutral 
elimination of the head group (-C2H7N) from ion (1) forming a diagnostic doubly charged ion 
[M-(C12H24)-(C2H7N]
2+
 (Pathway A, ion 2). On the other hand, the second mechanism includes 
a neutral loss of hydrophobic tail region with the attached head group from the precursor ion 
[M]
2+
 (Pathway B, ion 2). Product ion (2) is a predominant product ion in the MS/MS spectra of 
all gemini surfactants evaluated herein. 
The product ion (2) in ESI-QqToF MS/MS conditions undergoes three main fragmentation 
processes. The elimination of (NH3) forms the doubly charged fragment ion (3) [M-C14H32N-
(NH3)]
 2+
. This fragment ion is subjected to several fragmentation processes, producing different 
product ions which are shown in Figure 5.6 and have been discussed with specific examples in 
Figures 5.3b and 5.4b.  
The second elimination process results from the heterolytic cleavage between the second 
tail region and the attached head group yielding the fragment ion (8
++
). The subsequent loss of 
the ammonium head group from ion (8
++
) gives the product ion (9
++
) designated as [M-
170 
 
2(C12H24N -2(C2H8N))]
2+
. Product ion (9
++
) is further fragmented to ion (10
++
) via the neutral 
loss of (NH3).  
In the case of the di-peptide gemini surfactants, peptide bond cleavage occurs in the 
product ion (10
++
) producing two complementary fragment ions (B1) and (Y1).  
Finally, in the third mechanism product ion (9
+
) is formed directly from product ion (2) 
through the loss of the remaining tail region with the attached head group as a singly charged 
species of m/z 214.25 (product ion 11). Products ions (8
++
, 9
++
, 10
++
) were always observed as 
minor peaks supporting the argument that the predominant singly charged form (8
+
, 9
+
, 10
+
) is 
more stable.   
Several remarkable differences are observed in the MS/MS analyses of these novel amino 
acid substituted gemini surfactants in comparison with our recent study evaluating the ESI-
QqToF MS/MS behavior of the non-substituted diquaternary ammonium gemini surfactants[25]. 
For instance, product ion (2) is diagnostic for the amino acid/di-peptide substituted gemini 
surfactants since the formation of this ion was not observed in the analysis of non-substituted 
compounds[26-27]. This can be explained by the fact that the first generation diquaternary 
ammonium gemini surfactants do not have an amine group within the spacer region which can 
easily be charged. This ion was the source of all other fragments as shown in Figures 5.3a and 
5.4a. In addition, all diagnostic product ions formed through fragmentation within the spacer 
region are observed only in substituted gemini surfactants evaluated in this work. 
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Figure 5.6: Universal MS/MS Fragmentation Pattern for 12-7N[Amino acid(s)]-12 gemini 
surfactants. 
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5.5. Conclusion  
In this study, the molecular structure of six novel mono-amino acid/di-peptide diquaternary 
ammonium gemini surfactants was confirmed using ESI-QqToF MS with internal calibration. 
The tandem mass spectrometric analysis (QqTof-MS/MS) showed similarities in the 
fragmentation patterns of all tested compounds. This allowed us to establish a universal MS/MS 
fragmentation pathway which was confirmed through performing MS/MS/MS experiments. In 
addition, we performed the MS/MS analysis for a deuterated 12D25-7N(Glycine)-12D25which 
bears deuterated tail region.  It was observed that fragment ions identical to those observed when 
analyzing non-deuterated 12-7(Glycine)-12, were generated, differing merely by the ions bearing 
the deuterated tail region(s) [Table 5.4]. This confirms the proposed universal fragmentation 
pathway shown in Figure 5.6. The deuterated compound was synthesized as an internal standard 
that will be used during the development of HPLC-MS/MS quantification methods.  
In summary, eleven common product ions were observed in the MS/MS analysis of almost 
all tested gemini surfactants. Two abundant diagnostic product ions observed in all tested gemini 
surfactants resulted from the loss of one tail region with attached head group (ion 2) or both tails 
and heads (ion 9). The proposed fragmentation pathway can be used as a “fingerprint” for rapid 
and accurate identification of these compounds in different biological or pharmaceutical 
matrices. In addition, by utilizing the MS/MS fragmentation pattern, we are currently developing 
a multiple reaction monitoring (MRM) HPLC-MS/MS method for the purpose of quantitation of 
these novel non-viral gene delivery agents.
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Appendices  
Appendix 5.1: (a) The ESI-QqToF MS/MS spectra of 12-7N(Lysyl-Lysine)-12 a di-peptide 
gemini surfactants (Full MS spectrum in the box), (b) the MS/MS fragmentation pattern showing 
the most distinctive product ions, other non-diagnostic product ions are not included.  
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Appendix 5.2: (a) The ESI-QqToF MS/MS spectra of 12-7N(Glycyl-Glycine)-12 a di-peptide 
gemini surfactants (Full MS spectrum in the box), (b) the MS/MS fragmentation pattern showing 
the most distinctive product ions, other non-diagnostic product ions are not included.  
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Appendix 5.3: (a) The ESI-QqToF MS/MS spectra of 12-7N(Lysine)-12 a mono-amino acid 
gemini surfactants (Full MS spectrum in the box), (b) the MS/MS fragmentation pattern showing 
the most distinctive product ions, other non-diagnostic product ions are not included.  
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Appendix 5.4: (a) The ESI-QqToF MS/MS spectra of 12-7N(Histidine)-12 a mono-amino acid 
gemini surfactants (Full MS spectrum in the box), (b) the MS/MS fragmentation pattern showing 
the most distinctive product ions, other non-diagnostic product ions are not included.  
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Chapter 6 
Overall conclusions 
Ideal cationic lipid-based lipoplexes should conform to the following criteria 1) high 
transfection activity and low cytotoxicity, 2) ability of targeting specific sites and 3) ability to be 
produced as a pharmaceutical dosage form with acceptable shelf stability
1,2
. The cationic gemini 
surfactant family provides a wide variety of carriers that can be modified to achieve optimum 
gene transfection activity with the ability to be customized chemically for targeting purposes. In 
our drug delivery research group in the College of Pharmacy and Nutrition, in collaboration with 
Dr.Verrall’s research group in the Department of Chemistry, a series of quaternary ammonium 
gemini surfactants have been synthesized and characterized for the purpose of using as non-viral 
gene delivery agents.
3-6
 Significant enhancements in gene expression activity (in vitro and in 
vivo) were achieved by rational modifications in the chemical structure of the gemini surfactants. 
Comprehensive physiochemical characterization and evaluation of the biological activity  were 
implemented to optimize the transfection efficiency of the synthesized compounds.
3,7-10
 
However, in-depth analytical methods for the identification and quantification of the gemini 
surfactants in mixtures have not been developed and the physical and chemical stability of the 
gemini surfactant-based lipoplexes have not been addressed or investigated. 
In the present work, two research streams were identified and explored aiming to improve 
the long term stability of gemini surfactant-based lipoplexes. The first stream was the 
investigation of the influence of different formulation strategies combined with lyophilization on 
the physiochemical stability of gemini surfactant-based lipoplexes. The second component was 
the mass spectrometric analysis of six amino acid-modified gemini surfactants that can be 
utilized for the evaluation of the chemical stability of the DNA carrier. 
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6.1. Lyophilization of gemini surfactant-based lipoplexes  
6.1.1. Formulation development and pilot evaluation of stabilizing agents 
I evaluated the feasibility of lyophilization as a technique for preparing gemini surfactant-
based lipoplexes with long term stability. In the first stage I investigated the ability of the 
lyophilization to preserve the essential physiochemical properties and transfection activity of the 
lipoplex systems. The formulation development stage revealed that the lyophilization of 
plasmid/gemini surfactant/DOPE [P/G/L] lipoplexes without any stabilizing agents caused a 
complete loss of the optimal physiochemical properties of the lipoplexes (particle size and zeta 
potential) indicating the necessity of using stabilizing agents for  lyophilization. Among all 
stabilizing agents (cryo-/lyo-protectants) evaluated in this work, disaccharide sugars sucrose and 
trehalose and glycerin (a polyol agent) were shown to be capable of preserving the properties of 
the lipoplexes and their biological activity.  
The electrostatic interaction between the pDNA and gemini surfactant was able to protect 
the pDNA and (P/G) lipoplex structure against the stress resulting from the freeze-drying cycle 
even when no stabilizing agent was used. This finding suggests that the damage caused to the 
[P/G/L] lipoplexes by the lyophilization process was due to the changes in the supramolecular 
assembly resulting from the presence of DOPE in the formulation. The pilot stability study 
showed that the presence of glycerine in the formulation prevented the complete dehydration of 
the lyophilized formulation resulting in a lyophilized cake with high moisture content. As a 
result, a complete loss of gene activity was observed after one week of storage at both 25 ˚C and 
40 ˚C.        
During the formulation development stage, I had faced some limitations and challenges. 
The major limitation was the ineffectiveness of the freeze dryer (Lyph-Lock, 6 liter bench 
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freeze-dryer, Labconco, Kansas City, MO) that could not produce a fully dehydrated product. 
Consequently, the lyophilized formulations for the pilot stability study showed high moisture 
content that negatively impacted the physical and biological stability of the formulations. 
Therefore, the results from this stability study were relatively inconclusive and were not 
discussed in details. Nevertheless, I showed that preservation of the original physical 
characteristics (particle size and the positive zeta potential) during lyophilization and storage is 
not enough to maintain the transfection activity. The major challenge in this stage was the lack of 
a suitable method for extracting the pDNA from the [P/G/L] lipoplexes to quantify the pDNA 
content after freeze-drying cycle and during the stability study. I investigated several methods for 
this purpose but all were unsuccessful.     
6.1.2. Stability study  
 Based on the results obtained from the formulation developments stage, I selected 
sucrose and trehalose as stabilizing agents and designed a three month stability study to evaluate 
the long term stability of the lyophilized gemini surfactant-based lipoplexes. I investigated two 
preparation methods [Table 4.1]. In the first method, two [P/G/L] systems were prepared in the 
stabilizing agent solution (sucrose or trehalose) by complexing the plasmid with the gemini 
surfactant first, then combining with the DOPE dispersion, followed by the lyophilisation of the 
[P/G/L] lipoplexes. I also developed the second method to overcome the challenge associated 
with the extraction and quantification of pDNA content. In this case, the [G/L] system in the 
sugar solution was prepared and lyophilized without including the pDNA in the formulation. 
Fresh pDNA was incorporated into the formulation during the rehydration step.  
The influence of the freeze-drying on the physiochemical properties of the lipoplexes 
such as particle size, zeta potential, interaction between pDNA and gemini surfactant and pDNA 
188 
 
compaction were investigated. The physiochemical characterization of lyophilized lipoplexes 
revealed that the freeze-drying process caused an increase in particle size and zeta potential 
values [Table 4.2-B]. These changes in the physiochemical properties of the lipoplexes had no 
effect on the ability of the gemini surfactant to electrostatically interact with pDNA and provide 
complete protection as showed by the ethidium bromide/gel electrophoresis [Figure 4.4-C]. 
However, the CD analysis showed that all lyophilized lipoplexes altered the native structure of 
the pDNA in a different manner compared to their corresponding fresh lipoplexes [Figure 4.2]. 
The influence of the lyophilization process on the in vitro transfection activity of gemini 
surfactant-based lipoplexes revealed an unexpected finding: it caused a significant increase in 
gene expression of three formulations just after lyophilization/rehydration cycle. The two P-
[G/L]lyp systems showed the highest increase in transfection activity (about 3-fold increase) in 
comparison with the standard fresh formulation (P/G/L-S) [Figure 4.3]. Considering the changes 
in the physiochemical properties, I proposed two hypotheses to explain the increase in gene 
expression upon freeze-drying. In the first instance, I believe that the lyophilization process 
induced polymorphic changes in the [G/L] structure forcing the formation of an inverted 
hexagonal phase that is responsible for high gene expression activity. In the second explanation, 
I proposed that during the freezing cycle free gemini surfactant molecules or vesicles in the 
formulation were incorporated in the [G/L] phase, as a result of cryoconcentration effect. This 
effect caused the formation of P-[G/L] lipoplexes with an apparent higher +/ charge ratio which 
might improve the cellular uptake and consequently transfection activity. 
I conducted a three month stability study at 25 ˚C/75 RH to evaluate the ability of 
lyophilized formulations to maintain the stability of the gemini surfactant-based lipoplexes. 
Lyophilized formulations stored at 25 ˚C showed relatively good stability [Figure 4.8]. The 
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formulations lyophilized with the pDNA (i.e., [P/G/L-S]lyp and [P/G/L-T]lyp) were able to 
maintain more than 60% of original transfection activity at the last sampling point. The P-[G/L] 
lyp formulations retained their full transfection activity for two months. However, the transfection 
activity of both formulations dropped after three months of storage. The loss of the transfection 
activity of the [P/G/L]lyp formulations can be rationalized by two mechanisms. The first 
mechanism involves the degradation of pDNA and the loss of supercoiled form as a result of 
oxidative stress exerted by the presence of free radicals or reactive oxygen species as mediators.  
In the second mechanism presumes that the primary polymorphic morphology of the [P/G/L]lyp 
lipoplexes was lost during the storage by reorganization or chemical degradation of lipid phase 
(DOPE/gemini surfactant).  
In the case of P-[G/L]lyp formulations, the only mechanism that could explain the loss of 
transfection activity can be described by the loss of the  supramolecular structure during the 
storage, since the pDNA was added freshly at each sampling point. I proposed that the [G/L]lyp 
underwent a polymorphic phase transition during the storage at 25 ˚C resulting in the loss of 
inverted hexagonal rearrangement formed during the lyophilization/rehydration.  
  It should be noted that the physiochemical characterization of lyophilized formulations 
during the stability study revealed that there was no statistical correlation between the changes in 
physicochemical properties (particle size and zeta potential) and the changes in transfection 
activity. However, the particle size was maintained below 200 nm without any significant 
changes in particle size distribution as indicated by the unchanged PDI values [Table 4.2-B]. In 
addition, positive zeta potential was observed for all formulation during the stability study.  
In general, I achieved significant improvement in the stability of gemini surfactant based-
lipoplexes by employing lyophilization and both sucrose and trehalose performed well as 
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stabilizing agents. I developed a formulation method that can be utilized to prepare lipoplexes 
with high gene expression activity. However, more structural characterizations are required to 
understand the structural changes induced during the freeze-drying process. In addition, further 
investigation of the factors affecting the long-term stability of lyophilized gemini surfactant-
based lipoplexes is essential to optimize the formulation and lyophilization methods.      
6.2. Mass spectrometric analysis of amino acid modified gemini surfactants 
 Tandem mass spectrometric analysis was performed to establish a foundation for 
qualitative analysis of the gemini surfactant, detection of possible degradation by-products, and 
for pharmacokinetic and metabolomics studies. This was accomplished by utilizing a hybrid 
quadrupole orthogonal time-of-flight mass spectrometer (QqToF-MS) and a triple quadrupole –
linear ion trap mass spectrometer both equipped with an electrospray ionization (ESI) source.  
In this respect, the single stage QqToF-MS with internal calibration was used to confirm 
the molecular structure of six amino acid/di-peptide modified gemini surfactants with high mass 
accuracy (less than 10 ppm) [Table 5.1]. In addition, the tandem mass spectrometric (MS/MS) 
results contributed to establishing a universal (MS/MS) fragmentation pathway for all six 
compounds [Table 5.2, Figure 5.6]. Eleven common fragment ions were observed in all tested 
compounds. Two compound-specific diagnostic fragment ions were observed in all tested gemini 
surfactants originating from the loss of; one tail+head region [ion 2, Figure 5.6] or both tail+head 
regions [ion 9, Figure 5.6]. All fragment ions formed through two main pathways. Those in the 
first pathway resulted from the neutral loss of a tail region as (dodec-1-ene) moiety followed by 
the neutral loss of the attached head group as (N-methylmethanamine) moiety [Pathway A, 
Figure 5.6]. In the second pathway, the fragment ions originated from the complementary ion 
loss of one (tail+head) region as singly charged ion (N,N-dimethyldodecan-1-aminium, ion 11) 
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[Pathway B, Figure 5.6]. The fragmentation pathway was confirmed by two means: by 
performing multiple stage mass spectrometric analysis (MS/MS/MS) and by (MS/MS) analysis 
of a deuterated form of the 12-7N(Glycine)-12 (i.e., 12D25-7N(Glycine)-12D25) [Table 5.4]. The 
established fragmentation pathway can be used as a “fingerprint” for: 
- rapid and accurate detection of these compounds in biological matrices or pharmaceutical 
formulations, 
- the development of a multiple reaction monitoring (MS/MS) quantification method,   
- detection of possible degradation by-products during an accelerated stability study and 
- pharmacokinetic studies. 
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6.3. Future research directions  
 The present work was the first attempt to evaluate and improve the long-term stability of 
the gemini surfactant-based lipoplexes designed and developed by our research group. To further 
advance the research that was discussed in this work, different objectives can be investigated in 
the future. The following directions are relevant to my work and need to be addressed.      
6.3.1. Comprehensive characterization of lyophilized gemini surfactant lipoplexes 
 Novel cationic gemini surfactants are being developed in our research group to enhance 
the transfection activity and achieve specific targeting by the lipoplexes. The chemical structure 
of the new series compounds is more complicated than the gemini surfactant used in the present 
work. The data presented in this work showed that lyophilization can be used as a formulation 
technique to enhance the transfection activity. Therefore, detailed structural characterization is 
essential to investigate the actual influence of the formulation methods and freeze-drying cycles 
(freezing and drying) on the polymorphic phase behaviour of the lipoplex system. This can be 
achieved by employing synchrotron-based X-ray diffraction techniques such as small-angle X-
ray scattering (SAXS) or wide-angle X-ray scattering (WAXS). In addition, electron microscopy 
techniques such as freeze-fracture electron microscopy and scanning electron microscopy could 
be used to examine the lipid phase morphology. Determination of glass transition temperature is 
also essential to understand the influence of sugars on the stability of the lyophilized 
formulations.  The glass transition temperature can be measured via differential scanning 
calorimetric (DSC) technique. 
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6.3.2. Optimization of formulation and lyophilization technique  
 The full characterization of lyophilized formulations can assist further optimization of the 
formulation methods and freeze-drying parameters that could enhance the transfection activity 
and the stability of the lyophilized gemini surfactant-based lipoplexes. The optimization of 
preparative methods includes the removal of any possible oxidative stress mediators that could 
be found in the starting materials. In addition, the formulation improvement could include the 
replacement of the helper lipid DOPE by other lipids such as cholesterol. My results indicated 
that the higher concentration of DOPE lipid could be a reason for the loss of the transfection 
activity of the lyophilized lipoplexes during the storage.  
The optimization of the freeze-drying could include the investigation of the influence of 
other freezing methods such as super-freezing by immersion in liquid nitrogen or a ramped 
freezing cycle. In addition, freeze-thawing studies must be conducted to understand the exact 
effect of the freezing cycle on the physiochemical properties and the biological activity of 
lipoplexes. The determination of the glass transition temperature of freeze-concentrate 
component (Tg') could be useful in obtaining the optimum sugar to lipoplex weight ratio that 
provides the maximum cryo-protective effect.
11,12
 The improvement of the drying cycles through 
monitoring the glass transition temperature of lyophilized cake (Tg) and moisture content could 
significantly improve the long-term stability of lyophilized formulations.     
6.3.3. Mass spectrometric-based quantification method 
 The chemical stability of the lipid phase components of the lyophilized lipoplexes is a 
concern that to our knowledge has not been explored. The investigation of the stability of the 
gemini surfactant and helper lipid DOPE is important for the long-term stability of lipoplexes. 
Additionally, the determination of possible degradation by-products and the fate of the lipid 
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component upon uptake are critical during the development of lipoplex-based pharmaceutical 
products for clinical trials. In our research group, mass spectrometric and hyphenated mass 
spectrometric techniques (i.e., LC-MS) are employed for chemical characterization and 
quantification of drug delivery systems.
13-15
 MS-based techniques provide fast, sensitive, 
accurate and reliable results that can be utilized for stability study.
16-19
 My MS/MS results can be 
used to build a MS-base quantification method to investigate the influence of the lyophilization 
process and storage conditions on the stability of gemini surfactant and DOPE molecules. 
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